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Colorectal cancer (CRC) is an insidious disease, responsible for almost 700,000 deaths 
annually worldwide. The incidence of CRC in New Zealand is more than double the world 
average, at 48.1 and 36.7 cases per 100,000 annually for men and women respectively, with 
the highest rates of distant metastases on presentation around the world at 24% of cases. The 
predominance of this late stage presentation may be attributed to poor public awareness, 
exacerbated by the current absence of the nationwide screening program that is due to begin 
in 2017. Combined with limited long-term treatment options, the prognosis for patients 
diagnosed with CRC in New Zealand is relatively poor. The availability of alternative 
treatment options, such as immunotherapy, may help to improve patient outcomes, 
promoting remission and recovery while limiting the development of adverse side effects. 
Immunotherapy involves the engagement and manipulation of the patients own immune 
system, re-educating the effector cells of the immune system to recognise, respond and 
eliminate tumour cells. One of the most promising types of immunotherapy is vaccination, 
capable of reinvigorating the immune system to recognise and target molecules associated 
with CRC. 
This study used virus-like particles (VLP) derived from Rabbit hemorrhagic disease virus 
(RHDV) as a vaccine construct for the treatment of CRC. VLP are a form of subunit vaccine 
composed of components derived from a virus, but without the ability to infect or replicate. 
These inert shells can be modified to incorporate heterologous antigens, such as those derived 
from tumour cells, as well as additional molecules that can manipulate and modify the 
immune responses induced. In previous work undertaken with RHDV VLP, these molecules 
have included adjuvants such as α-galactosylceramide and deoxyribonucleic acid (DNA) 
oligonucleotides containing unmethylated CpG islands (CpGs), as well as compounds that 
promote uptake, such as mannose and surface conjugated CpGs. During this study, it was 
found that RHDV VLP have a natural affinity for CpGs, facilitating the co-delivery of this 
adjuvant into antigen-presenting cells (APCs) that uptake VLP. This property was identified 
based on the protection of CpG oligonucleotides from DNase digestion in the presence of 
RHDV VLP, and the further retention of CpGs following dialysis. The functionality of CpGs 
associated with RHDV VLP was investigated using the RAW-Blue reporter cell line, and 
confirmed in assays evaluating the activation of murine bone marrow-derived dendritic cells 
(BMDCs). CpGs delivered in association with RHDV VLP were found to induce enhanced 
activation of BMDCs in comparison to an equivalent quantity of CpGs administered alone. 
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This enhancement could not be explained by the direct effects of RHDV VLP on these cells, 
as VLP alone was found to be slightly suppressive relative to untreated controls. 
RHDV VLP were further found to have a natural affinity for other short nucleic acids, such 
as short interfering RNA (siRNA). This affinity was identified following dialysis of siRNA 
laced RHDV VLP. The efficacy of siRNA delivery was investigated using signal transducer 
and activator of transduction (STAT) 3 siRNA, based upon its ability to knockdown STAT3 
protein levels in a model cell line following administration in combination with RHDV VLP. 
The functionality of STAT3 siRNA delivery by RHDV VLP was further investigated based 
on the hypothesised ability to interfere with interleukin-6 (IL-6) secretion in activated murine 
macrophages. Although RHDV VLP was found to be capable of delivering STAT3 siRNA 
to murine macrophages, inducing a significant knockdown in STAT3 protein levels, this 
effect did not functionally translate into significant alterations in IL-6 secretion. 
RHDV VLP-based vaccines developed for the treatment of cancer have previously included 
the incorporation of model antigens, limiting direct relevance of these vaccines to targeting 
true tumour-associated antigens. More recently, a study involving the incorporation of the 
melanoma-associated antigen gp100 proved that RHDV VLP-based vaccines can induce 
responses against tumour-associated antigens. However, this study also showed that 
targeting gp100 alone was insufficient for inducing responses that could induce complete 
remission of murine melanoma tumours, indicating that escape mechanisms remained intact. 
This may be overcome by inducing simultaneous immune responses against multiple 
tumour-associated antigens, potentially limited the ability of tumours to adapt and escape.  
In order to test this hypothesis, RHDV VLP were produced that contained an epitope derived 
from murine topoisomerase IIα (T.VP60), an epitope derived from murine survivin (S.VP60) 
or both in combination (TS.VP60). The identity of these chimaeric VLP was confirmed 
through sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), electron 
microscopy and mass spectrometry. Their ability to induce targeted immune responses 
against their respective epitopes was assessed with in vivo cytotoxicity assays. The efficacy 
of these chimaeric VLP constructs to combat subcutaneously engrafted MC38-OVA murine 
CRC tumours in combination with CpGs as an adjuvant was evaluated in therapeutic tumour 
trials, with RHDV VLP containing the model chicken ovalbumin epitope SIINFEKL 
(SIIN.VP60) used as a model control. Both T.VP60 and S.VP60 delayed the growth of 
MC38-OVA tumours with comparable efficacy to SIIN.VP60, attributable to 60% overall 
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survival amongst mice combined across all trials. TS.VP60 exhibited further delays in the 
growth of MC38-OVA tumours, attributable to 67% overall survival amongst mice 
combined across all trials. Although this trend for enhanced efficacy with vaccination 
targeting multiple tumour-epitopes was repeatable between trials, the difference between 
mono- and multi-target therapies was not statistically significant. All mice that survived 
following vaccination were rechallenged with a subcutaneous MC38-OVA tumour on the 
opposing flank at day 100, and by day 200 none of these mice had grown tumours. Although 
these results are promising, combinations of greater than two target antigens may be required 
to provide significant benefits with a multi-target vaccine.  
Finally, RHDV VLP was assessed for its ability to be expressed by the oncolytic virus 
Vesicular stomatitis virus (VSV). The purpose of this investigation was to facilitate the 
development of a combination vaccine capable of utilising the targeted tumour cell-specific 
lytic infection of an oncolytic virus, and the therapeutic vaccination properties of RHDV 
VLP. To this end, recombinant VSV expressing RHDV VP60 (VSV-VP60), SIIN.VP60 
(VSV-SIIN.VP60) and TS.VP60 (VSV-TS.VP60) were produced. The viability of 
recombinant VSV was assessed by plaque assay, the incorporation of each VLP construct 
was confirmed through sequencing, and the production of each VLP in baby hamster kidney 
(BHK) cells was identified by Western blot and electron microscopy. In MC38-OVA tumour 
trials, none of the VLP expressing VSV constructs provided significant benefits in either 
growth rate or survival. The absence of the usual oncolytic properties of VSV may be due to 
impaired or altered activity in the MC38-OVA murine CRC model system, or through 
impairment in combination with RHDV VLP expression. The apparent inefficacy of the VLP 
vaccines expressed by each VSV construct may be due to inadequate dosage, with in vivo 
expression from the administered quantity of recombinant VSV possibly incapable of 
recapitulating levels known to be required for successful RHDV VLP vaccination. These 
results indicate that although VSV is able to express RHDV VLP, further work is required 
to facilitate the development of this potential combination therapy. 
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CCMV – Cowpea Chlorotic Mottle Virus 
CD – Cluster of Differentiation 
CDC – Complement-dependent 
Cytotoxicity 
CDCA1 – Cadmium-specific Carbonic 
Anhydrase 1 
cDCs – Conventional Dendritic Cells 
CEA – Carcinoembryonic Antigen 
CFSE – Carboxyfluorescein 
Succinimidyl Ester 
cIMDM – Complete Iscove’s Modified 
Dulbecco’s Media 
CIMP – CpG Island Methylator 
Phenotype 
CIN – Cervical Intraepithelial Neoplasia 
CLIP – Class II-associated Invariant 
Chain Protein 
CML – Chronic Myelogenous Leukaemia 
COX2 – Cyclooxygenase 2 
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cPBS – Coupling Phosphate Buffered 
Saline 
CPE – Cytopathic Effect 
CpG – Unmethylated CpG Island 
CRC – Colorectal Cancer 
CRISPR – Clustered Regulatory 
Interspaced Short Palindomic Repeats 
CsCl – Caesium Chloride 
CSF-1 – Colony Stimulating Factor 1 
CT – Core Tumour 
CTLA – Cytotoxic T-Lymphocyte-
associated Protein 
CXC – Cysteine-X-Cysteine 
DAMPs – Damage-associated Molecular 
Patterns 
DBS.VP60 – N-terminus HPV-16 DNA-
binding Site Recombinant VP60 
DCC – Deleted in Colorectal Cancer 
DC-SIGN – Dendritic Cell-specific 
Intercellular Adhesion Molecule-3-
grabbing Non-Integrin 
ddH2O – Double Distilled Water 
DFS – Disease-free Survival 
dH2O – Distilled Water 
DLS – Dynamic Light Scattering 
DMEM – Dulbecco’s Modified Eagle 
Media 
DMSO - Dimethylsulfoxide 
DNA – Deoxyribonucleic Acid 
DPBS – Dulbecco’s Phosphate Buffered 
Saline 
DPS – DNA-binding Proteins from 
Starved Cells 
DSS – Disease-specific Survival 
DTT - Dithiothreitol 
EBNA – Epstein-Barr Virus Nuclear 
Antigen 
EBV – Epstein-Barr Virus 
EGFR – Epithelial Growth Factor 
Receptor 
EGTA – Ethylene Glycol Tetraacetic 
Acid 
ELISA – Enzyme-linked Immunosorbent 
Assay 
EMT – Epithelial-to-Mesenchymal 
Transition 
ER – Endoplasmic Reticulum 
ERK – Extracellular Receptor Kinase 
ERMA – Environmental Risk 
Management Authority 
ESCC – Esophageal Squamous Cell 
Carcinoma 
ESO – Esophageal Cancer Antigen 
FACS – Fluorescence-activated Cell 
Sorting 
FAP – Familial Adenomatous Polyposis 
FAS – Fas Cell Surface Death Receptor 
FBS – Fetal Bovine Serum 
Fc – Fragment Crystallisable 
FCS – Fetal Calf Serum 
FDA – Food and Drug Administration 
FHV – Feline Herpesvirus 
FOLFOX – 5-FU, Leucovorin and 
Oxaliplatin 
FOX – Forkhead Box 
GATA – GATA-binding Factor 
GBM – Glioblastoma Multiforme 
17 
 
GD3 – Ganglioside Precursor 
Disialohematoside 3 
GGS – Glycine Glycine Serine 
GITR – Glucocorticoid-induced TNFR-
related Protein 
GM-CSF – Granulocyte Macrophage 
Colony Stimulating Factor 
Gr1 – GALEX Release 1 
GTP – Guanine-5’-Triphosphate 
HBV – Hepatitis B Virus 
HCAs – Heterocyclic Amines 
HCC – Human Hepatocellular Carcinoma 
HER2 – Human Epithelial Growth Factor 
Receptor 2 
HIF1α – Hypoxia-inducible Factor 1α 
HLA – Human Leukocyte Antigen 
HMGB1 – High Mobility Group Box-1 
hMLH – Human MutL Homolog 
HNPCC – Hereditary Non-polyposis 
Colon Cancer 
HNSCC – Head and Neck Squamous 
Cell Cancer 
HPV – Human Papillomavirus 
HSPs – Heat Shock Proteins 
HSV – Herpes Simplex Virus 
HuNoV – Human Norovirus 
IBDV – Infectious Bursal Disease Virus 
IBSC – Institutional Biological Safety 
Committee 
ICAM – Intercellular Adhesion Molecule 
ID – Inhibitor of DNA Binding 
IDO – Indoleamine 2,3-Dioxygenase 
IEDB – Immune Epitope Database 
IFA – Incomplete Freund’s Adjuvant 
IFN - Interferon 
Ig - Immunoglobulin 
IGF – Insulin-like Growth Factor 
IGF1R – IGF1 Receptor 
IgSF – Immunoglobulin Superfamily 
IL - Interleukin 
IM – Invasive Margin 
IMP-3 – IGF-II mRNA Binding Protein 3 
iNKT – Type I Natural Killer T Cell 
iNOS – Inducible Nitric Oxide Synthase 
IPCS – International Program on 
Chemical Safety 
IR – Infra-red 
IRS1 – Insulin Receptor Substrate 1 
iTreg – Induced T Regulatory 
JAK – Janus Kinase 
JCV – John Cunningham Virus 
JECFA – Joint FAO/WHO Expert 
Committee on Food Additives 
KCH3COO – Potassium Acetate 
KCl – Potassium Chloride 
KH2PO4 – Potassium Phosphate 
KHCO3 – Potassium Carbonate 
KIRs – Killer-cell Immunoglobulin-like 
Receptors 
KOH – Potassium Hydroxide 
KRAS – Kirsten Rat Sarcoma Viral 
Oncogene Homolog 
KRT – Keratin Cytoskeletal 
L/D – Live/Dead 
LAIR – Leukocyte-associated 
Immunoglobulin-like Receptor 
LB – Luria Broth 
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LCMV – Lymphocytic 
Chorionmeningitis Virus 
LCR – Non-coding Long Control Region 
LFA – Lymphocyte Function-associated 
Antigen 
LGP2 – Laboratory of Genetics and 
Physiology 2 
LIRs – Leukocyte Inhibitory Receptors 
LL-LCMV – Lewis’ Lung Carcinoma 
LMP1 – Epstein-Barr Virus Latent 
Membrane Protein 1 
LPS - Lipopolysaccharide 
LY6K – Lymphocyte Antigen 6 Complex 
Locus K 
mAb – Monoclonal Antibody 
MAGE – Melanoma Antigen 
MAIT – Mucosal Associated Invariant T 
Cells 
MAPK – Mitogen-activated Protein 
Kinase 
MDA5 – Melanoma Differentiation-
associated Gene 5 
MDSCs – Myeloid-derived Suppressor 
Cells 
MET – Hepatocyte Growth Factor 
Receptor Precursor 
MFI – Median Fluorescence Intensity 
MgCl2 – Magnesium Chloride 
MHC – Major Histocompatibility 
Complex 
miRNA – Micro Ribonucleic Acid 
MITF – Microphthalmia-associated 
Transcription Factor 
M-MDSCs – Monocytic Myeloid-derived 
Suppressor Cells 
MMP – Matrix Metalloproteinase 
MMR – Mismatch Repear 
MMTV – Wingless-type Mouse 
Mammary Tumour Virus 
MOI – Multiplicity of Infection 




MPL-A – Monophosphoryl Lipid A 
MR1 – MHC-related Protein 1 
mRNA – Messenger Ribonucleic Acid 
MS2 – Bacteriophage MS2 Coat Protein 
MUC1 – Mucin 1 
MVA-T7 – Replication Defective 
Vaccinia (T7 RNA Polymerase) 
MVD – Microvessel Density 
Na2HPO4 – Disodium Hydrogen 
Phosphate 
NaCl – Sodium Chloride 
NaH2PO4.2H2O – Sodium Dihydogen 
Phosphate Dehydrate 
NAT – N-Acetyltransferase 
NCBI – National Center for 
Biotechnology 
NFAT – Nuclear Factor of Activated T 
Cells 
NF-κB – Nuclear Factor-kappa-B 
NH4Cl – Ammonium Chloride 
NK – Natural Killer 
NKT – Natural Killer T 
NLRs – Nod-like Receptors 
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NOS2 – Nitric Oxide Synthase 2 
NRP - Neuropilin 
NSCLC – Non-Small Cell Lung Cancer 
nTreg – Natural T Regulatory 
OD – Optical Density 
ORFs – Open Reading Frames 
OS – Overall Survival 
OTI – Ovalbumin SIINFEKL-specific 
Transgenic Mice 
PAGE – Polyacrylamide Gel 
Electrophoresis 
PAHs – Polycyclic Aromatic 
Hydrocarbons 
PAMPs – Pattern-associated Molecular 
Patterns 
PAP – Prostatic Acid Phosphatase 
PBS – Phosphate Buffered Saline 
PCPS – Proteasome Cleavage Prediction 
Server 
PD – Programmed Cell Death Protein 
pDCs – Plasmacytoid Dendritic Cells 
PDCs – Poorly Differentiated Clusters 
PDGF – Platelet-derived Growth Factor 
PDL – Programmed Cell Death Ligand 
PFA - Paraformaldehyde 
PI3K – Phosphoinositide 3-Kinase 
PLAU – Plasminogen Activator 
Urokinase 
PMN - Polymorphonuclear 
PMN-MDSCs – Polymorphonuclear 
Myeloid Derived Suppressor Cells 
PP2A – Protein Phosphatase 2 
PRRs – Pattern Recognition Receptors 
PTEN – Phosphatase and Tensin 
Homologue 
Qβ – Bacteriophage Qβ Capsid Protein 
R8.VP60 – N-terminus Octaarginine 
Recombinant VP60 
RAG2 – Recombination Activating Gene 
2 
RAGs – Recombination Activating Genes 
RbCl – Rubidium Chloride 
RB-DMEM – RAW-Blue Dulbecco’s 
Modified Eagle Media 
RBPJ – Recombinant Binding Protein 
Suppressor of Hairless 
RHDV – Rabbit Hemorrhagic Disease 
Virus 
RIG-1 – Retinoic Acid-inducible Gene 1 
RLRs – RIG-1-like Receptors 
RNA – Ribonucleic Acid 
ROR – RAR-related Orphan Receptor 
ROSs – Reactive Oxygen Species 
S.VP60 – N-terminus Survivin 
Recombinant VP60 
S.VP60.T – N-terminus Survivin, C-
terminus Topoisomerase IIα Recombinant 
VP60 
SCF – Scientific Committee on Food 
SCFAs – Short Chain Fatty Acids 
SDS – Sodium Dodecyl Sulfate 
SEAP – Secreted Alkaline Phosphate 
Sf21 – Spodoptera frugiperda 21 




SHP2 – Src Homology Region 2-
containing Protein Tyrosine Phosphatase 
2 
shRNA – Short Hairpin Ribonucleic Acid 
SIIN.VP60 – N-terminus SIINFEKL 
Recombinant VP60 
siRNA – Small Interfering Ribonucleic 
Acid 
SOC – Super Optimal Broth with 
Catabolite Repression 
SOCS – Suppressor of Cytokine 
Signalling 
SP – Specific Binding Protein 
Spl – Splenocyte 
SSL – Serine Serine Leucine 
STAT – Signal Transducer and Activator 
of Transcription 
STNV – Satellite Tobacco Necrosis Virus 
SV – Sample Volume 
T.VP60 – N-terminus Topoisomerase IIα 
Recombinant VP60 
TAAs – Tumour-associated Antigens 
TAE – Tris Acetate EDTA 
TAMs – Tissue-associated Macrophages 
TAP – Transporter Associated with 
Antigen processing 
TC – Cytotoxic T cell 
TCF – T Cell Factor 
TCM – T Central Memory Cell 
TCR – T Cell Receptor 
Teff – T Effector Cell 
TEM – T Effector Memory Cell 
TEM – Transmission Electron 
Microscopy 
TEMED - Tetramethylethylenediamine 
TEX – T Exhausted Cell 
TGF – Transforming Growth Factor 
TH – T Helper Cell 
TILs – Tumour Infiltrating Lymphocytes 
TIM – T Cell Apoptosis through Binding 
to Mucin Domain-containing Protein 
TK – Thymidine Kinase 
TKK – TKK Protein Kinase 
TLRs – Toll-like Receptors 
TNF – Tumour Necrosis Factor 
TNFRSF – Tumour Necrosis Factor 
Receptor Superfamily 
TNM – Tumor Node Metastasis 
TopIIα – Topoisomerase IIα 
TRAIL – TNF-related Apoptosis 
Inducing Ligand 
TRAILR – TRAIL Receptor 
Treg – T Regulatory Cell 
TRM – T Tissue-resident Memory 
tRNA – Transfer Ribonucleic Acid 
TS.VP60 – N-terminus Topoisomerase 
IIα and Survivin Recombinant VP60 
TS.VP60.T – N-terminus Topoisomerase 
IIα and Survivin and C-terminus 
Topoisomerase IIα Recombinant VP60 
TSAs – Tumour-specific Antigens 
UICC – Union for International Cancer 
Control 
US – United States 
UT - Untreated 
VEGF – Vascular Endothelial Growth 
Factor 
VEGFR – VEGF Receptor 
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VITAL – In Vitro Cytotoxicity Assay 
VLP – Virus-like Particle 
VP60.T – C-terminus Recombinant VP60 
VPD – Violet Proliferation Dye 
VSV – Vesicular Stomatitis Virus 
VSV-SIIN.VP60 – SIIN.VP60 
Recombinant VSV 
VSV-TS.VP60 – TS.VP60 Recombinant 
VSV 
VSV-VP60 – VP60 Recombinant VSV 
WHO – World Health Organisation 








Cancer is a disease caused by the growth of a malignant neoplasm or tumour amongst normal 
tissue in any of a variety of organ systems, distinguishable from benign tumours primarily 
by its ability to invade tissues throughout the body. Amongst western countries, almost half 
of the population will be diagnosed with a cancerous tumour at some stage during their lives 
[1], representing a significant disease burden. In New Zealand, around 340 new cases of 
cancer per 100,000 people are registered annually, and cancer is responsible for around 120 
annual deaths per 100,000 people [2]. The most common cancers amongst New Zealand men 
are prostate cancer, colorectal cancer (CRC), melanoma and lung cancer, and amongst New 
Zealand women are breast cancer, CRC, melanoma and lung cancer. This shared propensity 
for melanoma is likely due to a combination of geographic and ethnic factors, with a 
significantly higher incidence rate amongst residents of European descent. Trends in both 
incidence rate and mortality appear to correlate with increasing ambient UV levels towards 
southerly latitudes, but differences between genders also suggest contributions from 
confounding factors such as lifestyle and recreational UV exposure [3]. The propensity for 
developing CRC is more difficult to explain, with New Zealand having amongst the highest 
incidence rates in the world at 48.1 and 36.7 cases per 100,000 annually for men and women 
respectively [4, 5]. Besides familial and other genetic factors, potential risk factors for 
developing CRC include living a sedentary lifestyle [6, 7], obesity [8] and diabetes mellitus 
[9, 10]. Additional site-specific risk factors also include cigarette smoking [11] and prior 
cholecystectomy [12, 13] in proximal or right-handed colon cancer, and alcohol consumption 
[14] and dietary habits [15] in distal or left-handed colon cancer. New Zealand is also still in 
the process of initiating a national screening programme for CRC beginning in 2017, and the 
absence of such screening may be at least partially responsible for these elevated rates. 
As with benign tumours, cancer arises from the neoplastic transformation of an individual 
cell, triggering a cascade of events that must fail to recognise and remedy the emergence of 
this aberrant cell if tumourigenesis is to be the result. It is important to emphasise that cancer 
is not a singular disease, but rather a term broadly used to describe multiple conditions with 
similarities in pathology. For each type of cancer, there is also a spectrum of disease, with 
individual subtypes distinguishable between patients. For example, distinctions can be made 
amongst a cohort of patients with CRC based on anatomical location, such as between 
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proximal (right-handed) from the caecum through to the splenic flexure or distal (left-handed) 
from descending colon to rectum [16]. Alternatively, they may be grouped based on broad 
genetic origins, such as between microsatellite stable and microsatellite instable cancer [17, 
18]. These subtypes present with different incidence rates, are associated with different risk 
factors and necessitate different treatment. This becomes further complicated at the patient 
level, with differences in genetic background rendering each cancer within the same subtype 
individually unique. Therefore, each case presents as its own personalised disease, and 
although it might fall within a broader sub-classification, there may be no guarantee that 
treatment recommended for that type will be effective for an individual patient. 
Personalisation of treatment is a complicated concept, and is heavily dependent upon our 
understanding behind some of the fundamental concepts in the pathology of cancer: how it 
originates, how it develops in the body, and how the body responds to it. 
 
1.1.1 Neoplasia 
Discernible from metaplasia and dysplasia, an alteration in mature cell state and phenotype 
respectively, neoplasia is the abnormal proliferation of a cell and may be preceded by either 
of these precursor aberrant changes. An individual neoplastic cell may arise through a 
multitude of modalities, but inherently possesses a generally shared phenotypic profile, even 
amongst differing source tissues. Dysregulated proliferation, abnormal maturation, and 
extended longevity, these hallmarks of neoplastic cells are a consequence of the principal 
origin of neoplasia, alterations in intracellular signalling or regulatory pathways commonly 
induced by genetic mutation. From the moment of conception, our cells begin their lifelong 
accumulation of somatic mutations, acquired companions of their inheritable germ-line 
counterparts. The rate of acquisition in the average human cell is estimated at around 1.06x10-
6 mutations per cell division [19]. Although this may appear relatively insignificant, when 
considering that we undergo an estimated total number of cell divisions in the order of 1x1016 
[20], we may each experience around 1x1010 mutations in our lifetime. Age is not in our 
favour, an increasing life expectancy worldwide increases the average number of cell 
divisions, and hence the number of somatic mutations we experience. These statistics might 
suggest the inevitability of tumourigenesis, but we also possess mechanisms that can 
recognise and respond to these early transformational events. 
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Besides the accumulation of spontaneous mutations during cell division, the genomic 
material in a cell can also be directly mutated by external environmental factors. Some key 
examples include the formation of pyrimidine dimers induced by exposure to light in the 
ultraviolet spectrum, DNA lesions or breaks induced by ionising radiation, or the various 
damaging effects of exposure to different chemical compounds or molecules. While exposure 
to some mutagenic agents is relatively fixed, such as background radiation from both natural 
and artificial sources estimated at around 3.01 mSv per year worldwide [21], many will vary 
depending on nation of residence, employment and lifestyle. Cigarette smoking, consumption 
of processed foods, or use of tanning beds are all commonly recognised sources of increased 
exposure to mutagenic agents, but some lesser known sources include the formation 
polycyclic aromatic hydrocarbons in chargrilled meats [22, 23], nitrate or nitrite 
contaminated drinking water [24], or the formation of trihalomethanes in disinfectant treated 
water [25, 26]. Occupational exposure is another important consideration, such as to 
chemicals prior to identification as carcinogens. Factory workers who worked with various 
chemicals such as dioxin and chlorophenols have been found to have an elevated risk of 
developing cancer [27, 28], possibly due to the absence of appropriate protective clothing. 
Some exposure is inevitable, and while it may be prudent to minimise it is impossible to 
negate. Exposure to carcinogens and the subsequent induction of mutations does not 
guarantee tumourigenesis, and this is inherently due to the nature of the mutations that result. 
Only mutations associated with specific types of genes tend to facilitate neoplasia. These 
genes may be referred to as either tumour suppressor genes or oncogenes. Tumour suppressor 
genes include many genes involved in regulating cell division, apoptosis or DNA repair. 
Deleterious or dysfunctionalising mutations in these genes can induce dysplasia, 
immortalisation or the accumulation of further mutations. Oncogenes are involved in similar 
pathways but from the opposing perspective, providing positive drive often under tight 
regulation. Overexpression or amplification of oncogenes boosts their activity above normal 
physiological levels, promoting neoplastic transformation. 
The concept of a single mutation inducing guaranteed spontaneous neoplastic transformation 
of a mutated cell is erroneous. The validity of this claim is probably best demonstrated with 
inheritable forms of cancer, such as breast cancer arising in a patient with either a breast 
cancer (BRCA) 1 or 2 mutation. BRCA1 and BRCA2 are tumour suppressor genes involved 
in DNA repair, and mutations in these have been linked with development of breast cancer 
and ovarian cancer [29, 30]. Inheritance of either of these mutations in women is associated 
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with a lifetime risk of breast cancer of between 60 to 85 percent, and a lifetime risk of ovarian 
cancer of between 15 to 40 percent [31, 32]. Although these risk levels are significantly 
elevated above normal, they do not provide a guarantee of cancer development in susceptible 
individuals. Subsequent accumulation of further mutations in alternative tumour suppressor 
genes, or activation of oncogenes drives the completion of mutation-induced neoplasia. This 
process can be viewed through the progressive stages of precancerous intestinal polyp 
formation through to the development of CRC especially under the context of microsatellite 
instability, although microsatellite instable CRC accounts for only around 15% of cases [33]. 
Mutations in the tumour suppressor gene adenomatous polyposis coli (APC), a key regulator 
of proliferation in the intestinal epithelium, are associated with both familial and spontaneous 
CRC [34]. Compounded with mutations that activate oncogenes such as Kirsten rat sarcoma 
viral oncogene homolog (KRAS), or disrupt additional tumour suppressor genes such as 
deleted in CRC (DCC), the dysregulated, hyperplastic epithelium can give rise to the 
formation of multiple benign polyps throughout the colon. Although initially benign, these 
precancerous polyps can accumulate further mutations during their dysregulated growth, 
such as in the tumour suppressor gene p53, can induce transformation into carcinoma [35]. 
Further mutations may alter the resulting tumour, enhancing its growth or allowing it to 
metastasise to distant tissues (Figure 1.1). 
 
 
Figure 1.1 Development of Colorectal Carcinoma through Accumulation of Mutations 
Combinations of mutations drive the progression of neoplastic transformation, beginning with the formation of 
precancerous lesions such as intestinal polyps, through to the development of carcinoma in situ and metastasis. 
Primary mutations capable of driving neoplastic transformation of cells include those that promote the 





The primary concern of each individual cell is self-preservation, activating a series of 
response mechanisms in response to significant DNA damage. Some of the first mechanisms 
engaged are regulators to cell cycle checkpoints such as 53BP1, BRCA1 and MDC1, through 
a signal transduction pathway mediated by ATM and ATR that leads to cell cycle arrest [36]. 
Cessation of cell division provides the opportunity to engage repair mechanisms before 
attempting genomic replication, which would result in subsequent inheritance of the mutation 
in progeny cells. If the damage induced is sufficiently severe, these signal transduction 
pathways can also activate mediators of apoptosis, such as p53, and other early prevention 
mechanisms of neoplastic transformation and tumourigenesis. DNA repair mechanisms are 
vast and varied in eukaryotic cells, ranging from methylguanine DNA methyltransferases for 
removal of the O6-methyl group from O6-methylguanine in DNA, individual base pair 
excision by DNA glycosylases, oligomer excision through RPA, TFIIH, XPA, XPC, XPF-
ERCC1 and XPG [37-39], and double-strand break ligation through homologous 
recombination or non-homologous end-joining mechanisms [40-44]. Intuitively, mutations 
or defects in many components of these pathways have been linked with dysfunctional DNA 
repair, mutation accumulation and neoplasia. The ultimate fate of the cell is defined by the 
efficacy of these mechanisms, with a failure to recover resulting in persistent senescence, 
apoptosis, or neoplastic transformation. 
An alternative important source of induced neoplasia is infection with specific pathogens, 
such as oncogenic strains of human papillomavirus (HPV) and Epstein-Barr virus (EBV). 
These viruses are noteworthy both for their oncogenic potential, but also for their ubiquity in 
infection amongst humans throughout the world, rendering their unique host interactions 
worthy of mention. The HPV genome contains eight open reading frames (ORFs) in addition 
to a non-coding long control region (LCR), and includes the two oncogenes, E6 and E7, 
which bind to two major tumour suppressor proteins, p53 and pRb respectively [45-48]. 
Proteasomal degradation of p53 through the ubiquitin ligase activity of E6 essentially 
immortalises the cell [49-51], while competitive binding of E7 for pRb allows the 
transcription factor E2F to drive progression through the cell cycle, inducing dysregulated 
cell proliferation [52]. Infection of cervical squamous epithelial cells induces transformation 
into koilocytes, with a hyperplastic and hyperchromic nuclei, and a perinuclear halo. The 
progression of HPV-induced neoplasia from carcinoma in situ through to cervical cancer is 
a model example of progressive neoplastic transformation induced by an oncogenic virus, 




Figure 1.2 Neoplastic Transformation of Cervical Squamous Epithelium 
Distinguishable stages of neoplastic transformation can often be visualised by histological staining of sections 
from cervical cancer biopsies. Cervical cancer is caused by infection of squamous epithelial cells with human 
papillomavirus, and it predominantly arises at the cervical transformation zone. The transformation zone 
contains metaplastic cells transitioning between squamous and columnar epithelium, rendering them 
particularly susceptible to virus-induced neoplastic transformation. Early stages of cervical carcinoma in situ, 
such as cervical intraepithelial neoplasia (CIN) 1-2 are characterised by the presence of HPV-infected 
koilocytes, with nuclear enlargement, hyperchromasia and a perinuclear halo. Further progression is marked by 
a significant increase in the nuclear to cytoplasmic ratio in CIN3, followed by invasion of the basement 
membrane with complete transition into invasive cervical cancer [53]. 
 
Lymphoblastoidal transformation of EBV infected latent B cells is a complex process 
induced by a combination of viral proteins, although the essential proteins for transformation 
are Epstein-Barr virus nuclear antigen (EBNA) 2, EBNA3C and Epstein-Barr virus latent 
membrane protein 1 (LMP1) [54]. EBNA2 is a transactivator that targets promoters through 
interaction with recombining binding protein suppressor of hairless (RBPJ) DNA-binding 
protein, a Notch signalling pathway component [55], and is essential for latency III 
transformation of the host cell [56]. EBNA3C is also required for transformation, and 
although it is known to disrupt the G1 cell cycle checkpoint in some cell lines [57], and 
induce aneuploidy by disrupting mitotic spindle checkpoints [57, 58], its role in 
transformation may actually involve suppression of p16INK4A and p14ARF [59]. Finally, LMP1 
induces constitutive (NF-κB) activation by ligating to molecules involved in signal 
transduction from TNF superfamily receptors [60, 61]. Chronic inflammation induced by 
persistent pathogenic infection, such as Helicobacter pylori infection in the stomach, can also 
induce changes in cells that can lead to neoplastic transformation [62, 63]. Further 
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information regarding the association between chronic inflammation and neoplasia will be 
discussed in a later section on the immune response to tumourigenesis. 
 
1.1.2 Tumourigenesis 
Upon neoplastic transformation, a cell will usually undergo dysregulated cell division to form 
a mass known as a neoplasm, or tumour. This process of tumour formation, or 
tumourigenesis, is dependent upon the source of the original neoplastic cell, as some 
malignancies such as those of haematological origin may not initially form a recognisable 
mass. The physiological process of tumourigenesis involves not just the proliferation of a 
neoplastic cell mass, but also the establishment of supportive vasculature through 
angiogenesis, and connective tissue through fibrogenesis. Growth in excess of nutrient supply 
may result in pockets of hypoxia, potentially leading to cell death and necrosis. The 
anatomical structure of a solid neoplasm differs depending on the cell type of origin, but is 
generally accepted to consist of heterogeneous populations of tumour cells, rather than a 
single clonal mass. Considering the mutagenic origin of neoplasia, this would suggest that 
tumour cells continue to evolve as they proliferate, accumulating further mutations and 
changing in phenotypic presentation. Early elucidations of this process focused on a linear 
progression model, in which the neoplastic progenitor cell seeds progeny that are increasingly 
aberrant as they acquire further mutations [64-67]. Although logical in principle, this model 
fumbles if the primary tumour breaches its anatomical confinement, often a basement 
membrane, and becomes metastatic. Tumour cells liberated from the tumour mass must have 
the ability to adapt and survive in transit within the lymph or blood, and have the capacity to 
invaginate into distal tissues to seed subsequent growth. These mechanisms would need to 
occur over timescales difficult to explain with the linear progression model alone. Current 
theories, such as the cancer stem cell and phenotype-switching hypotheses, attempt to 
account for and explain this discrepancy. 
 
1.1.2.1 Cancer Stem Cells 
Normal adult stem cell populations can be found throughout the body, providing a stable 
regenerative source for tissue growth and repair. Any individual stem cell population may be 
defined by possessing a combination of distinct characteristics, including self-regenerative 
potential, the ability to proliferate, and to produce multiple cellular lineages amongst progeny 
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[68]. The cancer stem cell hypothesis proposes that a small population of cells within a 
tumour possesses these characteristics, acting as a self-sustaining reservoir that drives and 
maintains tumour growth [69]. These cancer stem cells are thought to originate from the 
neoplastic transformation of normal stem cells, or through the acquisition of stem-like cell 
properties in a mutagenic progenitor cell [70]. The exact definition of a cancer stem cell 
varies between publications, an inconsistency that impairs the formation of a unified theory 
on the subject. Sometimes the cancer stem cell is considered the original source of a primary 
tumour, giving rise to multiple cell lineages to form the heterogeneous tumour mass. 
Alternatively, cancer stem cells are considered a subpopulation of tumour cells with the 
capacity to initiate tumour formation, or seed distant metastases. Finally, when viewed in the 
context of treatment efficacy, cancer stem cells may be defined as a reservoir of drug-resistant 
cells responsible for tumour regeneration, seeding recurrence following regression [71]. The 
erratic application of these definitions is the primary source of criticism for this theory, 
deviating significantly from direct equivalency with normal stem cells. 
The cancer stem cell hypothesis began to unravel due to compounding theoretical insight, 
flawed supporting experimental evidence, and the accumulation of opposing experimental 
evidence. References to equivalency between tumour initiating cells and cancer stem cells 
was made despite the absence of experimentation demonstrating self-regenerative potential 
[72]. This flaw was further exacerbated by the observation that isolated tumour initiating 
cells were unable to seed xenograft tumours with corresponding heterogeneity identical to 
that of the original tumour [73]. Another major assumption was that the accumulation of 
mutations occurred only in the cancer stem cell population, while the heterogeneous tumour 
bulk of progeny cells were generally static. This concept was challenged by the observation 
that differentiated progeny tumour cells have the potential to acquire stem-like cell properties 
through acquisition of mutations [73]. The primary benefit heralded by this theory was the 
proposed ability to selectively target the cancer stem cell population, but the ability of 
progeny cells to acquire this phenotype and potentially replace the target cancer stem cell 
population presents as a significant flaw in this rational. Development of therapeutic 
resistance was also inconsistent with this theory, as cancer stem cells, like normal stem cells, 
were theorised to be inherently resistant to the cytotoxic drugs used for chemotherapy that 
target rapidly dividing cells. The susceptible progeny that make up the bulk of the tumour 
would be eliminated, while the resistant cancer stem cells remained; however, this theory 
suggests that these cancer stem cells would seed a recurrent tumour similarly consisting of 
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susceptible progeny, but observations indicate that the entire recurrent tumour bulk acquires 
drug resistance [72]. This finding instead suggests that the administration of a therapeutic 
agent results in the selective proliferation of an inherently resistant subpopulation that passes 
its resistance on to its progeny.  
The assumed equivalency with normal stem cells resulted in the most criticism for the theory, 
with the suggestion that the term ‘cancer stem cell’ may have been hastily applied to a tumour 
subpopulation possessing some stem-like cell properties [74, 75]. Despite the controversies 
surrounding this theory, research continues to attempt to formulate a model of tumourigenesis 
involving cancer stem cells, incorporating the ability of differentiated tumour cells to acquire 
self-regenerative abilities through de-differentiation [76, 77]. The existence of cancer stem 
cells was recently independently verified by three groups, which included confirmation of 
the fluidity in the phenotype of this population of cells [78-80]. This fluid cancer stem cell 
model incorporates tumour heterogeneity and plasticity of progenitor cells, supported by 
work in breast cancer, most notably the observation of transition of breast cancer cells into a 
cancer stem cell-like state dependent on ZEB1, a epithelial-mesenchymal transition regulator 
[81-83]. Interestingly, this shift has seen this model become increasingly compatible with 
one of its major competitor theories, the phenotype-switching hypothesis. 
 
1.1.2.2 Phenotype-Switching 
The phenotype-switching hypothesis suggests that the heterogeneous population of cells 
within a tumour represents a phenotypic spectrum polarised by either proliferative or invasive 
properties, regulated by micro-environmental stimuli [75]. This hypothesis was formulated 
in studies on melanoma that identified distinct tumour cell populations with polar opposite 
phenotype based on migratory and proliferative potential, with concordant differences in 
transcriptional signature [84, 85]. Isolated melanoma cells with a proliferative phenotype 
were found to seed tumours that grew significantly quicker than those seeded with invasive 
phenotype cells, but the resulting excised tumour from either displayed an identical 
heterogeneous phenotype with immunohistochemical staining [85]. Strikingly, almost all 
individual melanoma cells appear to have this capacity to initiate tumour growth, with 
matching heterogeneity [86, 87]. The proposed trigger for phenotype instability was 
hypersensitivity of tumour cells to fluctuating micro-environmental conditions, promoting 
transition to a suitable phenotype by inducing activation of various signal transduction 
pathways [75]. Potential micro-environmental triggers include hypoxia and acidosis, known 
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factors associated with proliferative growth in excess of vascular supply. Alternative 
selective stresses may also include inflammation, or the administration of therapeutic 
regimens that target rapidly dividing cells, such as DNA-damaging agents and deactylase 
inhibitors [88]. 
One of the primary strengths of the phenotype-switching hypothesis is its ability to explain 
the seeding and growth of distant metastases. This theory suggests that as the primary tumour 
proliferates it experiences crises where its mass exceeds the capacity of supporting tissues, 
resulting in pockets of degeneration in local micro-environmental conditions, and stimulating 
the conversion of subpopulations of tumour cells into an invasive phenotype [75]. Acquiring 
an invasive phenotype allows these cells to seek more preferential conditions permissive to 
growth, migrating through the circulatory or lymphatic systems until a sufficiently supportive 
microenvironment is encountered, before converting back to a proliferative state. This 
mechanism may explain why metastatic tumours of different tumour types tend to form only 
in specific tissues and organs. A similar effect can be observed in normal melanoblast 
biology, which display inherent potential for activation of a migratory state to promote 
distribution from the neural crest along the dorso-lateral and ventral during embryogenesis, 
followed by deactivation upon reaching the epidermal basal layer and other specific sites 
around the body [89, 90]. A reversible invasive phenotype has also been observed amongst 
normal melanocytes in the presence of extracellular matrix modifying molecules secreted by 
metastatic melanoma cells [91]. 
The polarised distinction of phenotypic states in melanoma has been verified, and appears 
with be primarily defined by expression of either melanocyte differentiation markers such as 
microphthalmia-associated transcription factor (MITF) in a proliferative phenotype, or 
negative regulators of the wingless-type mouse mammary tumour virus (MMTV) integration 
site (Wnt)/β-catenin pathway such as Wnt5a in an invasive phenotype. High expression of 
Wnt5a has been previously implicated in melanoma metastasis [85, 92], and correlates with 
induced resistance to administration of serine/threonine-protein kinase B-Raf (BRAF) 
inhibitors in melanoma patients [93]. Proliferative melanoma cells have also been observed 
to adopt an invasive phenotype in response to mitogen-activated protein kinase (MAPK) 
inhibitors [94], indicating that targeted therapy may promote phenotype-switching and drive 
metastasis. This theory is corroborated by the observation that BRAF inhibition can enhance 
metastasis in drug resistant tumours [95]. A similar mechanism has also been observed 
amongst non-small cell lung cancer (NSCLC) cell lines, based on an epithelial-to-
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mesenchymal transition (EMT) in response to administration of an EGFR inhibitor [96, 97]. 
Resistant NSCLC cell lines express high ZEB1 and vimentin, known markers of 
mesenchymal cells, and had increased migratory potential [98]. Drug-induced EMT also 
correlated with an increase in tyrosine-protein kinase receptor UFO precursor (AXL) 
expression, an invasive cell marker in melanoma that is also upregulated in NSCLC patients 
with acquired epithelial growth factor receptor (EGFR) inhibitor resistance [99].  
The observed similarities between the phenotype-switching hypothesis and EMT suggest that 
these theories may be analogous, merely different means of explaining the same observed 
phenomena. This association also establishes a tentative link to the cancer stem cell 
hypothesis, as immortalized mammary epithelial cells have been demonstrated to acquire 
stem cell-like properties by undergoing EMT [100]. This link has been further corroborated 
by the observation of two distinct phenotypic states polarised in proliferative or migratory 
potential amongst cancer stem cells in epithelial tumours, with the ability to actively 
interconvert between states [101, 102]. Anatomically, populations of quiescent, migratory, 
mesenchymal-like cancer stem cells have been identified to predominantly colonise the 
invasive boundaries of breast cancer, while proliferative, epithelial-like cancer stem cells 
congregated within the tumour centre [101]. This distribution suggests that, similar to the 
theorised regulation of phenotype-switching in melanoma, that microenvironmental stimuli 
may regulate polarisation of cancer stem cell populations into these distinct phenotypic 
groups. Such similarities may be a manifestation of a shared EMT-like mechanism, that all 
these theories when compared side by side may be explaining the same phenomenon with 
subtle differences between tumour types (Figure 1.3). In particular, both the phenotype-
switching mechanism and EMT transformation process can be identified in the updated fluid 






Figure 1.3 Comparisons of Hypothesised Mechanisms of Tumourigenesis 
The cancer stem cell hypothesis has changed significantly over the years based on new experimental findings. 
It is notable that the most recent fluid model contains both the phenotype-switching hypothesis mechanism 
independent of cell division, and the well-defined phenomenon of epithelial to mesenchymal transformation. 
The similarities between these models may indicate that these hypotheses are describing the same mechanisms 






1.2 The Immune Response to Tumourigenesis 
Most theories that postulate the process of tumourigenesis appear to brush over what is 
probably the most important contributor towards shaping tumour formation, the immune 
system. Every cell in our body is subject to surveillance, intermittently scanned by sentinel 
immune cells. This concept provided the foundation for the cancer immunosurveillance 
hypothesis conceived by Burnet and Thomas in the 1950s [104, 105], which outlines the 
ability of specific immune populations to detect indicators of neoplastic transformation on 
the surface of cells. Although inherently logical based on the pathological knowledge of the 
time, subsequent experiments by Stutman involving tumour implantation in either athymic 
or nude mice called this relationship into question [106, 107], particularly due to evidence 
that marked immunodeficiency appeared to have no effect on cancer susceptibility. Although 
this resulted in the abandonment of the cancer immunosurveillance hypothesis, debate 
continued over the subject, and particularly on the ability of emerging tumour cells to provide 
necessary danger signals for stimulation of the immune system [108, 109]. It wasn’t until 
quite some time later that technology advanced sufficiently to provide meaningful insight. In 
particular was the identification of the role of interferon (IFN)-γ in promoting immune-
mediated rejection of implanted tumours [110], and the susceptibility of (RAG2)-/- mice 
lacking T cells, B cells and natural killer T (NKT) cells to spontaneous or carcinogen-induced 
tumours [111, 112]. As similar reports began to emerge from other laboratories, a major 
revision of the immunosurveillance hypothesis was undertaken. The result was the 
immunoediting hypothesis, which attempted to consolidate recent experimental findings by 
describing three discernible phases of interaction, and how each of these phases influenced 
both tumourigenesis and tumour composition [113-115].  
The initial elimination phase is a modified translation of the original immunosurveillance 
hypothesis, involving the detection of molecular indicators of neoplastic transformation 
secreted or expressed on the surface of each cell. Collaboration between specific components 
of the innate and adaptive immune systems promotes the establishment of a response specific 
for these aberrant markers, and the targeted elimination of susceptible tumour cells. 
Eradication brings the process to completion, the desired homeostatic outcome; however, 
tumour cells may evade detection through a variety of mechanisms, persistence establishing 
a dynamic equilibrium. Under the influence of selective pressure from the immune system, 
this equilibrium phase drives genetic and phenotype evolution of the tumour by eliminating 
susceptible progeny. The surviving population may become poorly immunogenic, or even 
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induce a tolerogenic phenotype amongst infiltrating leukocytes [116]. Proliferation of these 
immunoevasive tumour cells induces the final phase, escape, resulting in the formation of a 
clinically recognisable neoplasm (Figure 1.4). This mechanism brings to light several 
sobering truths regarding tumourigenesis, that subclinical neoplastic transformation may be 
a relatively common phenomenon controlled by immunosurveillance, and that a clinically 
relevant tumour represents an inherent or induced failure in immune function. 
 
 
Figure 1.4 The Immunoediting Hypothesis 
The immunoediting hypothesis encompasses three distinct phases during which the immune system responds 
to neoplastic transformation of cells, and the formation of a solid tumour mass. These phases include the 
elimination phase (A), in which detection of aberrant markers triggers detection of tumour cells by initially the 
innate, and then the adaptive immune systems. During this phase, susceptible tumour cells are eliminated, 
driving divergent evolution of the tumour. Failure to thrive can result in complete elimination of the tumour at 
this stage, and prevention of tumour persistence. However, if some of the tumour cells can adapt and survive, 
this interaction progresses to the equilibrium phase (B). During this phase, susceptible tumour cells continue to 
be eliminated, but resistant tumour cells compete through defensive mechanisms such as masking immunogenic 
molecules, or producing anti-inflammatory cytokines. Once the anti-tumour immune response subdues, the 
tumour reaches the escape phase (C), in which it proliferates to form a continuously growing tumour mass 
[116]. 
 
1.2.1 Innate Immune Response 
The innate immune system encompasses all immune cells and molecules with the capacity 
to detect and respond to an acute infection from a novel source. This response is generally 
non-specific, inflammatory, and rapid, conferring immediate protection to the host, but 
without generating memory. The innate immune system is not unique to vertebrates, and 
includes the restriction modification system in bacteria, the prophenoloxidase system in some 
invertebrates, and antimicrobial peptides produced by various organisms. In humans, the 
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primary components of the innate immune system that are involved in tumour immunoediting 
are sentinel mononuclear leukocytes such as macrophages and dendritic cells, and natural 
killer (NK) cells; however, complement proteins and polymorphonuclear (PMN) leukocytes 
can play a role in tumourigenesis. Normal cells in the body have inherent self-protection 
mechanisms against aberrant activation and recognition from the innate immune system. 
Unfortunately these mechanisms may be retained or even amplified in tumour cells, such as 
overexpression of membrane-bound complement regulatory proteins including CD46, CD55 
and CD59 [117, 118]. This added protection is beneficial, as the tumour microenvironment 
may be skewed towards complement activation, as demonstrated with immunofluorescently 
labelled C3 cleavage products bound along the tumour vasculature in a TC-1 syngeneic 
murine model of cervical cancer [119]. These complement cleavage products were found to 
originate from the classical pathway of activation, due to concordance in C1q and C3 
distribution in engrafted tumours, possibly due to localisation of complement activating 
immunoglobulins, or direct C1q deposition. Counterintuitively, complement activation has 
been suggested to promote tumourigenesis, based on impaired tumour growth in C3 deficient 
mice. Administration of a peptidic C5a receptor antagonist generated a similar effect, 
suspected to impair the formation of an immunosuppressive tumour microenvironment, 
which is usually mediated by C5a-based recruitment of myeloid-derived suppressor cells 
(MDSCs) [119]. 
 
1.2.1.1 Danger Signals 
The distribution of sentinel mononuclear leukocytes differs between tissues, but they each 
universally express a repertoire of non-specific receptors for detecting various groups of 
molecules commonly associated with specific types of infection. The Toll-like receptors 
(TLRs) are a group of pattern recognition receptors (PRRs) that recognise pathogen-
associated molecular patterns (PAMPs). They are evolutionarily conserved amongst 
vertebrates and invertebrates, and derivative forms can even be identified in bacteria and 
plants. TLRs compose an assortment of related receptors categorized into groups that 
recognise molecules associated with potential infectious agents, such as double-stranded 
RNA (TLR3) [120] and flagellin peptide (TLR5) [121]. Some TLRs can also be stimulated 
by components of degenerative tumour cells, such as DNA, RNA and nucleic acid 
degradation products [122], heat shock proteins [123, 124], uric acid [125] and high mobility 
group box-1 (HMGB1) nuclear protein [126]. HMGB1 detection is dependent upon TLR4, 
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with abnormal TLR4 expression accelerating metastatic progression in patients with 
anthracycline-treated breast cancer [127]. Stimulation of TLRs induces the release of 
inflammatory cytokines such as IL-12 and TNF-α, in addition to up-regulating expression of 
chemokine receptors such as CCR2, CCR5 and CCR7, and co-stimulatory molecules such as 
CD40, CD80 and CD86 [128]. 
The inflammasome complex consists of members of another PRR family, Nod-like receptors 
(NLRs), specifically NLRP1, NLRP3 and NLRC4 [129]. Inflammasome complexes formed 
from each of these proteins have been implicated in host defence against specific pathogens, 
including responses to Bacillus anthracis mediated by the NLRP1 inflammasome [130, 131], 
responses to Gram-negative bacteria mediated by the NLRC4 inflammasome [132-134], and 
responses to several species of bacteria, viruses and fungi mediated by the NLRP3 
inflammasome [135-137]. The NLRP3 inflammasome has also been implicated in some roles 
associated with cancer. Extracellular (ATP), such as that released by necrotic tumour cells, 
can be detected by dendritic cells through the P2X7 receptor, resulting in activation of the 
NLRP3 inflammasome complex [138]. This complex regulates IL-1B secretion from 
dendritic cells, which is associated with priming of naïve CD8+ T cells to secrete IFN-γ [139, 
140]. Interference with any step in this pathway has been demonstrated to detrimentally 
influence the immune response to oxaliplatin-treated tumour cells, highlighting the 
importance of the role of the NLRP3 inflammasome in this process [139]. The NLRP3 
inflammasome has also been implicated in dampening the inflammatory processes involved 
in colitis and colitis-associated cancer, acting as a negative regulator of tumourigenesis [141]. 
The final class of PRRs are the RIG-1-like receptors (RLRs), including laboratory of genetics 
and physiology 2 (LGP2), melanoma differentiation-associated gene 5 (MDA5) and retinoic 
acid-inducible gene (RIG-1). RLRs are RNA helicases, screening the cytoplasm for viral 
RNA, and inducing a type-1 interferon-mediated anti-viral response [142, 143].  
Through the pathological process associated with tumourigenesis, additional receptors 
present on the surface of innate immune cells can be stimulated. Damage-associated 
molecular patterns (DAMPs) released amidst the necrotic core of some tumours can trigger 
inflammatory processes and amplified recruitment of immune cell populations. DAMPs are 
important inducers of haematopoietic stem cell mobilization, and include mitochondrial 
DNA, formylpeptides, and ATP [144, 145]. Tumours themselves may also originate in a site 
of chronic inflammation induced by an infectious pathogen, or induced by alternative 
intrinsic factors. The inflammatory environment of each tumour differs depending on the 
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release of proinflammatory mediators by tumour or supporting stromal cells, and the presence 
of tissue damage, pathogens or commensal organisms. A proinflammatory wound-healing 
microenvironment predominated by M2 macrophages and T helper (TH) 2 cells promotes 
tumourigenesis and angiogenesis, and decreases expression of intracellular adhesion 
molecules, which can facilitate invasion of surrounding tissues [146, 147]. Local tumour-
associated inflammation is also associated with systemic comorbidities of cancer, such as 
anorexia, cachexia and immunosuppression [148]. Chronic inflammation can promote 
tumourigenesis by inducing genomic instability and DNA damage by increasing levels of 
reactive oxygen species, and may increase the rate of genetic and epigenetic mutations [149]. 
Some tumours can even directly influence haematopoiesis to skew immune cell populations 
by producing regulatory signalling molecules such as GM-CSF [147, 150]. 
 
1.2.1.2 Tumour-associated Macrophages 
Tumour-associated macrophages (TAMs) are a negative prognostic marker for multiple 
cancer types, including bladder cancer [151, 152], breast cancer [153, 154], CRC [155, 156], 
kidney cancer [157] and melanoma [158, 159]. When activated, macrophages may diverge 
towards either of two bipolar phenotypes with generally opposing functions, the M1 and M2 
phenotypes. Although these phenotypes appear starkly contrasted, recent evidence suggests 
that they may actually represent the polar ends of a broad phenotypic spectrum, with 
respecialisation of macrophages possible, and multiple intermediate phenotypes. M1 
macrophages are characterised by the expression of nitric oxide synthase 2 (NOS2) and pro-
inflammatory cytokines such as IL1β, IL6, IL12, IL23 and TNF-α. M1 macrophages are 
bactericidal, and promote anti-tumour immune function. M2 macrophages have completely 
opposing activity, promoting tissue repair and tumour progression. Although macrophages 
involved in the innate immune response to initial tumour formation may be proinflammatory 
[160], resident macrophages in established tumours are converted to promote tumourigenesis 
[161, 162].  
The tumour microenvironment is predominantly biased towards TH2 cells, characterised by 
the production of transforming growth factor (TGF) β1, arginase 1, and infiltration with CD4+ 
T cells [163]. Within this environment TAMs become polarised towards an M2 phenotype 
through production of molecules such as IL-4 from TH2 cells [164, 165], and growth factors 
such as colony stimulating factor 1 (CSF-1) and GM-CSF produced by tumour cells [166, 
167]. TAMs secrete (CCL) 20 to recruit natural T regulatory (nTreg) cells in CRC [168], and 
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express both IL-10 and TGF-β, stimulating upregulation of forkhead box (FOX) P3 
expression in CD4+ T cells and promoting an induced T regulatory (iTreg) phenotype [162, 
169-171]. The role of iTreg cells in CRC is heavily debated, as they appear to dampen both 
CRC-promoting inflammation, while also inhibiting anti-tumour immunity. Local production 
of IL-10 and TGF-β by TAMs can also impair cytotoxic T lymphocyte function, and inhibit 
TH1 and TH2 cell activity [172, 173]. TAMs can also deplete L-arginine in their local 
microenvironment by secreting arginase 1, producing urea and L-ornithine [174, 175]. 
Depletion of L-arginine inhibits re-expression of the CD3 ζ chain following internalisation 
from TCR signalling, impairing T cell function [176, 177]. 
 
1.2.1.3 Dendritic Cells 
There is a broad variety of DC populations throughout the body, some of which are 
specialised for canonical DC roles such antigen processing and presentation. Although most 
DCs originate from monocytes in humans [178], alternative progenitors are a more common 
source of DCs in mice [179, 180]. There are two major subsets of DCs, conventional DCs 
(cDCs) and plasmacytoid DCs (pDCs). While both subsets share common progenitors, their 
differentiation, morphology, markers and functions are distinct. In mice, cDCs can be sub-
classified as migratory DCs such as Langerhan cells, CD103+ dermal DCs and CD11b+ 
dermal DCs, and lymphoid resident DCs such as CD4+ DCs, CD8α+ DCs and CD8α-/CD4- 
DCs [181]. In humans, dermal DCs can also be classified into subsets that include CD1a+ 
DCs, CD14+ DCs, and CD141+ DCs [182]. pDCs share morphological characteristics with 
their namesake, plasma cells, express TLR7 and TLR9, and produce IFN-α following 
activation [183]. Abnormal myelopoiesis in cancer patients results in reduced production of 
functionally competent DCs, increased production of immature myeloid cells, and increased 
tumour infiltration with immature DCs [184]. The tumour microenvironment also impairs 
DC function due to hypoxia, and accumulation of extracellular adenosine and lactate [185, 
186]. Upregulation of hypoxia-inducible factor 1α (HIF1α) in DCs in this hypoxia tumour 
microenvironment promotes TH2 cell activation [187], while the presence of adenosine 
increases expression of vascular endothelial growth factor (VEGF), IL-6, IL-8, IL-10, 
cyclooxygenase (COX)-2, TGF-β and indoleamine 2,3-dioxygenase (IDO) [188]. Major 
histocompatibility complex (MHC)-II+, CD11b+, CD11c+ tumour-infiltrating DCs can 
actively suppress CD8+ T cells by producing arginase 1, a mechanism usually associated 
with TAMs and MDSCs [189]. IDO-expressing DCs can accumulate in some cancers [190, 
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191], depleting L-tryptophan, promoting T cell apoptosis, and enhancing the suppressive 
abilities of FOXP3-expressing Treg cells [192]. 
 
1.2.1.4 Granulocytes 
Granulocytes are characterised by the presence of cytoplasmic granules, the most common 
granulocyte being PMN leukocytes, also known as neutrophils. Mature granulocytes can 
infiltrate human tumours, and may promote tumour angiogenesis and metastasis [193-196]. 
Tumour cells and associated stromal cells can attract neutrophils by producing cysteine-X-
cysteine (CXC) chemokines and prokineticin 2 [197, 198]. Granulocytes may promote 
angiogenesis by expressing matrix metalloproteinase (MMP)-9, which induces VEGF 
expression in tumour cells [199]. Release of elastase can also degrade insulin receptor 
substrate 1 (IRS1), facilitating interactions between phosphoinositide 3-kinase (PI3K) and 
platelet-derived growth factor (PDGF) to promote proliferation of tumour cells [200]. Like 
macrophages, neutrophils can also shift between two polarised pro-tumour and anti-tumour 
phenotypes. TGF-β induces neutrophils to assume a pro-tumour N2 phenotype, expressing 
arginase 1, and reducing expression of TNF, CCL3 and intercellular adhesion molecule 
(ICAM) 1. Depletion of these N2 neutrophils can increase CD8+ T cell activity in tumour-
bearing animals [201]. 
 
1.2.1.5 Myeloid-derived Suppressor Cells 
In mice, MDSCs are defined as CD11b+ and GALEX release 1 (Gr1)+, markers of monocytic 
and granulocytic origin [202]. These cells can suppress T cell responses, and block DC 
maturation. The majority of MDSCs have a granulocytic or polymorphonuclear phenotype 
(PMN-MDSCs) characterised by expression Ly6G, while the remaining Ly6C+, Ly6G- 
MDSCs are termed monocytic MDSCs (M-MDSCs). M-MDSCs are significantly more 
immunosuppressive than their polymorphonuclear counterparts, and are associated with 
suppression of T cell activation through production of arginine 1 and inducible nitric oxide 
synthase (iNOS) [203-206]. M-MDSCs also express varying levels of classical monocytic 
markers, including F4/80, CD115, Ly6B and CCR2 [207]. Although M-MDSCs are similar 
to inflammatory monocytes in phenotype and morphology, these populations are functionally 
distinct. Similarly, PMN-MDSCs are functionally distinct from neutrophils, predominantly 
immunosuppressive with reduced phagocytic and chemotactic activity, increased expression 
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of arginine 1 and myeloperoxidase, higher expression of CD115 and CD244 and reduced 
expression of CXCR1 and CXCR2 [208, 209]. 
MDSC immunosuppressive activity is facilitated by a range of mechanisms. L-arginine and 
L-cysteine depletion induces downregulation of the CD3 ζ chain, inducing proliferative arrest 
of antigen-stimulated T cells [177, 210]. Production of reactive oxygen species (ROSs) and 
reactive nitrogen species such as hydrogen peroxide and peroxynitrite enable MDSCs to 
interfere with IL-2 receptor signalling [211], and can induce desensitisation of the T cell 
receptor [212]. Expression of a disintegrin and metalloproteinase domain 17 (ADAM17) on 
the surface of MDSCs decreases CD62L expression on naïve CD4+ and CD8+ T cells, 
limiting recirculation of T cells back to the lymph nodes [213]. Peroxynitrite-induced 
modification of CCL2 can also impair infiltration of CD8+ T cells into the tumour core [214]. 
Surface expression of galectin 9 on MDSCs can directly induce T cell apoptosis through 
binding to mucin domain-containing protein (TIM) 3. MDSCs also promote the clonal 
expansion of nTreg cells, and can convert naïve CD4+ T cells into iTreg cells [215]. While 
suppression by MDSCs in peripheral lymphoid organs is predominantly antigen-specifc, 
requiring antigen presentation by MDSCs and direct contact with T cells, within the tumour 
microenvironment MDSCs can function antigen-nonspecifically [212, 216, 217]. MDSCs 
can also hinder macrophage and dendritic cell function by producing IL-10, and impairing 
production of IL-12 [218, 219]. 
 
1.2.1.6 Natural Killer Cells 
Similar to other lymphocyte populations, NK cells express a complex assortment of both 
stimulatory and inhibitory cell surface receptors that activate competitive counteractive 
signalling mechanisms to regulate activation in response to stimuli. Other than their aptly 
named natural cytotoxicity receptors, NK cells also express the variant human leukocyte 
antigen (HLA)-E detecting receptor CD94, and the Ig receptor CD16. The primary inhibitory 
signalling receptor are the killer-cell immunoglobulin-like receptors (KIRs) with 
immunoglobulin-like extracellular domains for interacting with classical MHC-I (HLA-A, -
B and -C) and nonclassical HLA-G. Additional inhibitory signals can also be mediated by 
leukocyte inhibitory receptors (LIRs) and inhibitory isoforms of Ly49. The interactions 
between these receptors and their signalling pathways is orchestrated to enable NK cells to 
respond to both elevated expression of stimulatory ligands, and downregulated expression of 
the MHC-I receptor [220, 221]. Overexpression of stimulatory ligands can be induced by 
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neoplastic transformation and stress-induced DNA damage, while downregulation of MHC-
I expression is a mechanism of immunoevasion shared between both tumour cells and some 
viral infections [222]. Either the loss of inhibitory stimuli through detection of MHC-I, or the 
presence of overwhelming stimulatory signals can induce NK cell activation [223, 224]. Once 
activated, NK cell-mediated apoptosis of target cells is induced through the same 
mechanisms as in other cytotoxic lymphocyte populations, including secretion of granzyme 
and perforin, stimulation of death receptors such as TNF-related apoptosis-inducing ligand 
(TRAIL) or Fas, or through release of IFN-γ [225]. 
 
1.2.1.7 Natural Killer T Cells 
NKT cells are a population of T cells that share both the properties of T cells and NK cells. 
NKT cells are thought to contribute to immune surveillance for tumours in a similar fashion 
as NK cells [226, 227]. There are two types of NKT cells, type I NKT (iNKT) cells, which 
express the invariant Vα24Jα18 TCR in humans and Vα14Jα18 TCR in mice [228], and type 
II NKT cells with more variant TCRs. iNKT cells recognise lipids and glycolipids presented 
on the non-classical MHC protein CD1d. They can recognise and respond to exogenous 
glycolipids such as α-galactosylceramide, endogenous glycolipids such as 
isoglobotriosylceramide, and tumour-associated gangliosides such as ganglioside precursor 
disialohematoside 3 (GD3) [229]. When activated, iNKT cells upregulate expression of 
CD25, the IL-2 receptor α-chain, and CD69, as well as the cytokines IL-2, IL-4 and IFN-γ 
[230]. While iNKT cells are an important component of an anti-tumour immune response, 
especially through co-ordination of NK cells and CD8+ T cells through secretion of IFN-γ 
[231, 232], and cross-licensing of CD8+ DCs [233], type II NKT cells have been implicated 
in an immunosuppressive role [234, 235]. 
 
1.2.1.8 Mucosal Associated Invariant T Cells 
Mucosal associated invariant T (MAIT) cells are a form of T cell with innate-like properties, 
expressing a semi-invariant TCR. Tissue-infiltrating and circulating MAIT cells can be 
characterised based on the expression of CD161 or IL-18Rα on their surface, along with the 
Vα 7.2 TCR chain [236, 237]. The semi-variant TCR on MAIT cells can recognise microbial 
vitamin B metabolites presented on MHC-related protein 1 (MR1) [238, 239]. When 
activated, MAIT cells produce IFN-γ, TNF-α and IL-17A [240]. MAIT cells are 
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predominantly found in the lamina propria of the intestines, and are thought to provide innate 
protection against infection and inflammation. MAIT cells have been identified to provide 
protection against inflammatory bowel disease in humans [241], and confer protection 
against a range of infectious pathogens [242, 243]. Recent studies have found that MAIT 
cells infiltrate into the tumours of CRC patients, with a corresponding reduction in the 
circulating population. Based on this finding, MAIT cells have been proposed to have a role 
in surveillance of mucosal-associated cancer [244, 245]. Further work is required in order to 
fully elucidate the role of MAIT cells in CRC. 
 
1.2.3 Adaptive Immune Response 
The adaptive immune system is a shared feature amongst jawed vertebrates, and its activity 
is mediated through specific populations of lymphocytes. These lymphocyte populations 
possess recombination-activating genes (RAGs), responsible for rearranging their 
corresponding antigen receptor such as those encoded by the immunoglobulin (Ig) and T cell 
receptor (TCR) genes. Rearrangement of the sequences encoding the variable domains of 
these proteins generates sufficient combinations to enable the adaptive immune system to 
theoretically respond to any antigenic sequence in nature; however, each individual 
combination is only capable of binding a single antigen. This combination of broad coverage 
and high specificity allows the adaptive immune system to respond to any potential pathogen, 
but may be incapable of facilitating immediate protection against infection from a different 
strain of the same pathogen. An adaptive immune response induced against tumour cells 
follows identical rules, facilitated by detection of neo-antigens or tumour-associated antigens 
(TAAs) processed and presented on the surface of the tumour cells themselves, or APCs.  
Neo-antigens are tumour-specific, and can include mutagenic proteins or oncogenic viral 
proteins [246, 247]. TAAs on the other hand are otherwise normal ‘self’ molecules that are 
abnormally expressed by tumours, such as markers of differentiation (e.g. tyrosinase), 
cancer-testis antigens (e.g. oesophageal cancer antigen (ESO), melanoma antigen (MAGE)), 
oncofetal antigens (e.g. carcinoembryonic antigen (CEA), α-fetoprotein (αFP)) and various 
overexpressed proteins (e.g. p53, human epithelial growth factor receptor 2 (HER2)) [248-
251]. As TAAs represent inherently normal self-antigens, recognition by the adaptive 
immune system is usually suppressed through central deletion of reactive T cells in the 
thymus, or peripheral tolerisation [252]. Antigen recognition can also be hampered by 
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variability between HLA haplotypes [249, 253] and antigenic strength [254, 255], with 
relatively weak, cryptic antigens requiring prolonged exposure at an elevated concentration 
to induce a potent immune response [256].  
 
1.2.3.1 Antigen Presentation 
APCs such as macrophages, dendritic cells and B cells actively sample their local 
microenvironment for potential antigenic molecules through non-specific internalisation 
mechanisms such as phagocytosis and macropinocytosis. Specific molecules can also be 
internalised through receptor-mediated endocytosis by binding to receptors present on the 
surface of APCs, such as the Fc receptor for binding the fragment crystallisable (Fc) region 
of antibodies, C-type lectin receptors, and various scavenging receptors. Upon formation of 
a phagosome or endosome, ingested materials are exposed to degradative enzymes from 
fusion with a lysosome. Proteases activated by acidification of the resulting phagolysosome 
cleave proteins, liberating short peptide chains. These enzymes also cleave the invariant chain 
complexed with MHC-II along the internal surface of the phagolysosome, producing a short 
peptide called class II-associated invariant chain protein (CLIP) that binds to the peptide-
binding domain of MHC-II. HLA-DM subsequently facilitates the excision of CLIP from the 
groove, replacing it with peptides processed from endocytosed material [257, 258]. Fusion 
of the phagolysosome with the cell membrane results in presentation of the processed 
exogenous peptides loaded in MHC-II on the surface of APCs, recognisable by antigen-
specific CD4+ T cells.  
While predominantly only dedicated APCs are responsible for presenting exogenous antigens 
on MHC-II, all nucleated cells have the capacity to monitor their own intracellular 
microenvironment for endogenous antigens. Endogenous antigens are routinely degraded by 
the proteasome in the cytoplasm, marked for degradation through tagging processes such as 
ubiquitination. These can consist of any proteins translated by the cell, including viral 
proteins, tumour-associated antigens and normal self-antigens. Degraded endogenous 
antigens are transported to the endoplasmic reticulum (ER) by the transporter associated with 
antigen processing (TAP). MHC-I molecules can be found along the inner surface of the ER, 
complexed with β2-microglobulin. Peptides derived from endogenous antigens are loaded 
onto MHC-I by a peptide loading complex, which includes the chaparones calreticulin and 
tapasin, the thiol-oxidoreductase ERp57, and TAP [259]. Loaded MHC-I molecules are 
packed into vesicles, and sent to the cell membrane through the Golgi. Fusion of the vesicle 
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with the cell membrane and exocytosis results in the display of peptide loaded MHC-I on the 
surface of the cell, recognisable by antigen-specific CD8+ T cells. 
 
1.2.3.2 Cross-presentation 
Cross-presentation is the process of presenting exogenous antigens on MHC-I rather than 
MHC-II. This mechanism has primarily been studied in dendritic cells, but has also been 
identified in macrophages [260], B cells [261] and sinusoidal endothelial cells [262]. Cross-
presentation is important for providing protection against intracellular infections, and cellular 
abnormalities such as neoplastic transformation. Known mechanisms of cross-presentation 
include the endosome-to-cytosol pathway, ER-endosome fusion, the CD74-dependant 
pathway, and the receptor-recycling pathway (Figure 1.5) [263].  
 
 
Figure 1.5 Cross-presentation Pathways  
APCs cross-present epitopes derived from exogenous antigen onto MHC-I through multiple pathways 
including: (A) Gap Junctions; (B) Endosome-to-cytosol Pathway; (C) ER-Endosome Fusion; (D) CD74-
dependent Pathway; (E) Receptor Recycling; and (F) Exosomes. Adapted from Groothuis et al 2005 [264]. 
 
Internalised exogenous antigens can enter the cytoplasm through the endosome-to-cytosol 
pathway, undergoing proteasomal degradation and entering the MHC-I loading pathway 
through TAP [265, 266]. ER-endosome fusion bypasses both the proteasome and TAP, 
enabling direct loading of degraded proteins from the endosome onto MHC-I in the ER. 
CD74 is an invariant chain chaperone that escorts MHC-I molecules from the ER to 
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endolysosomes through intervening vesicles, and even facilitates the loading of MHC-I with 
exogenous antigen [263]. Completely independent of ER localised MHC-I, the receptor 
recycling pathway of cross-presentation can retrieve MHC-I molecules from the cell 
membrane, reload them with new peptides and return the MHC-I exogenous antigen complex 
to the cell surface. Additionally, mechanisms of sharing antigenic material between cells, 
such as gap junctions and formation of exosomes, can also indirectly facilitate cross-
presentation of antigen. 
 
1.2.3.3 Antigen Cross-Dressing 
In addition to processing exogenous and endogenous antigen for presentation through both 
the standard antigen presentation and cross-presentation pathways, there is a third mechanism 
through which APCs may present antigen. This process has been termed antigen cross-
dressing, as it involves APCs acquiring the preloaded MHC molecules from the surface of 
other cells, and displaying them on their own surface. It is important to note that this process 
is not unique to professional APCs, as the original study identifying intercellular transfer of 
MHC molecules observed the transfer of MHC-II from B cells to T cells [267]. The transfer 
of MHC between cells can be mediated by a process known as trogocytosis, the intercellular 
transfer of plasma membrane and anchored proteins between cells that come into close 
contact [268], such as during the formation of an immunological synapse. Alternatively, 
antigen cross-dressing can occur due to the phagocytosis of exosomes containing preloaded 
MHC molecules [269], or it can be mediated through the exchange of surface membrane 
proteins by tunnelling nanotubes [270]. The exchange of MHC molecules between cells has 
been observed between APCs and T cells, APCs and other APCs, epithelial cells and APCs, 
and even between tumour cells and APCs [269, 271, 272]. This last interaction is of particular 
interest, as it highlights an inherent alternative mechanism through which APCs may directly 
acquire tumour-associated antigens from tumour cells. 
 
1.2.3.4 Activation of CD4+ T Helper Cells 
In concert with the recognition of a specific antigen, cells of the adaptive immune system 
also require additional stimuli to indicate underlying abnormality, such as active infection or 
inflammation. CD4+ T cells are dependent upon the ability of APCs to recognise danger 
signals such as PAMPs and DAMPs, and upregulate the expression of co-stimulatory 
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molecules. APCs harbouring tumour antigens and activated by PAMPs/DAMPs drain from 
the tumour site through the lymph, entering the nearest draining lymph node through the 
subcapsular sinus perculates at the cortex. Interactions between APCs and T cells occur 
primarily within the lymph node paracortex [273], and are initially stabilised by cell-adhesion 
molecules, such as CD2, lymphocyte function-associated antigen (LFA)-1 and ICAM-3 on 
the surface of T cells, which bind to CD58, ICAM-1/2 and DC-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) on the surface of APCs respectively. Priming 
of CD4+ T cells is a biphasic process, beginning with the detection of antigen loaded in MHC-
II on the surface of an APC through the CD4+ T cell’s TCR, and completed by a cytokine-
driven polarisation phase that ultimately determines the phenotype of the active T cell. There 
are currently seven discernible subsets of CD4+ T cells, T helper (TH) 1, TH2, TH9, TH17, 
TH22, T follicular helper (TFH) cells and T regulatory (Treg) cells. Each CD4
+ T cell subset 
has its own characteristic gene expression and cytokine secretion profile, as illustrated in 
Figure 1.6. TH1 cells are predominantly involved in the cell-mediated arm of the adaptive 
immune system, while TH2 and TFH cells favour the humoral arm. TH9 cells are a pro-
inflammatory subset of CD4+ T cells [274, 275], with roles in tumour and parasite immunity 
identified in mice [276-278], and a potential penchant for fungal infection and dermatitis in 
humans [279, 280]. TH17 cells have roles in inflammatory disease processes [281-283], and 
fungal infections [284], while TH22 cells are a recently described variant that do not produce 






Figure 1.6 Subsets of CD4+ T Cells 
Upon activation following recognition of antigen/MHC-II complexes presented by APCs, naïve CD4+ T cells 
can differentiate into any of five distinct subsets of T helper cells. Which subset the CD4+ T cell will 
differentiate into is determined the factors involved in their activation, in addition to stimulation of particular 
activation pathways induced by specific cytokines present in the local microenvironment. These subsets include 
the classical TH1 and TH2 cells, induced through expression of either T-bet or GATA-3 respectively. 
Alternatively, naïve CD4+ T cells can differentiate into TH17 cells through induced expression of RORγt, iTreg 
cells through induction of FoxP3 expression, or TFH cells through induction of Bcl-6 expression. Adapted from 
Yamane et al 2013 [288-291]. 
 
Polarisation of CD4+ T cells begins with the strength of TCR signalling, with weak signalling 
favouring TH2 differentiation, while strong signalling promotes a TH1 phenotype [292]. 
Transient activation of extracellular receptor kinase (ERK) with weak TCR signalling 
induces expression of GATA-binding factor (GATA)-3 and production of IL-2, which in turn 
activates STAT5. These weakly stimulated T cells differentiate into TH2 cells, producing IL-
4 and retaining STAT5 activation [293]. Strong TCR signalling prevents this early GATA-3 
expression and suppresses STAT5 activation, with persistent ERK activation and endogenous 
production of IL-12 facilitating differentiation into TH1 cells. Differentiation of naïve CD4
+ 
T cells into TH17 cells is a multistep process, initiated by the presence of TGF-β and IL-6 
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during TCR stimulation. This combination induces expression of IL-23R and RAR-related 
orphan receptor (ROR)γt, and secretion of IL-17A, IL-17F and IL-21 [294-297]. IL-21 
synergises with TGF-γ to continue IL-17 production, dependent on STAT3. Naïve CD4+ T 
cells under similar conditions but with weak TCR stimulation express FoxP3 rather than IL-
23R and RORγt, promoting differentiation into iTreg cells [298-300]. TFH cells are essential 
for the formation of germinal centres [301-303], and support B cells during differentiation 
into memory or plasma cells [304]. 
In addition to signalling through the TCR, naïve CD4+ T cells require additional signals to 
activate completely, such as from co-signalling molecules and cytokines. Co-signalling 
molecules are predominantly members of either the immunoglobulin superfamily (IgSF) or 
the tumour necrosis factor receptor superfamily (TNFRSF), and can serve as either co-
stimulatory or co-inhibitory molecules. The IgSF group includes various receptor subfamilies 
such as CD28, B7, CD226, TIM, CD2, butyrophilin (BTN) and leukocyte-associated 
immunoglobulin-like receptor (LAIR), each containing multiple co-signalling molecules of 
various functions, including notable examples including CD28, cytotoxic T-lymphocyte-
associated protein (CTLA) 4, programmed cell death protein (PD) 1, PD ligand (PDL) 1 and 
CD80 [305]. Amongst the TNFRSF are subfamilies such as Type-V, Type-L and Type-S, 
with notable examples including CD137 (4-1BB), CD134 (OX40), CD27, glucocorticoid-
induced TNFR-related protein CD357 (GITR), Fas cell surface death receptor (FAS), CD40 
and TRAIL receptor (TRAILR) 1-4. The most well described co-signalling molecule 
interaction is that of CD28 with the B7 family of receptors. Binding between CD28 expressed 
on the surface of naïve CD4+ T cells and CD80/86 on the surface of an APC provides 
stimulatory signals that promote the activation of both cells [306]. This signalling interaction 
can be disrupted by expression of CTLA4 on the surface of the CD4+ T cell, which competes 
with CD28 for CD80/86 binding, and produces signals that inhibit activation. The net ratio 
of stimulatory to inhibitory signals amongst all co-signalling molecules involved determines 
whether the CD4+ T cell will be activated. The modality of stimulation, combined with co-
stimulation and cytokine signalling determines the type of T helper cell generated, or whether 





1.2.3.5 Activation of CD8+ T Cells 
The activation of CD8+ T cells follows the same essential steps as has been described for 
CD4+ T cells, including the recognition of antigen, and signalling through co-signalling 
molecules and cytokines. In this instance, the TCR of the CD8+ T cells recognises antigen 
loaded onto MHC-I, forming an interaction stabilised by CD8. The CD8+ T cell requires 
further stimulation in the form of co-stimulatory molecule interactions such as between CD28 
and CD80/86, and stimulation with cytokines such as IL-2, TNF-α and IFN-γ. These 
cytokines can be supplied by activated TH1 cells, a means of ‘help’ provided to induce 
proliferation and differentiation of the CD8+ T cell into a cytotoxic T cell (TC). CD8
+ T cells 
that do not receive appropriate co-stimulation, particularly from IL-2, will become anergic 
and non-responsive [307]. Similar to T helper cells, TC cells can be separated into three 
subsets as defined by their surface marker expression, cytokine profile and effector function. 
These subsets are TC1, TC2 and TC17 [308, 309], each of which are comparable with their T 
helper cell counterpart in regards to their primary differentiation regulator gene, cytokine 
profile, and function. Activated effector TC cells can induce apoptosis in target cells through 
either of two mechanisms, the calcium-independent Fas/Fas-L-mediated pathway, and the 
calcium-dependent perforin/granzyme-mediated pathway [310]. Both of these pathways are 
activated through engagement of the TC cells TCR with its specific epitope loaded MHC-I 
on the surface of target cells. Upon engagement, Fas-L molecules on the surface of the TC 
cell bind to Fas molecules on the target cell, inducing caspase-dependent apoptosis. This 
pathway is also utilised in the maintenance of lymphocyte homeostasis, and in the regulation 
of lymphocyte proliferation. The TCR-epitope-MHC-I interaction also stimulates the 
exocytosis of lytic granules from the TC cell, which contain cytotoxic effector molecules 
including serglycin, perforin and granzyme. Serglycin is a proteoglycan that acts as a scaffold 
for the cytotoxic perforin-granzyme complex. Perforin forms pores in the cell membrane of 
the target cells, facilitating entrance of granzyme. Granzyme is a serine protease capable of 
inducing apoptosis in the target cell. TC cell effector function can also be mediated through 
the release of cytokines, including IFN-γ, TNF-α and TNF-β [311]. 
In addition to becoming effector TC cells upon activation, CD8
+ T cells also have the capacity 
to become memory T cells. There are two primary described subsets of memory T cells, 
applicable to both CD4+ T cells and CD8+ T cells. These two subsets are T central memory 
(TCM) and T effector memory (TEM) cells, distinguishable based on differences in cell surface 
molecule expressions and effector function [312]. TCM cells express CCR7 and CD62L on 
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their surface and can localise to the lymph nodes, while TEM cells are devoid of these 
expression markers and localise to non-lymphoid tissues. Both subsets can be found in the 
spleen and circulating in the blood [313, 314]. While TCM cells are capable of expansive 
proliferation and produce IL-2, TEM cells are generally less proliferative and produce IFN-γ. 
A third subset of memory T cells that permanently reside in peripheral tissues has recently 
been described, and has been termed T tissue-resident memory (TRM) cells [315, 316]. TRM 
cells share the absence of CD62L and CCR7 surface expression with TEM cells, but also 
notably express CD69 and CD103. Memory T cells respond more rapidly when exposed to 
their specific antigen epitope loaded on MHC-I [317, 318]. 
 
1.2.3.6 Suppression of Effector T Cells 
The efficacy of T effector (Teff) cells upon reaching the tumour is largely dependent on the 
immune microenvironment. Infiltration with suppressive immune cell populations such as 
IL-10 secreting CD4+/CD25+/FoxP3+ T regulatory (Treg) cells, CD1d-restricted NKT cells, 
immature dendritic cells, pDCs and MDSCs can significantly impair Teff function in the local 
tumour microenvironment [212, 319, 320]. Further suppression is induced through 
expression of various inhibitory molecules such as PD-L1, B7x, CD276 (B7-H3), HLA-E 
and HLA-G [321-323], or by release of suppressive factors such as TGF-β, VEGF, IL-10 and 
gangliosides [324-326]. Acquired tolerance can be induced in Teff cells through expression 
of IDO by tumour cells or IDO-competent APCs. IDO-competent dendritic cells in particular 
can induce anergy, apoptosis or conversion of Teff cells into iTreg cells [191, 327, 328]. Treg 
cells secrete suppressive cytokines such as TGF-β and IL-35, and can directly suppress Teff 
cell function through contact-dependent mechanisms, potentially mediated through CTLA-4 
expressed on Teff cells [329]. MDSCs employ a complex suppressive mechanism involving 
inducible nitric oxide synthase or arginase-1, inducing apoptosis, inhibiting proliferation, or 
converting Teff cells into iTreg cells [211, 330, 331]. Although these suppressive mechanisms 
are crucial for preventing rampant autoimmunity, they present a major complication in both 





1.2.3.7 T cell Exhaustion 
Exhaustion of T cells was originally observed in CD8+ T cells during chronic lymphocytic 
chorionmeningitis virus (LCMV) infection in mice [332, 333]. The exhaustion phenotype is 
predominantly characterised by increased expression of inhibitory co-signalling molecules 
such as PD-1, CTLA-4, leukocyte activation protein (LAG)-3 and TIM-3 [334]. T cell 
exhaustion is usually observed in association with chronic infection or inflammation, induced 
by the persistence of antigen and inflammatory molecules. As a state of exhaustion develops, 
CD8+ T cells gradually lose effector function. IL-2 production and ex vivo cytolytic activity 
are the first functions lost, followed by loss of TNF-α and IFN-γ production, and the ability 
to degranulate. Terminally exhausted T (TEX) cells are deleted entirely, possibly due to 
overstimulation-induced death [334, 335]. TEX cells can no longer undergo antigen-
independent proliferation, and lose sensitivity to IL-7 and IL-15 [336-338]. PD-1+ tumour-
infiltrating lymphocytes (TILs) have been identified in breast [339], lung [340], ovarian 
[341], prostate [342] and melanoma [343, 344]. These dysfunctional TILs have reduced 
effector function, and may encompass T cells in various stages of exhaustion. Reinvigoration 
of TEX cells is possible, primarily induced using monoclonal antibodies to block inhibitory 
co-signalling molecules, particularly PD-1/PD-L1 [345-347]. PD-1 expression on T cells is 
induced upon activation, regulated by the transcription factors nuclear factor of activated T 
cells (NFAT), T-bet, B lymphocyte-induced maturation protein (Blimp)-1 and FoxO1 [348-
351]. TEX reinvigoration increases proliferation, cytokine production and restores cytolytic 
activity, returning towards normal T effector cell function [345]. 
 
1.2.3.8 Activation of B cells 
B cells are the primary mediator of the humoral arm of the adaptive immune system. Each B 
cell possesses a uniquely constructed receptor on their surface, known as the B cell receptor 
(BCR). The BCR binds to antigen in its native unprocessed form, allowing it to bind to a 
wide range of molecules such as proteins, glycoproteins and polysaccharides, as well as 
binding to the surface components of intact pathogens such as viruses and bacteria [310]. 
Binding of the BCR to its complementary antigen produces stimulatory signals, pre-
activating the B cell. The B cell internalises the BCR-antigen complex and processes the 
antigen through the exogenous pathway, loading epitopes onto MHC-II and presenting them 
on the surface. Activated TH cells capable of recognising these MHC-II-epitope complexes 
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on the surface of the B cell provide secondary activation signals through interactions between 
co-stimulatory molecules, and release of cytokines. 
Activated B cells, also known as plasma cells, secrete antibodies, immunoglobulins with an 
identical variable binding domain to their original BCR. This allows the antibody to bind to 
its complementary antigen in its native form, just as the BCR once did. Antibodies have three 
primary functional roles; neutralisation of toxins and viruses, opsonisation and agglutination 
of extracellular pathogens, and activation of the complement system. All plasma cells initially 
produce class M immunoglobulins (IgM), a pentameric form particularly effective at 
complement activation and extracellular pathogen agglutination. Dependent upon the 
cytokine signals it receives, a plasma cell can switch the class of its antibody to class G 
immunoglobulins (IgG), a monomeric class that predominates in the serum. Further 
stimulation with select cytokines can induce class-switching to enable the production of class 
A immunoglobulins (IgA), a monomeric class that can combine into a dimeric form for 
secretion along mucosal surfaces, or class E immunoglobulins (IgE), a monomeric class that 
bind to the surface of mast cells, capable of triggering mast cell degranulation and histamine 
release during inflammatory processes [310]. There also exists a fifth class of antibody, class 
D immunoglobulins (IgD), but its role is not well understood. It has been suggested that IgD 
antibodies may have a role in basophil activation [352]. 
B cells do not appear to play a major role in the primary immune response to cancer, probably 
limited to their function as an APC. However, antibodies capable of binding specifically to 
receptors on the surface of tumour cells, or that interfere with interactions between inhibitory 
receptors on the surface of immune cells have been extensively studied as a form of 
monoclonal antibody therapy. This type of anti-cancer therapy will be discussed in a later 
section. It is worth noting that there is a population of B cells that has been identified in mice 
that can promote tumour growth by suppressing the immune system [353, 354]. These 
regulatory B (Breg) cells secrete IL-10, and promote the generation of Treg cells [355]. They 
also play a role in suppressing inflammation through restoring balance between TH1 and TH2 
cell responses [354, 356]. Matching populations of Breg cells were also been identified in 
humans [357], and have recently been implicated in promoting immune privilege of cancer 
through PD-1-PD-L1 interactions [358]. 
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1.3 Colorectal Cancer 
CRC refers to the development of a malignant tumour anywhere throughout the colon or 
rectum, arising from the transformation of normal colonic epithelium into colon 
adenocarcinoma. CRC is the third most common cancer amongst men, and the second most 
common amongst women worldwide, with an annual incidence estimated at over 1.36 million 
in 2012, and is accountable for almost 700,000 deaths annually [359]. In New Zealand, it is 
the second most common form of cancer amongst both men and women, with an incidence 
in 2008 of 44.1 and 37.5 per 100,000 people respectively [360]. These rates are more than 
double the worldwide incidence of 20.6 and 14.3 per 100,000 people in men and women 
respectively, and attribute to a mortality rate in New Zealand comparable to both breast and 
prostate cancer combined. This places New Zealand jointly with Australia at the highest rates 
of CRC in the world [359]. Although CRC is more common amongst non-Maori, Maori have 
a higher mortality rate upon diagnosis, possibly due to disparities in access to treatment. The 
incidence rate amongst Maori is also increasing, and may eventually equate their non-Maori 
counterparts if observed trends continue [361]. Notably, 49% of patients diagnosed with CRC 
in New Zealand are already at an advanced stage of the disease, with 24% presenting with 
distant metastases [362]. This gives New Zealand the highest rate of metastatic disease at 
presentation in the world [363]. This rate is even higher amongst Maori and Pacific patients, 
with 32% and 35% respectively. 
 
1.3.1 Familial Colorectal Cancer 
Familial adenomatous polyposis (FAP) and hereditary non-polyposis colon cancer (HNPCC) 
are the two most common inheritable genetic conditions associated with increased risk of 
developing CRC. FAP is predominantly associated with mutations in APC, and manifests as 
the formation of multiple benign polyps throughout the colon. Each polyp has the potential 
to undergo malignant transformation, posing significant risk for recipients of the condition, 
and ensuring the development of CRC within third to fifth decade of life if the colon is not 
excised [35, 364]. As the mean age of CRC is only 36 years amongst patients with FAP [365], 
prophylactic removal of the colon is recommended. Germ-line APC mutations are the most 
common cause of FAP, with over 95% of FAP-associated APC mutations involving 
frameshift or nonsense mutations that prematurely truncate the APC protein during 
translation [365, 366]. Mutations located between codons 1250 and 1464 are associated with 
particularly profuse polyposis, while those N-terminal of codon 157 or near the C-terminus 
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give rise to attenuated polyposis. In addition to FAP-associated CRC, APC mutation or 
inactivation can be found in around 70-80% of sporadic colorectal adenomas and carcinomas 
[366-368]. APC mutations are also associated with several extra-colonic tumours, found in 
the brain in Turcot syndrome, and various connective tissues in Gardner syndrome [365]. 
HNPCC, also known as Lynch syndrome, results from defects in genes of the mismatch repair 
(MMR) system. These mutations induce microsatellite instability, promoting the rapid 
accumulation of somatic mutations [17, 18, 369, 370]. Genomic instability plays a significant 
role in the molecular pathogenesis of CRC, as individuals with germline mutations in DNA 
repair mechanisms such as the base excision repair (BER) system or the MMR system have 
increased risk of developing the disease [371-373]. In humans, the MMR system is largely 
dependent upon the integrity of two genes, human mutL homolog (hMLH) 1 and 2. Mutations 
in either hMLH1 or hMSH2 can account for over 90% of HNPCC cases [374]. The hMLH1 
gene can be found at chromosome 3p21-23, a candidate region highlighted in studies of 
HNPCC [375, 376]. The protein product of hMLH1 forms a heterodimer with hMLH3, 
hPMS1 or hPMS2, recruiting additional DNA repair proteins to form the mismatch repair 
complex. Similarly, the location of the hMSH2 gene at chromosome 2p21 is also within an 
area associated with HNPCC [370, 377]. The protein product of hMSH2 can form a 
heterodimer with either hMSH3 or hMSH6, and binds to incorrectly matched nucleotide pairs 
produced during DNA replication. Upon binding, this complex recruits the mismatch repair 
complex to excise and replace the error in the daughter sequence. Pathogenic mutations 
associated with impairment of mismatch repair can be found throughout all coding exons of 
both hMLH1 and hMSH2, with the broadest range of variants found in exon 16 of hMLH1 
and exon 3 of hMSH2 [374]. 
 
1.3.2 Spontaneous Mutagenesis 
The intervening benign adenomatous stage of colon adenocarcinoma is referred to as a polyp, 
often originating at the bottom of a colonic crypt and proliferating to fill the intestinal villi 
[368]. Early neoplastic transformation of colonic epithelial cells is thought to result from 
dysregulation of T cell factor (TCF)/β-catenin-induced gene expression [378], a key 
molecular pathway responsible for embryonic patterning [379]. Disruption of normal gene 
expression regulation may result from mutations in the glycogen synthase kinase 3β 
phosphorylation sites of β-catenin, preventing normal clearance of the TCF co-factor [380], 
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or through truncation of adenomatous polyposis coli (APC) [381, 382]. Genes targeted by 
TCF/β-catenin are associated with proliferation [383] and transformation of cells [384], 
although dysregulation of additional pathways is likely required [385, 386]. The genes that 
are most commonly mutated in association with CRC are illustrated in Figure 1.7. 
KRAS is a member of the RAS family of genes, which encode guanine-5’-triphosphate 
(GTP)-binding proteins. KRAS signals primarily but not exclusively through the BRAF and 
MAPK pathways, and is a crucial effector of EGFR signalling. Between 32-40% of CRC 
cases can be found to contain mutations in KRAS, and around 85-90% of these mutations are 
in codons 12 or 13 [387-389]. Mutations in KRAS interfere with GTPase activity, resulting 
in accumulation of an activated GTP-bound form and persistent activation of downstream 
signalling pathways. Downstream of KRAS, BRAF is mutated in approximately 15% of CRC 
cases [390, 391]. At a frequency of over 95%, the most commonly reported BRAF mutation 
is the V600E mutation within the kinase activation domain. This mutation increases 
activation of the BRAF target, MAP2K, and subsequently MAPK1/3 [388]. Additional 
signalling pathway involvement is likely, as BRAF and KRAS mutations have differing 
histology and clinical characteristics [392]. BRAF mutant CRC is also associated with the 
CpG island methylator phenotype (CIMP) and microsatellite instability, while KRAS 





Figure 1.7 Signalling Pathways Commonly Mutated in Colorectal Cancer 
While combinations of mutations are likely involved in the pathology of the disease, CRC is commonly 
associated with mutations in several specific genes, the most common of which have been circled. Mutations 
in KRAS, BRAF, PIK3CA and PTEN downstream of EGFR promote proliferation of CRC cells, while 
constitutive activation of P53 effectively immortalises the cell by inhibiting apoptosis, and regulating the cell 
cycle. Mutations in APC can be found in cases of familial adenomatous polyposis and sporadic CRC, resulting 
in the accumulation of β-catenin and the dysregulated expression of various oncogenes [393-395]. 
 
PIK3CA mutations are present in between 15-18% of CRC cases [396, 397], with over 80% 
of PIK3CA mutations occurring in either exon 9 or 20 [388]. PIK3CA encodes the p110α 
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isoform of the catalytic subunit of a class IA PI3K heterodimer. Exon 9 mutations result in 
functional independence from the regulatory p85 subunit and constitutive activation 
dependant on interaction with RAS-GTP, while exon 20 results in functional independence 
from RAS-GTP but are dependent on interaction with p85 [398]. PI3K signalling is inhibited 
by phosphatase and tensin homologue (PTEN). PTEN activity can be impaired through direct 
mutation, chromosomal aberrations or promoter hypermethylation, resulting in elevated 
PI3K activity [399]. 
 
1.3.3 Additional Risk Factors 
As has been previously discussed, CRC is associated with predisposing conditions such as 
obesity and diabetes mellitus, medical procedures such as cholecystectomy, and lifestyle 
factors such as smoking, alcohol consumption and diet. Recently, the World Health 
Organisation (WHO) classified processed meats as a group 1 carcinogen due to 
epidemiological studies demonstrating positive associations with development of CRC, and 
to a lesser extent pancreatic and prostate cancer [359]. Mechanistically, this association may 
be due to the presence of preservatives and other chemical compounds used in processed 
meats. Red meat was also classified as a group 2A carcinogen, although the association 
between red meat and cancer may be accounted for by the production of polycyclic aromatic 
hydrocarbons (PAHs) and heterocyclic amines (HCAs) during open flame or high 
temperature cooking, rather than by the meat itself. It may be postulated that countries with 
an elevated incidence of CRC, such as New Zealand, may favour these types of cooking 
methods. 
PAHs are organic compounds with two or greater fused aromatic rings, and tend to be 
lipophilic. Although they can be detected in the air, water and soil, most non-occupational 
exposure amongst non-smoking individuals is through food consumption [400-403]. PAHs 
are produced through a pyrolytic process during high temperature treatment of organic 
materials, and can even be found in alcoholic beverages due to toasting of raw materials in 
some production methods [404]. Several PAHs have been evaluated by chemical and food 
safety bodies including the International Program on Chemical Safety (IPCS), the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA), and the Scientific Committee on 
Food (SCF). Both the SCF and JECFA identified a range of PAHs with mutagenic and 
genotoxic activity on somatic cells, and carcinogenicity in experimental animals [405]. HCAs 
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are produced by chemical reactions that occur at high temperatures, originating from amino 
acids, sugars and creatine/creatinine [406, 407]. They have demonstrated potent mutagenic 
properties in bacterial assays, and have induced tumourigenesis in the gastrointestinal tract 
in animal models [408-410]. Epidemiological association of HCAs with CRC in humans is 
inconsistent, with evidence both indicative of an association [411-413], or disparative [414-
416]. Variations in acetylation of HCAs and PAHs by N-Acetyltransferase (NAT) 2 have 
been suggested as a potential contributor to discrepancies, as individuals with a propensity 
for rapid acetylation may more readily convert HCAs and PAHs into carcinogenic forms, 
increasing CRC risk [417, 418]. 
Another important dietary factor that may contribute to elevated incidence of CRC in New 
Zealand is consumption of dietary fibre. Unlike previous examples, this risk factor elevates 
in potency as its consumption is reduced, presenting rather as a preventative factor. 
Unfortunately, average Western diets have seen a significant reduction in dietary fibre, and 
New Zealand is no exception.  As far back as 430 BC, Hippocrates explored the association 
between whole grain flour and maintenance of gastrointestinal health. The term ‘dietary 
fibre’ was originally coined by Hipsley in 1953, defined as indigestible components of plant 
cell walls including cellulose, hemicelluloses and lignin [419]. Dietary fibre was further 
developed into a hypothesis that postulated an inverse relationship between consumption and 
incidence of CRC and coronary heart disease [420, 421]. The definition of dietary fibre was 
subsequently expanded to include indigestible polysaccharides such as gums, mucilages, 
oligosaccharides and pectin [422]. Dietary fibres are thought to reduce the contact time of 
carcinogenic molecules with the intestinal epithelia, and promote growth of commensal 
bacteria [423, 424]. For example, inulin, a polymer of fructose found in asparagus, garlic and 
onions, can promote growth of Bifidobacterium while hindering pathogenic E. coli, Listeria, 
and Salmonella [425, 426]. Low dietary fibre intake has been found to be associated with a 
reduced prevalence of Clostridium, Eubacterium and Roseburia spp., and an elevated 
prevalence of Enterococcus and Streptococcus spp. [427]. 
As originally postulated by Burkett, Painter and others, dietary fibre intake is inversely 
related to the incidence of CRC [428]. Fungal polysaccharides in particular have been linked 
with increased survival in advanced stages of gastric and CRC [429], and can enhance 
immune functional parameters such as natural killer cell activity, lymphocyte cytotoxicity, 
and alter proportions of effector and suppressor cells [430]. Dietary fibres have also 
demonstrated proficiency in counteracting the detrimental effects of HCAs and PAHs, and 
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consumption of cereals, whole grains, fibre-rich fruits and vegetables, and even marine algae 
can reduce the prevalence of CRC [431, 432]. The anti-carcinogenic and anti-mutagenic 
properties of dietary fibres have been predominantly attributed to the production of short-
chain fatty acids (SCFAs), although dietary fibres may also bind mutagenic or carcinogenic 
compounds, or dilute them through fecal bulking [433]. A diet particularly rich in non-starch 
polysaccharides has a significant effect on gut bacteria such as Ruminococcus bromii, which 
can degrade starch and produce SCFAs [434]. Fucoidan, a polysaccharide found in brown 
algae, can induce apoptosis in human CRC cells, stimulating death receptor pathways, 
increasing cleavage of caspases, and triggering mitochondria-mediated apoptosis [435]. 
Fucoidan can also induce apoptosis by downregulating the ERK pathway, and can induce 
cleavage of PARP, a mechanism of DNA repair. 
 
1.3.4 Angiogenesis in Colorectal Cancer 
Proliferation of tumour cells and the formation of solid tumour mass remains, like other 
tissues throughout the body, dependent upon adequate nutrient supply. Depletion of nutrients, 
such as the development of hypoxia within the tumour core, can result in tissue necrosis. 
Therefore, it becomes imperative for a growing tumour to maintain sufficient blood supply, 
especially as the mass of the tumour begins to restrict diffusion from surrounding vessels. 
Angiogenesis is the process of forming new blood vessels, extended from the endothelium 
of existing vasculature. This process is a balancing act, promoted by signalling molecules 
such as VEGF, which can be produced by supporting tissues or tumour cells. CRC cells can 
produce both IL-6 [436], a cytokine with proangiogenic properties, and VEGF [437]. 
Microvessel density (MVD), a surrogate measure of tumour vascularisation, and VEGF 
expression, are directly related with poor prognostic outcomes amongst patients with CRC 
[438]. The VEGF gene encodes eight individual exons interspaced by seven introns [439]. 
The pre-messenger RNA from VEGF can yield two families of proteins, VEGFxxx or 
VEGFxxxb. Each family contains multiple protein isoforms, with differences predominantly 
in the C-terminal domain, while the binding domains of the VEGF tyrosine kinase receptor 
are generally conserved [440]. The VEGFxxx family of variants are pro-angiogenic, with 
roles in promoting cell survival, migration and proliferation through stimulation of VEGF 
receptor (VEGFR) 2 [441, 442]. Major isoforms of VEGFxxx include VEGF121, VEGF165 
and VEGF189 [443], with minor published variants including VEGF145, VEGF183 and 
VEGF206 [439, 444-446]. The VEGFxxxb family of variants are anti-angiogenic, and result 
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from distal splicing in exon 8, within the C-terminal region of the VEGF pre-mRNA [447, 
448]. The predominant isoform of VEGFxxxb is VEGF165b, with several variants also 
mentioned in the literature including VEGF121b, VEGF145b, VEGF183b and VEGF189b [448, 
449]. Expression of VEGFxxx isoforms are upregulated across a multitude of tumour types, 
while expression of VEGFxxxb isoforms are notably downregulated in colon carcinoma 
[450], kidney cell carcinoma [448], melanoma [451] and prostate carcinoma [447]. 
VEGF165b acts as a competitive inhibitor of VEGF165, with relatively similar binding 
affinities between these two variant proteins [447, 452]. Overexpression of VEGF165b can 
inhibit the growth of various tumours, and administration of recombinant VEGF165b has been 
shown to be particular effective at inhibiting growth of colon carcinoma [447, 450, 453]. A 
similar therapeutic effect can be observed from neutralising VEGF with an antibody, such as 
Bevacizumab [454]. Bevacizumab binds with similar affinity to both VEGF165 and 
VEGF165b, and as some tumours are associated with an elevation in expression of VEGF165b, 
this presents a subtype of tumours that may grow slowly when compared to VEGFxxx 
expressing tumours, but that would be resistant to anti-VEGF therapy [450]. The immune 
system can also influence the expression of VEGF. Stimulation of CRC cells in vitro with 
IL-17, a cytokine predominantly released by TH17 cells, induces increased expression of both 
VEGF and IL-6, as well as other pro-tumourigenic genes such as plasminogen activator 
urokinase (PLAU), neuropilin (NRP) 2 and inhibitor of DNA binding (ID) 3 [455]. IL-17 
producing cells are frequently present in CRC tumours, with high prevalence amongst those 
still proficient in MMR [456]. Although expression of IL-17 by TH17 cells and macrophages 
has been implicated with elevations in MVD and poor survival amongst CRC patients [455], 
the role of TH17 cells in CRC is complex. In some cases, such as in the presence of an 
intraepithelial infiltrate, TH17 cells can correlate positively with improved survival [457]. 
 
1.3.5 Colorectal Cancer Staging 
For some time the progression of CRC was divided based on Dukes’ method, originally a 
three-grade ABC classification system separating carcinoma contained within the rectal wall 
(A), extrarectal invasion without lymph node metastases (B) and with lymph node metastases 
(C) [458]. The Dukes’ classification was later updated to include a fourth classification, (D), 
denoting the presence of distant metastases [459]. This outdated system was replaced by the 
Tumor Node Metastasis (TNM) staging outlined by the Union for International Cancer 
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Control (UICC) and the American Joint Committee on Cancer (AJCC), the 7th edition of 
which was released in 2009. This staging provides comprehensive classification, ranging 
from carcinoma in situ (Stage 0) through to metastasis in multiple organ sites (Stage IVB) 
[460]; however, there are some notable discrepancies between the TNM staging and patient 
prognosis, and controversies over changes made between iterations [461, 462]. 
Histopathologic tumour grading is an alternative approach to predicting pathogenesis of 
CRC, based on various anatomical features such as tumour vascularity, differentiation, and 
margination [463, 464]. Proposed alternatives to the TNM staging system include the 
assessment of tumour aggression based on budding along the leading edge, which has 
demonstrated potential prognostic value for resected CRC [465], and poorly differentiated 
clusters (PDCs) as a measure of CRC metastatic potential [466-468]. 
The immunoscore of Galon and colleagues was proposed as another alternative for staging 
of CRC (Figure 1.8) [469]. The immunoscore considers the distribution of immune cell 
populations throughout the core tumour (CT) mass, along the invasive margin (IM), and 
within organised lymphoid follicles, in addition to levels of immune effector and regulatory 
molecules as a determinant of tumour staging. Immune cell infiltrates in both the CT and 
along the IM are significantly correlated with patient outcome, and improves the accuracy of 
predicted survival [470]. In particular, infiltrates of CD3+, CD8+ and CD45RO+ T cells are 
positively associated with better prognosis amongst CRC patients [470-473]. Additionally, 
infiltrates consisting of TH1 cells are associated with a good prognosis in CRC patients [474-
476], while B cells, NK cells, macrophages and other T helper cell subsets differ in value 
between different tumour types and stages [477].  
The Immunoscore is a scoring system that involves the evaluation of immune cell infiltration 
at the CT and along the IM by two lymphocyte populations. These populations are selected 
from three subsets which are associated with improved prognosis amongst CRC patients, 
defined as CD3+/CD45RO+, CD3+/CD8+ or CD8+/CD45RO+. Results range from an 
Immunoscore of 0 (I0) with low densities of both populations, through to an Immunoscore 
of 4 (I4) with both at a high density [478]. The presence of these immune cell infiltrates are 
associated with improved prognosis amongst CRC patients, hence a higher immunoscore is 
preferable. The Immunoscore system is a prognostic factor for disease-free survival (DFS), 





Figure 1.8 The Immunoscore for Staging of Colorectal Cancer 
Calculating the Immunoscore is an alternative method for staging CRC that is significantly associated with 
patient prognosis. The immunoscore of a tumour is calculated by staining two immune cell populations, and 
assessing their distribution at the core of the tumour (CT) and along the invasive margin (IM) by 
immunohistochemistry. These populations are selected from three marker sets that define immune cell 
populations associated with good prognosis amongst CRC patients, CD3+/CD45RO+, CD3+/CD8+ or 
CD8+/CD45RO+ cells [469]. A high (Hi) distribution is indicative of an infiltrate consisting of the target immune 
cell population, while low (Lo) distribution indicates scant or absent distribution. A higher immunoscore with 
more immune cell infiltration of the selected populations is associated with an improved prognosis for the 
patient. 
 
1.3.6 Approved Treatment 
Current treatment for CRC involves a combination of surgical resection and chemotherapy, 
and radiotherapy in rectal cancer. Effective agents include 5-fluorouracil (5-FU), irinotecan, 
oxaliplatin and capecitabine. Monoclonal antibodies (mAb) are a promising alternative to 
conventional therapies, capable of directly facilitating immune-mediated anti-tumour activity 
by inducing complement-dependent cytotoxicity (CDC), antibody-dependent cellular 
cytotoxicity (ADCC) or through conjugation with radioactive or cytotoxic molecules [479]. 
mAbs can also be used to block growth receptors overexpressed by tumour cells, such as 
EGFR, HER2, hepatocyte growth factor receptor precursor (MET) and insulin-like growth 
factor (IGF) 1 receptor (IGF1R) [480-483]. An extensive variety of mAbs have been 
developed for their potential to bind to the surface of tumour cells, with targets including 
haematopoietic differentiation glycoproteins (e.g. CD20, CD30, CD33 and CD52) [484-486], 
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angiogenic factors (e.g. VEGF, integrin αVβ3 and integrin α5β1) [487] and components of 
the stroma or extracellular matrix (e.g. fibroblast activation protein, tenascin) [488-490]. 
Development of a novel mAb must follow a series of key checkpoints for evaluating both 
clinical efficacy and safety. These checkpoints include: (1) Preclinical characterisation of the 
mAbs chemical and physical properties; (2) Analysis of specificity against a panel of 
malignant and normal tissues; (3) Assessment of immune effector activity; (4) Determination 
of in vivo localisation and distribution in relation to a transplanted tumour model; (5) 
Humanisation; and (6) Evaluation of in vivo therapeutic activity [484, 490, 491]. Regulatory 
approval of mAb therapy is primarily based on benefits to overall survival over conventional 
therapy in large Phase III clinical trials; however, when there are limited standard therapeutic 
options available, surrogate markers of anti-tumour immune responses may be sufficient 
[479]. mAbs approved for use by the United States (US) Food and Drug Administration 
(FDA) include HER2-specific trastuzumab (Roche) [492], EGFR-specific cetuximab 
(ImClone LLC) [493, 494] and CD20-specific rituximab (Genentech) [495]. 
mAbs such as bevacizumab (Genentech), targeting VEGF, and cetuximab and panitumumab 
(Amgen) targeting EGFR can be effective in colorectal patients that are negative for KRAS 
mutations [480, 496, 497]. Bevacizumab was the first monoclonal approved for treatment of 
metastatic CRC in 2004, followed by cetuximab also approved in 2004, and panitumumab 
approved in 2006. Panitumumab is the only completely human monoclonal antibody 
approved for treatment of CRC, while cetuximab is chimaeric and bevacizumab is humanised 
[480, 496, 497]. Bevacizumab is often used in first and second line treatments of metastatic 
CRC in combination with fluoropyrimidine-based chemotherapy. Cetuximab and 
panitumumab are only suitable for wild-type KRAS CRC, as constitutive activation of KRAS 
overrides effective blockade of EGFR, which lies upstream of the KRAS signalling pathway. 
Alternative monoclonal therapies have also been considered for treatment of CRC, including 
labetuzumab targeting carcinoembryonic antigen, pemtumomab and oregovomab targeting 
mucin, trastuzumab and pertuzumab targeting HER-2, mapatumumab targeting TRAILR1 
and sibrotuzumab targeting fibroblast activation protein [479]. These monoclonal antibodies 
are yet to receive approval for use in patients, and primarily target CRC-associated surface 
receptors or molecules, with modes of action beyond signalling pathway blockade. The 
modalities of action of these monoclonals will be discussed further in a later section. 
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In New Zealand since 2011, 95% of patients with non-metastatic colon cancer underwent 
surgical resection of their primary tumour [362]. Amongst patients that had a stage III colon 
cancer resected, 59% received adjuvant chemotherapy. Current recommendations include the 
post-operative administration of the FOLFOX chemotherapy combination of 5-FU, 
leucovorin and oxaliplatin, or alternative combinations of oral capecitabine or 5-FU with or 
without leucovorin where FOLFOX is not appropriate [498]. 92% of patients with non-
metastatic rectal cancer underwent surgical resection of their primary tumour, with 52% of 
patients also receiving either pre- or post-operative radiotherapy, predominantly with a long 
exposure course [362]. Only 36% of patients with non-metastatic rectal cancer received 
adjuvant chemotherapy. Rates of resection were much lower amongst patients with 
metastatic CRC at 52%, with treatment recommendations generally palliative in the most 
advanced cases. 49% of patients with metastatic disease received adjuvant chemotherapy. 
Although the New Zealand public health system does not include the use of modern 
immunotherapies such as bevacizumab, cetuximab and panitumumab for treatment of CRC, 
these agents and various others are available through the private sector or in clinical trials 
[362]. 
 
1.3.7 Monoclonal Antibodies in Clinical Trials for Colorectal 
Cancer 
CTLA4 and PD1 are T cell receptors that have been targeted with immunotherapeutic mAbs. 
CTLA4 is a primary immune-checkpoint receptor involved in early T cell activation, counter-
acting the activity of the T cell co-stimulatory receptor CD28 [499-501]. While CTLA4 and 
CD28 share the ligands CD80 and CD86, CTLA4 has a higher binding affinity [502]. This 
enables CTLA4 to induce signalling-independent T cell inhibition by outcompeting CD28, 
and even actively removing CD80 and CD86 from the surface of APCs [503-507]. CTLA4 
may also block T cell activation through activation of protein phosphatases (e.g. Src 
homology region 2-containing protein tyrosine phosphatase 2 (SHP2) and protein 
phosphatase 2 (PP2A)), which counteract TCR and CD28 induced kinase signalling 
pathways; however the details of this mechanism are still under investigation [500]. Despite 
predictions of immune toxicity from the observed lethal hyperimmune and autoimmune 
phenotype of Ctla4-knockout mice [508, 509], partial blockade of CTLA4 was demonstrated 
to yield an achievable therapeutic window [510]. This enabled the production and testing of 
humanised anti-CTLA4 mAbs [511], with ipilimumab (Bristol-Meyers Squibb) subsequently 
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approved for treatment of metastatic melanoma [512]. Ipilimumab is currently in a phase I/II 
clinical trial for treatment metastatic colon cancer in combination with the anti-PD1 
monoclonal nivolumab (Bristol-Meyers Squibb) [513]. A recent phase II clinical trial with 
an alternative anti-PD1 monoclonal, tremelimumab (Pfizer), for treatment of refractory 
metastatic CRC had a single partial responder amongst 47 patients [514]. Alternative anti-
CTLA4 monoclonals in clinical trials for CRC include AMP224 (Amplimmune) [515], 
PDR001 (Novartis) [516], REGN2810 (Regeneron) [517], BGB-A317 (BeiGene) [518] and 
MEDI0680 (MedImmune/AstraZeneca) [519]. 
PD1 is primarily involved in limiting T cell activity in peripheral tissues during inflammation 
[520-522], significantly contributing to immunoregulation in the tumour microenvironment 
[523-525]. PD1 expression is induced during T cell activation [522], known to inhibit 
signalling pathways through activation of the phosphatase SHP2 when triggered by its 
respective ligand [526]. PD1 has two ligands, PDL1 (CD274) and PDL2 (CD273) [527], 
which are thought to also have a corresponding co-stimulatory T cell receptor with a 
relationship reminiscent of the interaction between CD80/CD86 and CD28/CTLA4 [528]. 
Initial clinical trials of Anti-PD1 treatment produced promising results, with a lower 
frequency of immune-related toxicities than observed with anti-CTLA4 treatment. 
Pembrolizumab (Merck) is an anti-PD1 monoclonal that has recently gained FDA approval 
for use in CRC based on the results of its phase II clinical trial [529]. In this trial, the immune-
related objective response rate was 40% in MMR-deficient CRC patients, with an immune-
related progression-free survival rate of 78%. These rates were comparably lower amongst 
non-MMR-deficient CRC patients, at 0% and 11% respectively, indicating clear differences 
in treatment efficacy respective to MMR state. Alternative anti-PD1/anti-PDL1 monoclonals 
in clinical trials for CRC include MEDI4736 (MedImmune/AstraZeneca) [530], nivolumab 
(Bristol-Meyers Squibb) [513], azetolizumab (Roche) [531] and avelumab (EMD Serono) 
[532]. 
In addition to CTLA-4 and PD-1/PDL-1 there are multiple alternative immune receptors that 
have been explored as potential targets for monoclonal therapy. These include targeting 
alternative inhibitory receptor pathways for blockade, or targeting stimulatory immune 
receptors to promote activation of immune cells. Alternative inhibitory receptor blockade 
monoclonals currently in trial for CRC include BMS-986016 (Bristol-Meyers Squibb), an 
anti-LAG-3 antibody [533], and ARGX-110 (arGEN-x), an anti-CD70 antibody [534]. LAG-
3 (CD223) is a member of the immunoglobulin superfamily expressed by activated T cells, 
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B cells, NK cells and plasmacytoid DCs [535]. LAG-3 binds to MHC-II, and has a role in 
the negative regulation of T cell proliferation. A member of the tumour necrosis factor family 
of receptors, CD70 is normally expressed by activated T and B cells, and mature DCs. 
Tumour cells can also express CD70, and through interactions with it complementary 
receptor CD27, CD70 drives T cell exhaustion, induces T cell apoptosis and increases the 
amount of Treg cells [536]. CD70-expressing tumours can also recruit an infiltrate of CD27
+ 
Treg cells [537, 538]. Only around 9% of CRC tumours are CD70
+ [539], so it is uncertain 
how effective targeting this pathway will be for treating this disease. 
The repertoire of immunostimulatory receptors targetable by agonistic monoclonals includes 
OX40, 4-1BB, GITR, CD40 and CD27. OX40 (CD134) is a member of the tumour necrosis 
factor family of receptors, and is transiently expressed by CD4+ and CD8+ T cells following 
antigen-specific priming [540]. Its ligand, OX40L, can be found on the surface of activated 
APCs, as well as endothelial and epithelial cells [541]. OX40 agonists directly regulate Treg 
cells, impairing their immunosuppressive effects, and subsequently promoting anti-tumour 
TC cell responses [540]. OX40 agonist monoclonals currently in clinical trials for treatment 
of CRC include MEDI6469 (AgonOx) [542], MEDI6383 (AgonOx) [543] and MOXR0916 
(Genentech) [544]. 4-1BB (CD137) is a member of the tumour necrosis factor family of 
receptors, expressed primarily by activated T cells [545]. Its ligand, 4-1BBL, is expressed by 
activated APCs and stimulates T cell proliferation and differentiation. Expression of 4-1BBL 
is suppressed in CRC, and impairment of this pathway is implicated in promoting immune 
escape [546]. Targeting 4-1BB with agonistic antibodies has already demonstrated efficacy 
against CRC in animal models [547, 548], and monoclonals currently in clinical trials include 
urelumab (Bristol-Meyers Squibb) [549] and PF-05082566 (Pfizer) [550].  
GITR (CD357) is a costimulatory receptor constitutively expressed by Treg cells, and 
transiently expressed by activated CD4+ and CD8+ T cells [551]. Its ligand, GITRL, is 
expressed by activated APCs. GITR provides costimulation for effector T cells, while also 
impairing the suppressive activity of Treg cells [552]. Stimulation of GITR with agonistic 
antibodies can promote tumour regression, while inducing lineage instability in Treg cells 
[553]. GITR agonistic monoclonals currently in clinical trials include TRX518 (Tolerx) [554] 
and MK-4166 (Merck) [555]. CD27 is the ligand for CD70, and is a tumour necrosis factor 
family receptor involved in activation, proliferation and survival of T cells [556]. There is 
currently only one agonistic monoclonal in clinical trials for CRC, which is varlilumab 
(Celldex) [557]. There are several additional receptors that are also currently under 
68 
 
investigation as immunotherapeutic targets, including B- and T-lymphocyte attenuator 
(BTLA), TIM3 and adenosine A2A receptor (A2aR) [558, 559]. With a multitude of avenues 




1.4 Therapeutic Vaccination 
Prophylactic cancer vaccination has already demonstrated significant success in the form of 
Cervarix [560] and Gardasil [561]; however, an approved therapeutic vaccine suitable for 
treatment of established tumours is yet to surface from clinical trials. Therapeutic cancer 
vaccination is foreshadowed by several limiting factors that impair the induction of an 
effective antitumour response, including the non-ubiquitous expression of target tumour-
specific or tumour-associated antigens throughout the heterogeneous tumour mass, or the 
presence of an overwhelmingly immunosuppressive tumour microenvironment. Despite 
these daunting obstacles, many new therapeutic vaccination methods are currently being 
developed and refined to improve upon the induction of an antitumour immunity.  
Some of the earliest cancer vaccines were based on the administration of selected proteins or 
peptides, including heat-shock proteins (HSPs) [562], peptide epitopes/agonist peptides [563-
565], fusion proteins [566] and anti-idiotype antibodies [567, 568]. Suitable peptide vaccines 
can be produced with reverse immunology, using computer algorithms to predict epitopes 
present in tumour-specific antigens (TSAs) and TAAs. These predicted epitopes are 
subsequently validated in vitro for binding specificity and stability, prior to consideration for 
clinical trials. Alternatively, direct immunology involves isolation of patient-derived 
autologous tumour-specific CTLs, which can be screened to identify the corresponding 
peptide for vaccine validation [569]. While these vaccines are relatively simple to produce, 
they often suffer from poor immunogenicity, susceptibility to tumour escape and induction 
of an ineffective TH2 immune response [570, 571]. Vaccination efficiency can be improved 
by utilising a surrogate delivery system, such as preloading ex-vivo-derived DCs with the 
vaccine [572, 573]. Exposing DCs produced from haematopoietic progenitor cells to the 
vaccine ex vivo avoids interference from endogenous regulatory mechanisms that may impair 
activation, and enables controlled administration of stimulatory cytokines (e.g. GM-CSF). 
Sipuleucel-T (Provenge) is a prostatic acid phosphatase (PAP)-based DC vaccine which 
demonstrated particularly significant potential in clinical trials, now approved for treatment 
of metastatic prostate cancer [574, 575]. 
Unlike transient peptide vaccination, DNA-based vaccines have the potential to establish an 
endogenous supply of the protein antigen to prolong exposure and incite a potent immune 
response. While the therapy can be delivered directly, an enhanced delivery system (e.g. 
Gene Gun, cationic liposomes) may be used to circumvent degradation by DNases and 
enhance treatment efficiency [576, 577]. DNA-based vaccines can also be improved by 
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modification of the plasmid-encoded antigens [578, 579], the addition of biological adjuvant 
genes (e.g. hepatitis B surface antigen) [580] and simultaneous cytokine administration (e.g. 
granulocyte macrophage colony-stimulating factor (GM-CSF) or IL2) [581]. mRNA-based 
vaccines are another intriguing prospective immunotherapeutic for cancer treatment, based 
on the transient transfection of non-dividing cells [582, 583]. An mRNA-based vaccine can 
also be electroporated into DCs ex vivo to improve transfection efficiency, enhancing 
therapeutic delivery [584, 585]. As mRNA does not integrate into the host genome, mRNA-
based vaccines are considered relatively safe [586]; however, antigen expression will be 
limited by mRNA degradation mechanisms. Genes encoding TSAs and TAAs can also be 
incorporated into recombinant vectors including viruses, bacteria and yeast. Poxviruses are 
the most commonly used vector for recombinant vaccine delivery, with a relatively large 
double-stranded DNA genome of 130 kb in mammalian strains allowing insertion of over 10 
kb of foreign DNA [569]. This method harnesses the expression of poxvirus gene products 
to produce a potent immune response against recombinant antigen products, further enhanced 
by expression of T cell co-stimulatory molecules and cytokines induced by some modified 
poxviruses. 
 
1.4.1 Virus-like Particles 
Virus-like particles (VLP) can be formed from self-assembling virus-derived capsid proteins, 
or viral proteins embedded in a phospholipid bilayer. VLP can be differentiated from their 
parent virus due to the absence of viral genomic material, and are roughly comparable to a 
hollow shell. This also renders VLP incapable of infection or replication, making them a safe 
subunit alternative to intact virus-based vaccines. The viral capsid proteins that form VLP 
retain their natural conformation, with respective antigenic motifs presented in a state more 
immunologically relevant than those present in an inactivated virus vaccine. VLP are a 
natural by-product that is formed during the infection cycle of some viruses, and were first 
identified in patients infected with hepatitis B virus (HBV) [587]. VLP can be manufactured 
in vitro using various protein expression systems, such as in bacteria, yeast, mammalian and 
insect cell lines, plants and cell-free expression systems. Expression of virus capsid proteins 
for production of VLP in vitro also enables the formation of VLP from viruses that cannot be 
routinely cultured, such as hepatitis C virus and human norovirus [588, 589]. VLP have also 
been found to be highly stable through prolonged storage [590-592], an important 
consideration in vaccine development. An HBV vaccine, Engerix (GlaxoSmithKline), was 
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the first VLP-based vaccine to be approved for use in humans [593]. Additional VLP-based 
vaccines that have been approved include Epaxal (Crucell), a vaccine for hepatitis A virus 
[594], Inflexal V (Crucell), a vaccine for influenza A [595], and Gardasil (Merck) and 
Cervarix (GlaxoSmithKline), vaccines previously mentioned for HPV [596]. 
The morphology of a VLP is defined by its parent virus, inheriting both its size and 
characteristic shape (e.g. spherical, icosahedral, rod-like). VLP can be produced with 
multiple degrees of complexity, ranging from a single type of capsid protein in a single layer, 
through to multi-layer and enveloped VLP (Figure 1.9) [597]. Some examples of simple VLP 
with a single layer include HBV VLP produced from the HBV surface antigen [593], 
norovirus VLP produced from the VP1 capsid protein [598], and Qβ VLP produced from Qβ 
bacteriophage coat protein [599-601]. Simultaneously expressing multiple viral structural 
proteins can facilitate the production of VLP with multiple distinct capsid layers, such as in 
double or triple layered rotavirus VLP [602, 603]. VLP can also be produced from multiple 
strains of the same virus, creating a mosaic VLP that can theoretically confer protection 
against each of the strains incorporated into the particle. Further complexity can be added 
through supporting the formation of a phospholipid envelope around VLP derived from 
enveloped viruses, such as influenza A virus. Co-expression of influenza A virus 
haemagglutinin, neuraminidase, matrix protein and ion channel protein results in the 
formation of influenza VLP encapsulated inside a phospholipid envelope [604]. Influenza A 
virus VLP retain the characteristic surface haemagglutinin and neuraminidase spikes of their 
parent virus, and can be produced from multiple influenza strains. Expression of only the 
membrane anchored influenza A virus proteins can also form a single-layered VLP called a 





Figure 1.9 Structural conformation repertoire of VLP 
The structural variation amongst VLP is as diverse as the broad range of viruses from which they can be 
assembled. The simplest form, (A) Single Protein VLP, can be formed by expressing a single self-assembling 
capsid protein from their parent virus. Examples with increased complexity include multi-protein VLP arranged 
in (B) a Single Layer, (C) Multiple Layers, or (D) a Mosaic pattern. Some types can even include a phospholipid 
bilayer in their structure, forming (E) an Enveloped VLP or (F) a virosome particle. VLP can also be used as a 
scaffold for various molecules, incorporated into the particle through (G) Recombination or (H) Chemical 
Conjugation depending on the type of molecule [606]. 
 
VLP are a versatile vaccine vector due to their ability to support modification. These 
modifications include the recombinant insertion of peptides, or the chemical conjugation of 
peptides, proteins, lipoproteins, carbohydrates and entire cellular lysates. Modifications that 
incorporate heterologous antigens produce chimaeric VLP capable of inducing immune 
responses against antigens other than those derived from the parent virus of the VLP. VLP 
can support recombinant peptide insertion of considerable length without impairing structural 
integrity, variably depending on the type of VLP. For example, polyomavirus VLP can 
support the insertion of up to 120 amino acids in its VP1 capsid protein [607-610]. 
Polyomavirus VLP can also be produced containing an additional non-structural capsid 
protein, VP2, which can support insertion of large truncated proteins [611]. A wide variety 
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of commercially available vaccines are based on the recombinant insertion of epitopes into 
the HBV core antigen of HBV VLP, such as the pan-influenza A vaccine ACAM-FLU A 
[612], and the Plasmodium falciparum anti-malaria vaccine Malariavax [613]. VLP can also 
be used as a scaffold for chemical conjugation through standard protein conjugation methods, 
such as through carboxylic acid, sulfhydryl groups or amine groups of amino acids, azide-
alkyne click chemistry [614], biotin-streptavidin complexes [615], and through 
heterobifunctional or biorthogonal cross-linkers. 
The repetitive structure of VLP promotes the internalisation, processing and presentation of 
integrated antigens by various APCs, including DCs, macrophages and B cells [616]. The 
route of administration and the physical properties of the VLP predominantly determine 
which immune cells will preferentially internalise the particles, and how they will be 
processed. One of the most important determinants is VLP size, with particles larger than 
200 nm in diameter requiring uptake into APCs for efficient transport into lymph nodes [617]. 
VLP can be internalised through various mechanisms including micropinocytosis, 
phagocytosis and receptor-mediated endocytosis. VLP that retain receptor ligands can gain 
entry into cells through the same mechanisms as their parent virus, such as influenza A VLP 
binding to sialic acid through haemagglutinin. VLP can also be modified to target specific 
receptors for receptor-mediated endocytosis, such as the conjugation of superantigen onto 
HBV VLP for internalisation through MHC-II [618]. VLP are potent activators of the 
humoral arm of the adaptive immune system, their repetitive surface promoting cross-linking 
of the BCR. The capacity of VLP to stimulate activation of B cells and the production of 
antibodies is particularly useful in prophylactic vaccines against the parent virus of the VLP, 
such as in vaccines for HBV [593], HPV [596] and influenza A virus [619]. Some VLP can 
also be cross-presented by specific APCs onto MHC-I for stimulation of the cell-mediated 
arm of the adaptive immune system [620, 621]. VLP that can be cross-presented include Qβ 
VLP, which are cross-presented through TAP-dependent pathways in DCs and TAP-
independent pathways in macrophages [621], and rabbit haemorrhagic disease virus VLP, 
which are cross-presented through the MHC-I receptor recycling pathway [622]. Additional 
examples of VLP that are cross-presented include hepatitis C virus VLP [623], human 




1.4.1.1 VLP as Therapeutic Cancer Vaccines 
VLP have a broad range of potential applications, including as potential vectors for cancer 
vaccines. Where the prophylactic HPV VLP vaccines Gardasil and Cervarix provide 
protection against the causative agent of cervical cancer, HPV, a vaccine has also been 
developed that can therapeutically treat existing cervical cancer. This vaccine is based on 
VLP formed from the infectious bursal disease virus (IBDV) VP2 capsid protein. These VLP 
are formed from 20 trimeric clusters of VP2 with a T=1 structural symmetry, and can support 
insertion at the N- and C-terminus of VP2, or in the hypervariable loops [627, 628]. 
Recombinant insertion of a C-terminal fragment of the HPV-16 E7 protein into IBDV VLP 
and subsequent vaccination of TC1 cervical cancer tumour-bearing mice induced complete 
remission of tumours in all vaccinated mice [629]. VLP can also deliver TAAs in an 
immunogenic manner, potentially stimulating immune responses against tolerised epitopes. 
For example, incorporation of three B cell epitopes derived from the extracellular domain of 
HER2/neu into influenza A virosome VLP produces a vaccine capable of inducing 
production of HER2/neu-specific antibodies. This vaccine has completed a phase I clinical 
trial, producing HER2/neu-specific antibodies in 80% of patients, and reducing the number 
of Treg cells [605]. The Qβ VLP has also been adapted for use as a cancer vaccine, through 
recombinant insertion of a peptide from the melanoma antigen Melan-A/Mart-1. In a phase 
I/II clinical trial, the Melan-A/Mart-1 Qβ VLP induced detectable Melan-A/Mart-1-specific 
T cell responses in 64% of patients [630]. RHDV VLP has also demonstrated promise in pre-
clinical studies, capable of inducing potent cytotoxic immune responses that delay tumour 
growth and improve survival in subcutaneous murine tumour models [631-633]. 
 
1.4.1.2 Rabbit Hemorrhagic Disease Virus VLP 
RHDV is a member of the Caliciviridae family of the genus Lagovirus, consisting of non-
enveloped single-stranded positive-sense RNA viruses, and is responsible for a contagious 
haemorrhagic disease in rabbits [634]. The RHDV viral capsid consists of 180 copies of the 
60 kDa major capsid protein, VP60, arranged as 90 dimers into a T=3 icosahedral structure 
with a diameter of around 40 nm [635]. The VP60 protein can be divided into four 
individually identifiable domains, the N-terminal domain (amino acids 1-65) contained 
within the capsid, the shell domain (amino acids 66-229) that forms the backbone of the 
icosahedral capsid, a short hinge domain (amino acids 230-237) and the C-terminal 
protruding domain (amino acids 231-579) exposed on the surface [636-639]. Recombinant 
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expression of the RHDV VP60 protein results in the spontaneous formation of VLP that are 
structurally indistinguishable from the native virus [634, 635]. Expression of RHDV VLP 
has achieved in bacteria [640], yeast [641, 642], plants [643, 644] and in insect cells [633-
635, 638, 645]. 
RHDV VLP were originally developed for vaccination of domestic rabbits against RHDV, 
but have since proven to be particularly versatile as a vector for constructing cancer vaccines. 
Vaccination using VLP derived from non-human viruses are particularly desirable as vaccine 
vectors, as pre-existing immunity can be detrimental to the generation of anti-tumour immune 
responses for some VLP vaccines [646]. RHDV VLP are internalised by APCs through 
phagocytosis and macropinocytosis, and are cross-presented through the MHC-I receptor 
recycling pathway [622]. Conjugation onto the surface of RHDV VLP can enhance the 
immunogenicity of antigens, as evidenced by the significantly greater degree of ovalbumin-
specific OT-II cell proliferation in OT-II splenocytes pulsed with ovalbumin conjugated on 
VLP in comparison to ovalbumin protein alone [647]. Several MHC-I restricted model 
peptide epitopes have also been recombinantly inserted at the N-terminus of RHDV VP60, 
or conjugated onto the surface of RHDV VLP, including the H-2Kb-restricted chicken 
ovalbumin epitope SIINFEKL [633, 648], and the H-2Db-restricted LCMV gp33 epitope 
SAVYNFATM [632, 649]. These model antigens are used due to the availability of mice 
transgenic for specificity of their TCR against these epitopes [650, 651], and are commonly 
used model targets genetically engineered for expression in tumour cell lines. Ovalbumin-
expressing melanoma (B16-OVA)-bearing mice vaccinated with RHDV VLP containing the 
SIINFEKL epitope have delayed tumour growth and enhanced survival [633]. A similar 
response can also be observed in gp33-expressing Lewis’ lung carcinoma (LL-LCMV)-
bearing mice vaccinated with RHDV VLP containing SAVYNFATM [632]. More recently, 
RHDV VLP have been developed containing epitopes derived from the melanoma antigen 
gp100, singularly or in multiple copies [652]. Vaccination of B16-bearing mice with RHDV 
VLP containing gp100 epitopes can also delay tumour growth and improve survival. These 
responses were further improved by vaccination with RHDV VLP containing two copies of 
the gp100 epitope, indicating that antigen dosage plays an important role in the potency of 
cancer vaccines. Improved functionality of the RHDV VLP vaccine has also been explored 
through the conjugation of adjuvants, such as CpG oligonucleotides and α-
galactosylceramide [649, 653], or by targeting alternative internalisation pathways, such as 




1.5 Project Objectives 
RHDV VLP have already demonstrated themselves as an exceptional cancer vaccine vector 
in model antigen systems. They have the ability to naturally associate with various molecules 
and compounds, producing composite vaccines capable of stimulating targeted immune 
responses. This PhD project is composed to two interrelated objectives: (1) Investigating the 
interactions between RHDV VLP and nucleic acids for modification of immune responses to 
vaccines; and (2) The development of a VLP-based vaccine for CRC. These objectives 
combine to explore the potential for a CRC vaccine capable of inducing a targeted anti-
tumour immune response, while simultaneously manipulating components of the immune 
system.  
Modification of immune responses to vaccines can be achieved through the use of adjuvants 
that selectively induce the activation of particular immune cell subsets, or promote a specific 
type of immune response. In this project, DNA oligonucleotides containing unmethylated 
CpG islands (CpG) were investigated for their potential ability to be encapsulated inside 
RHDV VLP, based on the ability of VLP to encapsulate short nucleic acids during assembly. 
In addition, targeted manipulation of expression pathways in APCs was assessed by 
investigating the ability of RHDV VLP to encapsulate siRNA, with the potential for selective 
knockdown of suppressive pathways to promote activation. This PhD project concludes with 
the development of a VLP-based vaccine for CRC. In a recent study, epitopes derived from 
the melanoma-associated antigen gp100 were inserted at the N-terminus of RHDV VP60, 
forming VLP that delayed tumour growth and prolonged survival in a subcutaneous murine 
melanoma model [652]. Despite the induction of a targeted immune response, most mice in 
this study eventually succumbed to their tumours. It is possible that the tumours present in 
vaccinated mice consisted of populations of cells with low gp100 expression, through 
changes either in expression or through selective elimination of high gp100 expression cells. 
This study will investigate whether targeting multiple epitopes simultaneously in the same 






1. Nucleic acids will associate with RHDV VLP, as has been previously observed for α-
galactosylceramide and mannose. 
2. Chimaeric RHDV VLP will support the insertion of multiple peptides derived from 
murine CRC-associated antigens. 
3. Chimaeric RHDV VLP containing peptide epitopes derived from murine CRC-
associated antigens will induce targeted immune responses against their inserted 
epitopes. 
4. Chimaeric RHDV VLP containing peptide epitopes derived from murine CRC-
associated antigens will be an effective immunotherapeutic vaccine in a murine model 
of CRC. 
5. Chimaeric RHDV VLP containing multiple peptide epitopes derived from murine 
CRC-associated antigens will impair tumour growth, and enhance survival in a 
murine model of CRC compared to chimaeric RHDV VLP containing single epitopes.  
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2 Materials and Methods 
2.1 Development of Chimaeric RHDV VLP 
This study involved the use of both previously constructed and newly developed chimaeric 
RHDV VLP. Each construct was based on the ‘Sugar Loaf’ variant of VP60 from a locally 
identified strain of RHDV. Both VP60, and the recombinant form containing the H-2Kb-
restricted chicken ovalbumin epitope SIINFEKL at the N-terminus of VP60 (SIIN.VP60), 
were provided pre-constructed and packaged in verified recombinant baculovirus inoculums. 
The recombinant constructs containing either an octaarginine sequence (R8.VP60) or a DNA 
binding site derived from HPV-16 (DBS.VP60) at the N-terminus of VP60 were provided 
pre-cloned into pAcUW51(GUS) plasmids. Each of the constructs that contained epitopes 
derived from the CRC-associated antigens topoisomerase IIα and survivin were developed 
from custom synthetic sequences provided in pUC57 or pUC57-Simple plasmids (Genscript, 
New Jersey, USA). These constructs included insertions of either the epitopes from 
topoisomerase IIα (T.VP60), survivin (S.VP60) or both (TS.VP60) at the N-terminus of 
VP60, each of these epitopes at the N- or C-terminus (S.VP60.T), and a modified version of 
TS.VP60 with a C-terminus insertion of the topoisomerase IIα epitope (TS.VP60.T). These 
constructs and their respective sequences are summarised in Table 2.1. 
 
2.1.1 Permits and Approvals 
The development, production and use of recombinant baculoviruses expressing each RHDV 
VP60 construct were undertaken under the Institutional Biological Safety Committee (IBSC) 
approval number GM010/UO006, including Environmental Risk Management Authority 
(ERMA) approval numbers GMD100300, GMD100301 and GMD100302, or BOK numbers 















* H-2Kb epitope sequences are highlighted in blue, DNA-binding sequences are highlighted in purple, 
and linker sequences are highlighted in red. 
 
2.1.2 Construction of Expression Plasmids 
Each RHDV VLP construct that was developed completely for the purposes of this study 
(e.g. T.VP60, S.VP60, TS.VP60, S.VP60.T and TS.VP60.T) were ligated together through a 
multi-step process into pAcUW51 (GUS) supplied by the Ward Laboratory (Department of 
Microbiology and Immunology, University of Otago, NZ) using established methods [652]. 
The N-terminus of each recombinant VP60 was supplied pre-synthesised, and supplied in 
either pUC57 of pUC57-Simple (GeneScript, New Jersey, USA). Each construct was 
designed to insert the recombinant sequence between the initial methionine and glutamic acid 
residues, and included sequences corresponding to the N-terminus of VP60 up to and 
including its PstI restriction digestion cleavage site. These epitope sequences were obtained 
from the National Center for Biotechnology Information (NCBI) database (Mus musculus 
topoisomerase IIα Gene ID: 21973, Mus musculus baculoviral IAP repeat-containing 5 also 
known as survivin Gene ID: 11799). Each epitope sequence was manually codon optimised 
for expression in Spodoptera frugiperda using the Kazusa Codon Usage Database [654]. The 
sequences supplied are provided below in Table 2.2. Linker sequences incorporated into each 
construct included a spacer consisting of glycine-glycine-serine (GGS) between the 
recombinantly inserted sequences and the remainder of VP60, and an immunoprotease 
cleavage linker consisting of alanine-lysine-lysine (ALL) between epitopes. While the GGS 
spacer has been historically used in RHDV VLP constructs produced by our laboratory, the 
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ALL linker was only recently investigated for its ability to enhance the immunogenicity of 
multiple epitopes incorporated into the same construct [652].  
 


















* H-2Kb epitope sequences are highlighted in blue and restriction enzyme target sequences are 
highlighted in red and purple for BglII and PstI respectively. The methionine initiation codon for each 
sequence has been underlined. 
 
2.1.2.1 Plasmid Transformation and Production 
Stocks of calcium competent E. coli XL-1 Blue MRF cells were supplied at -80 °C by the 
Ward Laboratory for plasmid transformation, replication and extraction. These stocks were 
produced by streaking E. coli XL-1 Blue MRF cells out onto Luria-Bertani (LB) agar plates 
containing 12.5 μg/mL tetracycline, incubated overnight at 37 °C. A single colony was 
isolated from the plate, and was used to inoculate 5 mL of LB broth containing 12.5 μg/mL 
tetracycline. The inoculated broth was incubated at 37 °C for 16 hours under agitation. 1.2 
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mL of this culture was used to inoculate a flask containing 120 mL of LB broth, and was 
incubated as previously described until the optical density at 600 nm (OD600) reached 
approximately 0.4. Upon reaching the desired density, the flask culture was incubated on ice 
for 15 minutes, and then centrifuged at 3000 xg at 4 °C for 10 minutes. Upon removal of the 
media, the pelleted cells were resuspended in 40 mL of Transformation Buffer I pre-chilled 
at 4°C. The resuspension was then centrifuged at 3000 xg at 4 °C for 10 minutes, after which 
the pelleted cells were resuspended in 40 mL of Transformation Buffer II pre-chilled at 4°C. 
This resuspension was distributed into 100 uL aliquots that were subsequently stored at -80 
°C. 
Plasmids were transformed into these calcium competent E. coli cells by heat shock. For each 
transformation, a stock aliquot of cells was removed from -80 °C storage and was thawed on 
ice for 15 minutes. A 10 μL solution containing either the pre-synthesised plasmids diluted 
in Milli-Q H2O, or ligation reaction products, was then added to the cell aliquot and incubated 
for a further 15 minutes on ice. The cells were then heat shocked at 37 °C for 5 minutes, 
before returning to ice for 2 minutes. 100 uL of the resulting transformation solution was 
streaked onto a LB agar plate containing 50 μg/mL ampicillin, and incubated at 37 °C 
overnight. Selected colonies were used to inoculate 5 mL of LB broth containing 50 μg/mL 
ampicillin, and incubated at 37 °C for 16 hours. 3 mL of the resulting culture broth was 
centrifuged as two 1.5 mL aliquots at 12,000 x g for 1 minute for plasmid extraction from 
pelleted cells. 
 
2.1.2.2 Plasmid Extraction 
Heat shock transformed, antibiotic-selected plasmid producing E. coli cells pelleted as 
previously described were processed for plasmid extraction using the AxyPrep Plasmid 
Miniprep kit (Axygen, California, USA) following the instructions provided by the 
manufacturer. Briefly, 2x 1.5 mL aliquots of plasmid containing E. coli cultured overnight at 
37 °C in LB broth containing 50 μg/mL ampicillin were centrifuged at 12,000 xg for 1 
minute. The pelleted bacteria were resuspended in 250 μL of Buffer S1 by briefly vortexing. 
250 μL of Buffer S2 was added, and the tubes were inverted 6 times. 350 μL of Buffer S3 
was added, and the tubes were inverted 8 times. The lysed material was centrifuged at 12,000 
xg for 10 minutes, and the supernatant from both tubes was transferred into a Miniprep 
column loaded into a collection tube. The column was centrifuged at 12,000 xg for 1 minute. 
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As XL1-Blue E. coli are EndA deficient, Buffer W1 was skipped and 700 μL of Buffer W2 
was added to the spin column. The column was centrifuged at 12,000 xg for 1 minute, before 
adding a further 700 μL of Buffer W2 and repeating centrifugation. The spin column was 
then centrifuged again at 12,000 xg for 1 minute, and transferred to a 1.5 mL microfuge tube. 
50 μL of Milli-Q H2O was added, allowed to stand for 1 minute at room temperature, and the 
column was centrifuged at 12,000 xg for 1 minute. Purified plasmids were analysed for both 
quality and quantity using a NanoDrop 1000 (Thermo Scientific, Delaware, USA), and were 
then stored at -20 °C. 
 
2.1.2.3 Restriction Digestion 
Restriction digests were performed using 1-5 μg of plasmid DNA, added to 2 μL of a 10X 
Restriction Buffer (Roche Diagnostics, Germany) appropriate for the restriction enzyme 
combination used, 1 μL of each appropriate restriction enzyme, and sufficient Milli-Q H2O 
as to bring the total reaction volume up to 20 μL. Restriction digestion reactions were 
incubated at 37 °C for 2 hours, prior to separation of digestion fragments by agarose gel 
electrophoresis. 
 
2.1.2.4 Agarose Gel Electrophoresis 
For each restriction digestion reaction, 2 μL of 6X loading dye was added to a 10 μL of the 
reaction product. The resulting solution was loaded on a 1-2 % agarose gel containing 1X 
Tris acetate EDTA (TAE) buffer, and digestion fragments were separated by electrophoresis 
in 1X TAE buffer for 1 hour at 100 V. Samples were run alongside an aliquot of 1 Kb Plus 
DNA ladder (Invitrogen, California, USA) for size comparison. Upon completion of 
electrophoresis, gels were incubated in a solution of 1 μg/mL ethidium bromide in H2O for 
30 minutes, before being visualised under ultraviolet light using a Bio-Rad ChemiDoc gel 
visualisation system (Bio-Rad, California, USA). 
 
2.1.2.5 Gel Extraction of Digestion Fragments 
Following restriction digestion and separation by agarose gel electrophoresis, select digestion 
fragments were excised from the gel for extraction. These fragments were excised using a 
scalpel under reduced ultraviolet light exposure on a Bio-Rad ChemiDoc gel visualisation 
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system (Bio-Rad, California, USA). Excised agarose gel segments containing each digestion 
fragment were processed immediately for DNA extraction, or were frozen at -20 °C for later 
extraction. DNA extraction was performed using an AxyPrep DNA Gel Extraction kit 
(Axygen, California, USA) following the instructions provided by the manufacturer. Briefly, 
the extracted fragment of gel was weighed and assigned a volume as per the manufacturer’s 
instructions, based on 100 mg of gel equating roughly 100 μL sample volume (SV). 3X SV 
of Buffer DE-A was added to the gel and heated at 75 °C for 6 minutes. 1.5X SV of Buffer 
DE-B was added and mixed gently by inversion. 1X SV of isopropanol was then added if the 
DNA fragments were known to be less than 400 bp in length. The solubilised gel solution 
was transferred to a spin column loaded into a collection tube, and centrifuged at 12,000 xg 
for 1 minute. 500 μL of Buffer W1 was added, and the column was centrifuged at 12,000 xg 
for 30 seconds. 700 μL of Buffer W2 was added, and the column was centrifuged at 12,000 
xg for 30 seconds. A further 700 μL of Buffer W2 was added, and centrifugation was 
repeated. The spin column was centrifuged for a further 1 minute at 12,000 xg, before 30 μL 
of MilliQ H2O was added to the spin column. The spin column was allowed to equilibriate 
for 1 minute at room temperature, then centrifuged at 12,000 xg for 1 minute. Extracted DNA 
fragments were analysed for both quality and quantity using a NanoDrop 1000, and were 
then stored at -20 °C. 
 
2.1.2.6 DNA Ligation 
Ligation of appropriate combinations of DNA fragments was used to complete the formation 
of plasmids that could be amplified through transformation into E. coli. For each ligation 
reaction, 14 μL of a single or a 1:1 ratio of a double solution of digestion fragments was 
added to 3 μL of plasmid linearised through the restriction digestion and agarose gel 
extraction procedures previously described. Concentrations of gel-extracted digestion 
fragments varied between 50-200 μg/μL, while gel-extracted linearised plasmids varied 
between 200-300 μg/μL. 2 μL of 10X Ligation Buffer (Roche Diagnostics, Germany) and 1 
μL of T4 DNA Ligase (Roche Diagnostics, Germany) were added, and the resulting ligation 
solution was incubated overnight at 4 °C. The ligation products were directly transformed 




2.1.2.7 Expression Plasmid Construction 
Pre-synthesised recombinant VP60 N-terminus sequences provided in pUC57 or pUC57-
Simple plasmids were transformed, amplified and purified from E. coli as previously 
described in sections 2.1.2.1 and 2.1.2.2. The N-terminus sequence was excised from each 
plasmid by restriction digestion with BglII (Roche Diagnostics, Germany) and PstI (Roche 
Diagnostics, Germany) restriction enzymes, separated by agarose gel electrophoresis and 
purified by gel extraction as previously described. The remainder of VP60 C-terminus was 
excised from a pAcpol-.VP60 expression plasmid purified from E. coli stocks supplied by 
the Ward Laboratory using PstI and EcoRI (Roche Diagnostics, Germany) restriction 
enzymes and the fragments were gel extracted. pAcUW51(GUS) expression plasmid purified 
from E. coli stocks supplied by the Ward Laboratory was linearised using BglII and EcoRI 
restriction enzymes and gel extracted as described in section 2.1.2.5. A combination of the 
recombinant N-terminus and VP60 C-terminus digestion fragments were ligated with the 
linearised pAcUW51(GUS) plasmids as previously described. 
The expression plasmids for the dual N-terminus and C-terminus insertion constructs 
S.VP60.T and TS.VP60.T were derived from the expression plasmids of S.VP60 and 
TS.VP60 respectively, in addition to the expression plasmid of a C-terminus topoisomerase 
IIα construct (VP60.T) supplied by the Ward Laboratory. The N-terminus of each 
recombinant construct was excised by restriction digestion with BglII and PstI restriction 
enzymes, separated by agarose gel electrophoresis and purified by gel extraction as 
previously described. The C-terminus of VP60.T was excised by restriction digestion with 
PstI and EcoRI restriction enzymes, separated and purified. These digestion fragments were 
ligated together into the pAcUW51(GUS) expression plasmid, which had been linearised as 
previously described. Each of the resulting completed expression plasmids were transformed 
into E. coli, amplified and extracted for verification. A summary of the expression plasmid 





Figure 2.1 Development of Recombinant VP60 Expression Plasmids 
Recombinant VP60 expression plasmids were constructed using the plasmid backbone of (A) pAcUW51(GUS) 
linearised with BglII and EcoRI, the modified N-terminus of VP60 (X.VP60) in (B) pUW57-Simple.X.VP60 
extracted with BglII and PstI, and the C-terminus of VP60 in (C) pAcpol-.VP60 extracted with PstI and EcoRI. 
These fragments and the plasmid backbone were ligated together to form the VP60 expression plasmid, (D) 
pAcUW51(GUS).X.VP60. 
 
2.1.2.7 Verification of Expression Plasmids 
The expression plasmid for each recombinant VP60 construct was verified initially by 
restriction digestion and gel electrophoresis, and subsequently by sequencing. The initial 
check was undertaken by digesting each expression plasmid with BglII and EcoRI, and 
separating the digestion fragments by agarose gel electrophoresis as previously described in 
section 2.1.2.4. This protocol was used to screen for plasmids containing fragments of an 
appropriate length prior to sequencing. For sequencing, 600 ng of each expression plasmid 
selected for positive fragment incorporation was diluted in 28 μL aliquots Milli-Q H2O 
containing 0.2 pmol/μL of either P10F, VP60intF or VP60intF3 sequencing primer supplied 
by the Ward Laboratory. The combination of sequence reads from these three primers 
provides full coverage of the VP60 gene, and their sequences are provided below in Table 
2.3. These samples were sequenced by the Massey Genome Service (Massey University, 
NZ), and the results were analysed using the SeqMan Pro application of the Lasergene 




Table 2.3 Expression Plasmid Sequencing Primers 
Primer Binding Location* Sequence 
P10F -217 to -230 CTAGAGTCGAGCAAGAAAATAAA 
VP60intF 487 to 503 CTCGAACCTGTTACCAT 
VP60intF3 1452 to 1475 GTACGGCACAGGCTCCCAACCACT 
* Binding location is relative to the first base of the VP60 gene. 
 
2.1.3 Production of Recombinant Baculovirus 
Each recombinant Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV), 
henceforth generically referred to as ‘baculovirus’, was produced through co-transfection of 
each expression plasmid into Spodoptera frugiperda IPLB-Sf21 (Sf21) cells along with the 
FlashBAC ULTRATM expression system (Oxford Expression Systems, Oxford, UK). This 
expression system was used as it negates the requirement to separate recombinant and 
unmodified parent virus produced, as the parent virus is non-viable in its unmodified form 
[655]. 
 
2.1.3.1 Sf21 Cell Culture 
Sf21 seed cultures were supplied by the Ward Laboratory, and were maintained in 
Spodoptera frugiperda 900-III (Sf900-III) serum-free media (Gibco Invitrogen, New York, 
USA). Cultures were maintained at 27 °C with agitation at 125 rpm, and were split routinely 
every 3-4 days after reaching a density of >5 x 106 cells/mL. New cultures were seeded at 8 
or 10 x 105 cells/mL for a 4 or 3 day growth period respectively. Cell viability and density 
was monitored using a haemocytometer loaded with culture samples mixed 1:1 with trypan 
blue. 
 
2.1.3.2 Sf21 Co-transfection 
Cultures of Sf21 cells were seeded into each well of a 6-well plate at 5 x 105 cells/mL in 3 
mL of Sf900-III media, and incubated at 27 °C for 1 hour. During this time, a transfection 
solution was prepared that consisted of 6 μL of FuGENE 6 transfection reagent (Promega, 
87 
 
Wisconsin, USA) in 100 uL of Sf900-III media. This solution was added to another 100 μL 
aliquot of Sf900-III media containing 1 μg of a select recombinant VP60 expression plasmid, 
and 80 ng of the FlashBAC ULTRATM plasmid. The resulting transfection mixture was 
incubated at room temperature for 30 minutes. Upon completion of the co-ordinated 
incubation times of both the 6-well cell cultures and the transfection mixture, the media was 
carefully removed from the 6-well cell cultures. The transfection mixture was added 
dropwise onto the cell monolayer, rocked to ensure even distribution across the well, and 
incubated for a further 1 hour at room temperature with additional rocking every 20 minutes. 
After incubation, 3 mL of Sf900-III media containing 100 U/mL penicillin and 0.1 mg/mL 
streptomycin (1X Pen/Strep) (Roche Diagnostics, Germany) was added to each well, and 
incubated at 27 °C for 4 days. Afterwards, media containing budded baculovirus was 
removed and stored at 4 °C for screening. 10 μL of X-gluc was added to each well of the 6-
well culture plate after complete removal of the media. Identification of a blue colour change 
was indicative of a successful transfection reaction, based on expression of the GUS reporter 
gene from each expression plasmid. 
 
2.1.3.3 Baculovirus Plaque Assay 
Plaque assays were used to screen, purify and to determine the titres of recombinant 
baculovirus preparations. Cultures of Sf21 cells were seeded into each well of a 6-well plate 
at 5 x 105 cells/mL in 3 mL of Sf900-III media, and incubated at 27 °C for 1 hour. During 
this time, a 10-fold serial dilution ranging from 10-3 to 10-8 of the baculovirus preparation 
was prepared. Upon completion of the incubation time, the media was removed from each of 
the wells and replaced with 100 μL of the baculovirus dilutions assigned to respective wells. 
The plate was rocked to ensure even distribution over the cell monolayer, and then incubated 
at room temperature for 1 hour with additional rocking every 20 minutes. Afterwards, the 
baculovirus dilution solutions were removed from each well, and replaced with a 2 mL 
overlay of 1.5% SeaPlaque agarose (Lonza, Maine, USA) in Sf900-III media containing 10% 
fetal bovine serum (FBS) pre-warmed to 41 °C. The overlaid wells were incubated at room 
temperature for 2-3 minutes to allow the SeaPlaque agarose to set, after which 1.5 mL of 
Sf900-III media containing 10% FBS and 1X Pen/Strep was added to each well, and the plate 
was incubated at 27 °C for 4 days. Plaques were visualised by adding 10 μL of neutral red 
stain to each well, and incubating for 2 hours at room temperature. The viral titre was 
determined by counting the number of plaques that correlated with each well of the 10-fold 
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serial dilution. Suitable plaques were picked using a sterile Pasteur pipette to purify a selected 
baculovirus, and inoculated into 10 mL cultures of Sf21 cells to propagate the virus. 
 
2.1.3.4 Baculovirus Inoculum Preparation 
Upon plaque purification, each recombinant baculovirus was propagated in a 10 mL culture 
of Sf21 cells grown over 4 days at 27 °C with agitation at 125 rpm. These cultures were 
subsequently spun at 500 xg for 5 minutes, with the supernatant inoculum retained and 
filtered through a 0.2 μm Minisart hydrophilic filter (Satorius Stedium Biotech GmbH, 
Gottingen, Germany). Inoculums were stored at 4 °C, and serially amplified through at least 
two rounds of inoculation of 1 mL of inoculum into 50 mL cultures of Sf21 cells. Viral titres 
in subsequent amplified inoculums were determined by plaque assay as previously described. 
 
2.1.4 Production and Purification of RHDV VLP 
2.1.4.1 Inoculation of Sf21 Cultures 
400 mL cultures of Sf21 cells seeded at 1 x 106 cells/mL, and containing 1X Pen/Strep, were 
inoculated with recombinant baculovirus at a multiplicity of infection (MOI) of 1. Inoculated 
cultures were incubated for 3 days at 27 °C with agitation at 125 rpm. Cell viability was 
checked as previously described following these 3 days, with a proportion of approximately 
40% dead cells desirable for optimal yields of RHDV VLP. 
 
2.1.4.2 Purification of RHDV VLP 
RHDV VLP were harvested from inoculated Sf21 cell cultures through a combination of cell 
lysis and centrifugation. Triton-X 100 (Sigma-Aldrich, Montana, USA) was added to a 
concentration of 0.5% in each culture, and incubated at room temperature for 30 minutes to 
ensure complete cell lysis and inactivation of recombinant baculovirus. The lysed material 
was then centrifuged at 10,000 xg for 30 minutes to remove cellular debris. The supernatant 
was retained, and spun at 100,000 xg for 1.5 hours on an Optima L-90K Ultracentrifuge 
(Beckman Coulter, California, USA) to pellet the VLP and other remaining material. These 
pellets were resuspended in 1 mL of insect phosphate buffered saline (iPBS) at 4 °C 
overnight. Further debris was removed from these resuspensions with an additional spin at 
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10,000 xg for 30 minutes. The resulting supernatants were overlaid onto gradients of caesium 
chloride (CsCl), consisting of 3 mL of 1.4 g/cm3 CsCl carefully underlaid beneath 3 mL of 
1.2 g/cm3 CsCl in a SW32.1 polyallomer tube. Each tube was topped up and balanced with 
additional iPBS carefully overlaid over the VLP containing supernatant. Gradients were spun 
at 100,000 xg for 18 hours at 4 °C. As RHDV VLP have a density of 1.34 g/cm3 [645], they 
form a band that can be harvested from the gradient interface. VLP harvested from CsCl 
gradients were stored at 4 °C, or dialysed for 30 minutes with 10,000 Da dialysis tubing into 
a sterile 50% glycerol solution for storage at -20 °C. 
 
2.1.5 Analysis of RHDV VLP 
2.1.5.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
RHDV VLP production was monitored, screened and verified primarily using sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). 5 μL of each sample was 
diluted into 45 μL Milli-Q H2O, then added to 50 μL of 2X sample buffer and boiled for 5 
minutes. Boiled samples, along with Broad Range protein marker (New England Biolabs, 
Maryland, USA), were loaded onto 10% polyacrylamide gels containing SDS, and were 
resolved at 170V for around 60 minutes in a Mini-PROTEAN III gel tank (Bio-Rad, 
California, USA). Gels were stained for 30 minutes in Coomassie blue stain and then 
incubated overnight in destain solution, with a submerged absorptive paper pad included to 
absorb any liberated dye. Stained gels were visualised using a Bio-Rad ChemiDoc system. 
 
2.1.5.2 Western Blot 
The identity of the VP60 band separated by SDS-PAGE was verified for each chimaeric 
RHDV VLP construct by Western blot. Instead of staining with Coomassie blue, the resolved 
proteins in SDS-PAGE gels were transferred into Immobilon PVDF membrane with a 
TransBlot SD Semi-Dry Transfer System (Bio-Rad, California, USA). Each transfer arranged 
from anode plate to cathode plate consisted of two layers of Whatman 3 mm filter paper 
soaked in anode buffer I, one layer of filter paper soaked in anode buffer II, a section of 
PVDF membrane soaked in cathode buffer for 10 minutes, the gel soaked in cathode buffer 
for 10 minutes, and three layers of filter paper soaked in cathode buffer. 22 V was applied 
for 20 minutes to induce the transfer, after which the membrane was air dried on filter paper 
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for 20 minutes. The membrane was then blocked for 1 hour in a 20 mL solution of phosphate 
buffered saline (PBS) containing 1% casein alanate (Fonterra, NZ). Membranes were washed 
5 times for 5 minutes in 20 mL of PBS containing 0.02% Tween-20 (Sigma-Aldrich, 
Montana, USA), before being probed for 30 minutes with rabbit anti-VP60 polyclonal 
antibody supplied by the Ward Laboratory, diluted 1 in 2000 in PBS containing 1% casein 
alanate and 0.02% Tween-20. Membranes were again washed 5 times for 5 minutes in 20 mL 
of PBS containing 0.02% Tween-20, before being probed for 30 minutes with DyLight 800-
labelled donkey anti-rabbit monoclonal antibody (Clone SA5-10044, Lot QC1998302, 
Thermo Scientific, Delaware, USA) diluted 1 in 20,000 in PBS containing 1% casein alanate 
and 0.02% Tween-20. Membranes were washed a final time, 5 times for 5 minutes in 20 mL 
of PBS containing 0.02% Tween-20, and visualised at 800 nm using an Odyssey FC 
fluorescence imager (LI-COR, Nebraska, USA). 
 
2.1.5.3 Mass Spectrometry 
Verification of the identity of each chimaeric VLP produced was performed using mass 
spectrometry, providing indications of masses corresponding to peptide sequences associated 
with the recombinant insertion. Resolved VP60 bands were excised using a scalpel blade 
from an SDS-PAGE gel, digested in trypsin, and analysed using MALDI-TOF/TOF or LTQ-
Orbitrap hybrid mass spectrometry by the Centre for Protein Research (University of Otago, 
NZ). 
 
2.1.5.4 Electron Microscopy 
Assembly of intact VLP derived from each recombinant VP60 construct was confirmed by 
visualising samples of VLP by electron microscopy. VLP samples were diluted to 0.2 mg/mL 
in Milli-Q H2O, and 10 μL of the diluted VLP was incubated for 1 minute on a plasma glowed 
carbon-coated grid. Excess sample was removed using absorptive filter paper, and replaced 
with 10 μL of a negative stain consisting of 1% phosphotungstic acid at pH 6.8. This negative 
stain was immediately removed using absorptive filter paper. Each grid was dried under a 
lamp for 5 minutes, before viewing on a CM100 BioTWIN transmission electron microscope 
(TEM) (Phillips/FEI Corporation, Netherlands). Images of negatively stained VLP were 
obtained using the MegaVIEW III Soft Imaging System, in combination with the iTEM 
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Universal Imaging Platform (Soft Imaging System, Germany) at the Otago Centre for 
Electron Microscopy (University of Otago, NZ). 
 
2.2 Association of Nucleic Acids with RHDV VLP 
2.2.1 Detection of Endogenous Nucleic Acids in RHDV VLP 
Endogenous nucleic acids were detected in purified RHDV VLP samples by electrophoresis 
on an agarose gel. 2 μL of 6X loading dye was added to 10 μL of RHDV VLP diluted to 1 
mg/mL in iPBS, loaded onto a 2% agarose gel containing 1X TAE buffer, and 
electrophoresed at 100V in 1X TAE buffer. Samples were run alongside an aliquot of 1 Kb 
Plus DNA ladder for size comparison. Upon completion of electrophoresis, gels were 
incubated in a solution of 1 μg/mL ethidium bromide in H2O for 30 minutes, before being 
visualised under ultraviolet light using a Bio-Rad ChemiDoc gel visualisation system. 
 
2.2.1.1 Benzonase Treatment of RHDV VLP 
Samples of RHDV VLP were treated with benzonase in an attempt to remove endogenous 
nucleic acids present in purified RHDV VLP samples that are not directly associated with 
and protected by the VLP. 100 IU of benzonase was added to 50 μL of RHDV VLP diluted 
to 1 mg/mL in iPBS, and incubated for 1 hour at 37 °C. Benzonase was inactivated by adding 
25 mM EDTA and heat inactivation for 10 minutes at 65 °C. The sample was then incubated 
for 2 hours at 56°C with the addition of 3% SDS and 50 μg proteinase K. 
 
2.2.2 Disassembly and Reassembly of RHDV VLP 
RHDV VLP were disassembled and reassembled using methods previously published by El 
Mehdaoui et al [656], with some minor modification. Samples of VLP were initially dialysed 
into disassembly buffer in 10,000 Da dialysis tubing over 18 hours, with the buffer exchanged 
after 2 and 6 hours. Disassembly was initiated by diluting VLP to 1 mg/mL in a solution 
consisting of disassembly buffer with the addition of 20 mM dithiothreitol (DTT) and 10 mM 
ethylene glycol tetraacetic acid (EGTA). This solution was incubated for 12 hours at room 
temperature to achieve maximal disassembly of VLP. Reassembly was induced by diluting 
disassembled VLP 1:5 in a reassembly solution consisting of disassembly buffer, 
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dimethylsulfoxide (DMSO) and calcium chloride (CaCl2), with a final concentration of 1% 
DMSO and 5 mM CaCl2. 
 
2.2.2.1 Differential Ultracentrifugation 
Gradients of CsCl were constructed by underlaying 1 mL of 1.4 g/cm3 CsCl solution beneath 
1 mL of 1.2 g/cm3 CsCl in SW55 polypropylene tubes (Beckman Coulter, California, USA). 
0.3 mL of untreated or treated VLP was overlaid over the gradient, and the tubes were topped 
up and balanced with disassembly buffer. Gradients were ultracentrifuged at 100,000 xg for 
18 hours. 0.1 mL was harvested from the 1-1.2 g/cm3 interface, and the 1.2-1.4 g/cm3 
interface. Samples from each of these interfaces were separated by SDS-PAGE, transferred 
onto nitrocellulose membrane and blotted by western blot as previously described in sections 
2.1.5.1 and 2.1.5.2. VP60 was semi-quantified using Odyssey FC software based on band 
intensity. The proportion of VP60 detected at each interface was calculated as a percentage 
with respect to the total amount of VP60 retrieved. 
 
2.2.2.2 Dynamic Light Scattering 
0.5 mL of VLP at 2 mg/mL was stabilised at 25 °C in a disposable cuvette, prior to analysis 
on a Zetasizer ZS-90 (Malvern Instruments, Worcestershire, UK). VLP were analysed with 
settings including an RI of 1.45 and an absorption of 0.001, with PBS as a dispersant. PBS 
viscosity was set at 1.02 cP, with a refractive index of 1.33. These values were derived from 
previous analyses of RHDV VLP on this instrument. Upon reaching thermal stability within 
the Zetasizer, 0.5 mL of test solution was added to the cuvette. This test solution consisted 
of disassembly buffer for the untreated group, and disassembly buffer containing 40 mM 
DTT and 20 mM EGTA for the treated/disassembly group. Average particle diameter was 
monitored over time as determined from instrumental calculations of particle volume. Each 




VLP were analysed spectrophotometrically on a NanoDrop 1000, using a custom protein 
analysis protocol that included settings of ε at 78000 M-1cm-1, and a molecular weight of 60 
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kDa. For disassembly samples, a disassembly blanking solution was used that consisted of 
disassembly buffer containing 20 mM DTT and 10 mM EGTA. This blanking solution was 
incubated under the same conditions and for the same period as the disassembly samples, 
accounting for any background changes in the absorbance profile of the solution. 
Measurements of absorbance at A250 and A280 were recorded at each time point for 
calculation of the A250/A280 ratio.  
 
2.2.3 Loading/Association of CpGs with RHDV VLP 
Custom CpG oligonucleotides based on the ODN 1826 sequence were synthesised 
(GeneWorks, South Australia, Australia) for loading into RHDV VLP through disassembly 
and reassembly, or by association through direct incubation. A second, benzonase digestible 
CpG oligonucleotide was also supplied by the Ward Laboratory for select experiments 
involving benzonase. 25 μg of CpG was added to 100 μL of untreated or disassembled VLP 
at 1 mg/mL, and incubated for 30 minutes at room temperature. Disassembled VLP were 
subsequently reassembled, as previously described. 
 
2.2.3.1 Dialysis to Remove Free CpGs 
Samples of RHDV VLP loaded or associated with CpG were dialysed to remove free CpG 
remaining in solution. Dialysis was performed using 1,000,000 Da dialysis tubing into 
coupling PBS (cPBS) at 4 °C over a period of 18 hours, with the buffer exchanged after 2 
and 6 hours. 
 
2.2.3.2 TAE Acrylamide Gel Electrophoresis 
CpG remaining in samples of VLP following dialysis or benzonase digestion was detected 
by acrylamide gel electrophoresis. 2 μL of 6X loading dye was added to 10 μL of each VLP 
sample, loaded onto a 20% acrylamide gel containing 1X TAE buffer, and electrophoresed 
at 100V in 1X TAE buffer. Samples were run alongside an aliquot of 1 Kb Plus DNA ladder 
for size comparison. Gels were stained with 1X Gel Green (Biotium, California, USA) at 





2.2.3.3 Quantification of VLP Associated CpGs 
The quantity of CpG associated with each VLP sample was determined using the Image 
Studio Software for the Odyssey Fc (LI-COR, Nebraska, USA) by comparing the CpG band 
isolated from each sample against a concentration curve derived from a 2-fold serial dilution 
of a sample with a known CpG concentration. Post-dialysis concentrations of VLP were 
determined by running each sample on an SDS-PAGE gel, using the aforementioned software 
to compare the VP60 band from each sample against a concentration curve derived from a 2-
fold serial dilution of sample with a known VP60 concentration. Together, the concentration 
of CpG and VP60 was used to calculate the relative amount of CpG that associated with each 
chimaeric VLP tested. 
 
2.2.4 RAW-Blue SEAP/NF-κB Reporter Cell Line 
2.2.4.1 Culture of RAW-Blue Cells 
The RAW-Blue cell line was supplied by the Ward Laboratory, previous acquired from the 
American Type Culture Collection (ATCC, Virginia, USA), and cultured under ERMA 
approval NOC000707, BOK number GMD101729. RAW-Blue cells were maintained in 
Dulbecco’s modified eagle medium (DMEM) GlutaMax media (Gibco Invitrogen, New 
York, USA) containing 10% FBS, 1X Pen/Strep, 1X Normocin (InvivoGen, California, 
USA) and 1X Zeocin (Invitrogen, New York, USA) (RB-DMEM). Cells were grown in 
culture at 37 °C with 5% CO2, and split every 2-3 days upon reaching confluency of around 
70-90%. 
 
2.2.4.2 Treatment of RAW-Blue Cells 
RAW-Blue cells were seeded into a 24-well plate at a concentration of 4 x 105 cells/mL in 
500 μL of RB-DMEM, and incubated overnight at 37 °C + 5% CO2. Assigned wells were 
treated with 25 μL of attributed treatment groups, consisting of cPBS and CpG treated cPBS 
control groups, or 1 mg/mL VLP samples pre- or post-dialysis. Treated plates were incubated 
for 24 hours at 37 °C + 5% CO2, after which 300 μL of media was harvested from each well 




2.2.4.3 QUANTI-Blue Assay 
The QUANTI-Blue assay is a colourimetric enzyme assay for determining the concentration 
of SEAP, or any other alkaline phosphatase present in a solution. 20 μL aliquots of media 
isolated from treated RAW-Blue cells, or 20 μL samples from a 2-fold serial dilution of 
recombinant SEAP at a known concentration, were incubated with 180 μL of QUANTI-Blue 
reagent (InvivoGen, California, USA) at room temperature for 1 hour. Measurements were 
taken at 651 nm using a Multiskan microplate reader (MTX Lab Systems, Florida, USA) and 
concentrations of SEAP were determined relative to a concentration curve established by the 
2-fold serially diluted recombinant SEAP. 
 
2.2.5 Murine Bone Marrow-derived Dendritic Cells 
BMDCs compose a heterologous population of dendritic cells, monocyte-derived 
macrophages and various other cell populations [657], produced through maturation of 
haematopoietic progenitor cells under the influence of GM-CSF. This procedure produces a 
large number of mature DCs with a phenotype most closely resembling conventional DCs, 
making BMDCs a favoured model for emulating the potency of DC activation induced by 
vaccine and adjuvant combinations. 
 
2.2.5.1 Ethical Approvals 
Tissues retrieved for use in vitro were obtained from male and female C57BL/6 mice supplied 
by the Hercus Taieri Research Unit (University of Otago, NZ), undertaken in accordance 
with ethical approvals and permits granted by the Animal Ethics Committee (University of 
Otago, NZ) (ET 22/11, ET 10/13). All animals were euthanised humanely by either cervical 
dislocation or through administration of carbon dioxide. 
 
2.2.5.2 Generation of BMDCs 
BMDCs were generated following pre-established laboratory protocols. Hind legs were 
excised under strict sterile conditions from euthanised C57BL/6 mice, using tools frequently 
decontaminated with 70% ethanol. Muscle and other connective tissues were removed from 
the surface of the bones, which were subsequently washed in 70% ethanol followed by two 
washes in sterile Dulbecco’s PBS (DPBS) (Gibco Invitrogen, New York, USA) containing 
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5% foetal calf serum (FCS). Both ends of the cleaned bones were cut, and the marrow space 
was flushed with DPBS + 5% FCS. The flushed marrow material was passed through a 70 
μm cell strainer, and centrifuged at 250 xg for 5 minutes. The pelleted cells were resuspended 
in 1 mL of red blood cell (RBC) lysis buffer pre-warmed to 37 °C, and incubated at 37 °C 
for 1 minute. 9 mL of DPBS + 5% FCS was added to dilute the RBC lysis buffer, and the 
cell solution was spun at 250 xg for 5 minutes. The pelleted cells were resuspended at 5 x 
105 cells/mL in complete Iscove’s modified Dulbecco’s media (cIMDM) (Gibco Invitrogen, 
New York, USA) containing 5% FCS and 20 ng/mL recombinant murine GM-CSF (ProSpec, 
New Jersey, USA). 4 mL of the cell suspension was seeded into each well of a 6-well plate 
and incubated at 37 °C + 5% CO2 for 6 days, with 2 mL of the media replaced per well on 
day 3 with 2 mL of DMEM + 5% FCS containing 20 ng/mL murine GM-CSF. Upon day 6, 
BMDCs were harvested by gently resuspending clumps of proliferated non-adherent cells 
into the media, and transferring the combined suspension from multiple wells into an 
appropriate tube. These cells were then spun at 250 xg for 10 minutes, and resuspended in 
cIMDM + 5% FCS at concentrations determined by the specific down-stream application 
intended for each BMDC preparation. 
 
2.2.5.3 BMDC Activation Assay 
BMDCs harvested from day 6 cultures as previously described were resuspended at 1 x 106 
cells/mL in cIMDM + 5% FCS, and plated out at 200 μL per well in a rounded bottom 96-
well culture plate. Assigned wells were treated with 10 μL of attributed treatment groups, 
consisting of cPBS and CpG treated cPBS control groups, 1 μg LPS, or 1 mg/mL VLP 
samples pre- or post-dialysis. Treated plates were incubated for 24 hours at 37 °C + 5% CO2, 
after which the cells were harvested for flow cytometry. 
 
2.2.5.4 Flow Cytometry 
Harvested BMDCs from each treatment group were washed twice with 1 mL DPBS + 5% 
FCS, and then stained for 15 minutes with 50 μL DPBS containing near infra-red (IR) 
live/dead (L/D) stain (Life Technologies, California, USA) at 1:1000 dilution. The cells were 
then washed with 1 mL of fluorescence-activated cell sorting (FACS) buffer, before being 
stained for 30 minutes at 4 °C with 50 μL of a cocktail of fluorescently labelled antibodies, 
including anti-CD11c/APC (Clone N418), anti-CD40/PE-Cy7 (Clone 3123), anti-
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CD80/Pacific Blue (Clone 16-10A1), anti-CD86/PE (Clone GL-1) and anti-I-A/I-E/FITC 
(Clone M5/114.15.2) (BioLegend, California, USA) at lot-specific dilutions of 1:300-1:500. 
The cells were then washed with 1 mL DPBS + 5% FCS, before being fixed for 15 minutes 
at 4 °C in 50 μL of 2% paraformaldehyde (PFA). The cells were washed a final time with 1 
mL DPBS + 5% FCS, resuspended in 200 μL of FACS buffer, and stored at 4 °C until they 
were analysed by FACS. FACS was performed on a Gallios Flow Cytometer (Beckman 
Coulter, California, USA), and the data was analysed using Kaluza version 1.2 (Beckman 
Coulter, California, USA). 
 
 
Figure 2.2 Flow Cytometry Gating Strategy 
An example of the gating strategy used for assessing DC activation markers. (A) Non-cellular debris was 
excluded from analysis by gating cells from a forward scatter area (INT) linear versus side scatter INT linear 
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plot. (B) Doublets were excluded from analysis by gating for single cells from a side scatter height (PEAK) 
linear versus side scatter INT linear plot. (C) Dead cells were excluded from analysis by gating for live cells, 
unstained with near-IR L/D stain under FL8 INT log. (D) DCs were selected for analysis by gating for CD11c 
positive cells under FL6 INT log. DC activation markers were assessed from the respective channel INT log 
plots for: (E) CD40; (F) CD80; (G) CD86; and (H) I-A/I-E. 
 
2.2.6 Association of siRNA with RHDV VLP 
Synthetic mouse-specific SignalSilence Stat3 siRNA II (Cell Signalling Technology, 
Maryland, USA) and SignalSilence Control siRNA (Cell Signalling Technology, Maryland, 
USA) were obtained for experiments involving association of siRNA with RHDV VLP. 0.5 
μg of siRNA was added to 100 μL of RHDV VLP at a concentration of 1 mg/mL, and 
incubated for 30 minutes at 4 °C. Non-associated siRNA was removed by dialysis as 
previously described. 
 
2.2.6.1 Quantification of siRNA Associated with RHDV VLP 
The quantity of siRNA associated with each VLP sample was determined using the Image 
Studio Software for the Odyssey Fc by comparing the siRNA band isolated from each sample 
against a concentration curve derived from a 2-fold serial dilution of a sample with a known 
siRNA concentration. Post-dialysis concentrations of VLP were determined by running each 
sample on an SDS-PAGE gel, using the aforementioned software to compare the VP60 band 
from each sample against a concentration curve derived from a 2-fold serial dilution of 
sample with a known VP60 concentration. Together, the concentration of siRNA and VP60 
was used to calculate the relative amount of siRNA that associated with each chimaeric VLP 
tested. 
 
2.2.6.2 siRNA-associated RHDV VLP Delivery 
The ability of RHDV VLP to deliver an associated siRNA was tested in the RAW-Blue cell 
line. RAW-Blue cells were seeded into 96-well plates at a concentration of 4 x 105 cells/mL 
in 200 μL of RB-DMEM, and incubated overnight at 37 °C + 5% CO2. Assigned wells were 
treated with 10 μL of attributed treatment groups, consisting of cPBS and siRNA + FuGENE 
HD (Promega, Wisconsin, USA) transfection control groups, or 1 mg/mL VLP samples pre- 
or post-dialysis. Treated plates were incubated for 8 hours at 37 °C + 5% CO2, after which 1 
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μg/mL lipopolysaccharide (LPS) was added. The plates were incubated for a further 12 or 24 
hours at 37 °C + 5% CO2, when the media from each well was removed and stored at -20 °C 
for an IL-6 enzyme-linked immunosorbent assay (ELISA). The cells were lysed with 60 μL 
2X Laemmli buffer, and the resulting lysates were stored at -20 °C for Stat3 Western blots. 
 
2.2.6.3 Stat3/Actin Western blot 
Knockdown of Stat3 was identified by Western blot, using Actinβ as a loading control. 30 
μL of each lysate was loaded onto extra-thick 1.5 mm SDS-PAGE gels, and were separated 
by electrophoresis and transferred onto PVDF membrane as previously described. In this 
instance, the membranes were probed with rabbit anti-Stat3 (Clone 79D7, Lot 7, Cell 
Signalling Technology, Maryland, USA) and goat anti-β-Actin (Clone I-F1, Lot G3115, 
Santa Cruz Biotechnology, California, USA) antibodies diluted 1:1000 in PBS containing 
1% casein alanate and 0.02% Tween-20. These where subsequently probed for using a 
combination of fluorescently labelled anti-rabbit mAb, and a DyLight 680-labelled anti-goat 
mAb (Clone SA5-10090, Lot QC1989644, Thermo Scientific, Delaware, USA) diluted 
1:20,000 in PBS containing 1% casein alanate and 0.02% Tween-20. Following the washing 
steps previously described, the membranes were visualised at 700 and 800 nm using an 
Odyssey FC fluorescence imager. Relative quantification of STAT3 was calculated based on 
the fluorescence intensity of the Dylight 800 labelled secondary antibody, normalised by the 
fluorescence intensity of the Dylight 700 labelled secondary corresponding to actin. 
Quantities were then determined as a percentage in comparison to the average amongst 
untreated controls, with this average set as 100%. 
 
2.3 In Vivo Assays and Trials 
2.3.1 Ethical Approvals 
The C57BL/6 mice used throughout the in vivo assays and trials were supplied by the Hercus 
Taieri Resource Unit. Experiments were conducted in accordance with those outlined in the 
ethical approvals granted by the Animal Ethics Committee (AEC 39/13 and AEC 12/15). All 
animals were euthanised humanely by either cervical dislocation or through administration 




2.3.2 In Vivo Cytotoxicity Assay 
In vivo cytotoxicity assays were used to test the capability and specificity of each chimaeric 
RHDV VLP construct to induce a targeted immune response against their respective 
incorporated epitope(s). This process involves vaccinating mice with each VLP construct, 
and then testing the ability of the induced immune responses to selectively eliminate a target 
population of splenocytes laced with the same epitope. 
 
2.3.1.1 Vaccination with RHDV VLP 
For each in vivo cytotoxicity experiment, 6 female C57BL/6 mice aged 6-8 weeks were 
assigned to each of 6 treatment groups, cPBS, VP60, T.VP60, S.VP60, TS.VP60 and T + S 
Peptides. At day 0, each mouse was vaccinated with their assigned vaccine, consisting of 100 
μL cPBS, 100 μL cPBS containing 100 μg VLP with 25 μg CpG, or 100 μL cPBS containing 
an equimolar amount of synthetic topoisomerase IIα and survivin peptide (JPT Peptide 
Technologies, Germany) with 25 μg CpG. Each vaccine was administered subcutaneously 
into the left flank. At day 21, each mouse received a second dose of the same vaccine they 
had previously received. 
 
2.3.1.2 Preparation of Target Cells 
The target cells used in these in vivo cytotoxicity assays consisted of splenocytes derived 
from naïve female C57BL/6 mice. Splenocytes were isolated by pressing excised spleens 
through a 70 μm cell strainer, washed with DPBS + 5% FCS. The resulting splenocyte 
solution was centrifuged at 300 xg for 10 minutes, and the pelleted cells were resuspended in 
2 mL of RBC lysis buffer pre-warmed to 37 °C. This solution was incubated for 2 minutes at 
37 °C. 18 mL of DPBS + 5% FCS was added to dilute the RBC lysis buffer, and the 
splenocyte solution was centrifuged at 300 xg for 10 minutes. The pelleted cells were 
resuspended at 2 x 107 cells/mL in cIMDM + 5% FCS, and separated into four equal 
populations corresponding with an unpulsed population, a population pulsed with 10 μM of 
topoisomerase IIα peptide, a population pulsed with 10 μM of survivin peptide, and a 
population pulsed with 10 μM of topoisomerase IIα peptide and 10 μM of survivin peptide. 
Each population of splenocytes was pulsed respectively, and incubated for 2 hours at 37 °C 
+ 5% CO2. Following this incubation, each population was washed three times with DPBS 
containing no FCS, with centrifugation at 300 xg for 10 minutes between each wash, and 
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were resuspended at 2 x 108 cells/mL. These populations were assigned to one of four 
corresponding dye staining group, including 0.2 μM carboxyfluorescein succinimidyl ester 
(CFSE) (CFSELo), 2 μM CFSE (CFSEHi), 5 μM violet proliferation dye (VPD) (VPDHi), and 
2 μM CFSE and 5 μM VPD (CFSEHi/VPDHi). Each assigned target cell population was 
stained according, incubated for 7 minutes at room temperature shielded from light. The 
staining reactions were quenched by adding an equal volume of FCS. Each population was 
washed three times DPBS containing no FCS, with centrifugation at 300 xg for 10 minutes 
between each wash, and were resuspended at 1 x 108 cells/mL. Equal volumes of each target 
cell population was then combined together to produce the target cell mixture suitable for 
infusion into vaccinated mice. 
 
2.3.1.2 Target Cell Infusion and Detection 
At day 28, each vaccinated mouse was infused intravenously with 200 μL of the target cell 
mixture. Mice were culled 48 hours later at day 30, and their spleens were excised. Each 
spleen was processed to produce a single suspension of splenocytes using the same procedure 
previously described for production of the target cells. These single cell suspensions were 
spun at 300 xg for 5 minutes, resuspended in 100 μL of DPBS + 5% FCS containing Near-
IR live/dead dye at 1:1000 dilution, and were incubated for 15 minutes at room temperature. 
The cells were then washed with 1 mL DPBS + 5% FCS, before being fixed for 15 minutes 
in 100 μL of 2% PFA. The cells were washed a final time with 1 mL DPBS + 5% FCS, 
resuspended in 500 μL FACS buffer, and stored at 4 °C until they were analysed by FACS. 
FACS was performed on a Gallios Flow Cytometer, and the data was analysed using Kaluza 





Figure 2.3 In Vivo Cytotoxicity Assay 
An in vivo cytotoxicity assay was used to assess the ability of chimaeric RHDV VLP vaccines to induce epitope-
specific immunity. A) Vaccines were administered subcutaneously into 6-8 week old C57BL/6 mice, with a 
prime vaccination at day 0 and a boost vaccination at day 21. B) Target splenocytes were prepared from the 
spleens of naïve C57BL/6 mice. C) Target cells were infused intravenous into vaccinated mice on day 28. D) 
Spleens were harvest from vaccinated mice on day 30, and processed to identify target cell populations for the 
calculation of percent specific lysis. 
 
2.3.1.3 Calculation of Specific Lysis (%) 
The determination of relative cytotoxicity against each target cell population between 
vaccinated mice was determined using an equation, which includes a correction for 
background cytotoxicity against a control cell population. 
 
 
2.3.3 In Vitro (VITAL) Cytotoxicity Assay 
An in vitro cytotoxicity assay was trialled as a rapid means to determining relative 
immunogenicity of VLP vaccines. The method used was derived from the VITAL assay 
originally developed by Hermans et al [658]. The principles behind the in vitro cytotoxicity 
assay are similar to those of the in vivo cytotoxicity assay, except that the targeted elimination 
of peptide pulsed cells by epitope specific CD8+ T cells is performed in an in vitro co-culture. 
 
2.3.3.1 Vaccination with RHDV VLP 
For each in vitro cytotoxicity experiment, 9 female C57BL/6 mice aged 6-8 weeks were 
assigned to each of 3 treatment groups, VP60, SIIN.VP60 and S.VP60. At day 0, each mouse 
was vaccinated subcutaneously with their assigned vaccine, consisting of 100 μL cPBS 
containing 100 μg VLP with 25 μg CpG. For each treatment group, 6 mice were selected and 
received an additional dose of their respective vaccine on day 1. From these mice, 3 were 
selected from each group to receive a final dose of their respective vaccine on day 2. This 
provided 3 mice from each treatment group who had received 1 dose (1D), 2 doses (2D) or 3 




2.3.3.2 Isolation of CD8+ T Cells 
Each vaccinated mouse was culled on day 7, and the lymph nodes draining the area of 
subcutaneous vaccination were excised. These lymph nodes were pressed through a 70 μm 
cell strainer, washed with DPBS + 5% FCS. The resulting lymph node solution was 
centrifuged at 300 xg for 5 minutes at 4 °C, and the pelleted cells were resuspended in 1 mL 
of RBC lysis buffer pre-warmed to 37 °C. This solution was incubated for 2 minutes at 37 
°C. 9 mL of DPBS + 5% FCS was added to dilute the RBC lysis buffer, and the splenocyte 
solution was centrifuged at 300 xg for 5 minutes at 4 °C. The pelleted cells were resuspended 
in 10 mL of DPBS + 5% FCS, counted, and centrifuged again at 300 xg for 5 minutes at 4 
°C. The cells were resuspended in 90 μL of AutoMACS buffer per 1 x 107 cells, and 10 μL 
of CD8α (Ly-2) microbeads (Miltenyi Biotec, Germany) was added per 1 x 107 cells. This 
solution was incubated for 15 minutes at 4 °C, after which 2 mL of AutoMACS buffer was 
added per 1 x 107 cells. These samples were run through an AutoMACS Pro cell separator 
(Miltenyi Biotec, Germany) on a positive selection protocol. The resulting separated cell 
solution was spun at 300 xg for 5 minutes at 4 °C, and resuspended at 1 x 106 cells/mL in 
cIMDM + 5% FCS. 
 
2.3.3.3 Co-culture and Analysis 
Peptide pulsed target splenocytes were prepared from the spleens of naïve C57BL/6 mice as 
previously described. In this instance, the unpulsed population was stained CFSEHi, the 
SIINFEKL peptide pulsed population was stained VPDHi, and the survivin peptide pulsed 
population was stained CFSEHi/VPDHi. These populations were combined in equal 
proportions, and resuspended at 1.5 x 105 cells/mL in cIMDM + 5% FCS. 100 μL of this 
mixed target cell solution was added to each well of a 96-well U bottom plate. CD8+ T cells 
isolated from the draining lymph nodes of vaccinated mice and separated as previously 
described were added to assigned wells, at an effector:target ratio of 0.1:1. Sufficient cIMDM 
+ 5% FCS was added to bring these co-culture volumes up to 200 μL. These co-cultures were 
incubated for 4 hours at 37 °C, after which the cells were gently harvested from the wells. 
These co-cultured cell suspensions were spun at 300 xg for 5 minutes, resuspended in 100 
μL of DPBS + 5% FCS containing Near-IR live/dead dye at 1:1000 dilution, and were 
incubated for 15 minutes at room temperature. The cells were then washed with 1 mL DPBS 
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+ 5% FCS, before being fixed for 15 minutes in 100 μL of 2% PFA. The cells were washed 
a final time with 1 mL DPBS + 5% FCS, resuspended in 500 μL of FACS buffer, and stored 
at 4 °C until they were analysed by FACS. FACS was performed on a Gallios Flow 
Cytometer, and the data was analysed using Kaluza version 1.2. A summary of the in vitro 
cytotoxicity assay is provided in figure 2.4. Calculation of Specific Lysis (%) was made using 
the equation outlined above for the in vivo cytotoxicity assay in section 2.3.1.3. 
 
 
Figure 2.4 In Vitro Cytotoxicity Assay 
The in vitro cytotoxicity protocol used for assessing the potential benefit of sequential vaccination. A) Vaccines 
were administered subcutaneously into 6-8 week old C57BL/6 mice, with each mouse receiving 1, 2 or 3 doses 
over a 3-day period. B) At day 7, CD8+ T cells were isolated and sorted from the draining lymph node. C) 
Target splenocytes were prepared from the spleen of a naïve C57BL/6 mouse. D) CD8+ T cells from vaccinated 
mice were co-cultured with target splenocytes for 4 hours. E) Each target cell population was identified by flow 
cytometry, and the percent specific lysis was calculated.  
 
2.3.4 MC38-OVA 
The MC38-OVA cell line is a derivative of the MC38 C57BL/6 murine colon 
adenocarcinoma cell line originating from the laboratories of James W. Hodge and Jeffrey 
Schlom (National Cancer Institute, National Institutes of Health, USA). The MC38-OVA 
variant has been modified to stably express chicken ovalbumin, and was provided for these 
studies by Nicole Haynes (Peter MacCallum Institute, Australia). Cells were split every 2-3 
days by removing the media, and adding 0.5 mL, 2 mL or 3 mL of trypsin-EDTA (Gibco 
Invitrogen, New York, USA) to the T25, T75 or T150 flask respectively. Trypsinised cells 
were washed with 20 mL DMEM + 10% FCS, spun at 300 xg for 5 minutes, and resuspended 
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at 5 x 106 cells/mL in DMEM + 10% FCS. 0.5 mL, 2 mL or 5 mL of this cell suspension was 
used to seed a T25, T75 or T150 flask respectively, topped up with 4.5 mL, 18 mL or 45 mL 
of DMEM + 10% FCS respectively. Cells were cultured in DMEM + 10% FCS incubated at 
37 °C + 5% CO2, and were monitored closely for adverse clumping. 
 
2.3.3.1 Verification of Topoisomerase IIα and Survivin Expression 
During the modification of the original MC38 cell line to produce the MC38-OVA variant, 
the expression of some proteins may have been altered. The expression of topoisomerase IIα 
and survivin was confirmed by Western blot as previously described, comparing lysate 
prepared from MC38 and MC38-OVA cells. The probing antibodies used included rabbit 
anti-topoisomerase IIα (Clone 4733S, Lot 1, Cell Signalling Technology, Maryland, USA) 
and rabbit anti-survivin (Clone 7164B7, Lot 13, Cell Signalling Technology, Maryland, 
USA) antibodies, in combination with mouse anti-Actinβ antibody diluted 1:1000 in PBS 
containing 1% casein alanate and 0.02% Tween-20. The membranes were visualised at 700 
and 800 nm using an Odyssey FC fluorescence imager. 
 
2.3.3.2 Verification of Ovalbumin Expression 
The expression of ovalbumin by MC38-OVA cells was confirmed using an IFN-γ release 
assay. MC38-OVA cells were resuspended at 1x105 cells/mL in DMEM + 10% FCS, and 
100 μL was added to each well of a 96-well U bottom plate. Splenocytes were prepared from 
the spleen of a naïve C57BL/6 mouse (Spl), resuspended at 1x105 cells/mL in DMEM + 10% 
FCS, and 100 μL was added to each well of a 96-well U bottom plate, separate from those 
wells containing MC38-OVA cells. 10 μM of SIINFEKL peptide was added to the Spl wells, 
and the plates were incubated for 2 hours at 37 °C. Splenocytes were prepared from the spleen 
of an OT-I mouse, consisting of a C57BL/6 mouse engineered to predominantly express 
TCRs specific for SIINFEKL on their CD8+ T cells (OTI). Further splenocytes were also 
prepared from another naïve C57BL/6 mouse, and each of these splenocyte preparations were 
resuspended at 1x105 cells/mL in DMEM + 10% FCS. 100 μL of either population was added 
to appropriate wells such that 4 different co-cultures were prepared, consisting of Spl + OTI 
cells, SIINFEKL pulsed Spl + OTI cells, MC38-OVA + Spl cells and MC38-OVA + OTI 
cells. These co-cultures were incubated for 48 hours at 37 °C, with media sampled at 24 and 
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48 hours. The concentration of IFN-γ present in these samples was determined with an IFN-
γ ELISA. 
 
2.3.3.3 IFN-γ ELISA 
For the IFN-γ ELISA, 50 μL of capture antibody consisting of purified anti-mouse IFN-γ 
(Clone RA-6A2, BD Biosciences, California, USA) diluted to 2 μg/mL in coating buffer was 
added to each well of a 96-well plate. The plate was incubated overnight at 4 °C, after which 
it was washed 5 times by filling the wells with ELISA wash buffer, and ejecting out the wash 
solution from the inverted plate. 200 μL of PBS + 1% BSA was added to each well, and 
incubated for 2 hours at room temperature. The plate was then washed 5 times as previously 
described. 50 μL of each sample was added to assigned wells, in addition to 50 μL in 
appropriate wells of each concentration of recombinant murine IFN-γ (BD Biosciences, 
California, USA) from a 2-fold serial dilution in PBS + 1% BSA. The plate was incubated 
for 4 hours at room temperature, and then washed 5 times as previously described. 50 μL of 
biotinylated anti-mouse IFN-γ (Clone XMG1.2, BD Biosciences, California, USA) diluted 
to 2 μg/mL in PBS + 1% BSA was added to each well, and incubated for 45 minutes at room 
temperature. The was washed 5 times as described above, and then 50 μL of Steptavidin-
HRP (BioLegend, California, USA) diluted at 1/3000 in PBS + 1% BSA was added to each 
well. The plate was incubated for 30 minutes at room temperature, and then washed 5 times 
as previously described. 100 μL of TMB substrate (Invitrogen, California, USA) was added 
to each well, and incubated in the dark at room temperature for 5-10 minutes until colouration 
had sufficiently developed. The reaction was stopped with 100 μL of 1N H2SO4 added to 
each well. Absorbance at 450 nm was determined for each well using a Model 550 microplate 
reader (Bio-Rad, California, USA), and IFN-γ concentrations were determined using 
Microplate Manager Software version 5.0 (Bio-Rad, California, USA). 
 
2.3.3.4 MC38-OVA Tumour Trials 
For each tumour trial, MC38-OVA cells were thawed from liquid nitrogen and cultured for 
at least 3 passages prior to use. These cells were washed 5 times by centrifuging at 300 xg 
for 10 minutes at 4 °C, and resuspending in 50 mL DPBS pre-chilled at 4 °C. Following their 
final centrifugation, the MC38-OVA cells were resuspended at 2 x 107 cells/mL. On day 0, 
50 μL of these cells were infected subcutaneously on the left flank of an appropriate number 
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of mice, defined as the number of treatment groups multiplied by 10. At day 7, the developing 
tumours were palpated and measured. Tumour-bearing mice were assigned to each treatment 
group, such that the average tumour size and the distribution of tumour sizes were even 
between each treatment group. These treatment groups consisted of cPBS, VP60, SIIN.VP60, 
T.VP60, S.VP60 and TS.VP60. Each mouse was then vaccinated subcutaneously with their 
assigned treatment, consisting of 100 μL cPBS, 100 μL cPBS containing 100 μg VLP with 
25 μg CpG, at a site separate and superior to the tumour site on the left flank. Each mouse 
also received a second and third vaccination of their assigned treatment on days 8 and 9. 
Tumours were measured every 2-3 days, and mice were culled when the tumours reached 
150 mm2 in cross-sectional area. Mice were monitored for a period of 100 days, at which 
time the remaining mice received a rechallenge of 50 μL MC38-OVA cells resuspended at 2 
x 107 cells/mL in DPBS injected subcutaneously on the right flank. A group of 10 naïve 
C57BL/6 mice were also engrafted with MC38-OVA tumours in the right flank as a control 
group. These mice were monitored for a further 100 days with tumour measurements every 
2-3 days, and were culled when the tumours reached 150 mm2 in cross-sectional area. Mice 
that survived until the completion of the trial were culled at day 200. 
 
2.4 Recombinant Vesicular Stomatitis Virus 
Vesicular stomatitis virus (VSV) is an enveloped member of the Rhabdoviridae family. 
Recombinant insertion of a gene at a specific site between the G and L genes of the VSV 
genome results in the production of a virus that can induce expression of the inserted gene in 
host cells. The protocol used in this study for the production of recombinant VSV is routinely 
used by the Vile Laboratory (Mayo Clinic, Minnesota, USA) [659]. For this study, the RHDV 
VLP constructs VP60, SIIN.VP60 and TS.VP60 were adapted for insertion into the 
recombinant VSV expression system. 
 
2.4.1 Construction of Expression Plasmids 
The recombinant VSV expression plasmid, pVSV-NX2, contains an insertion site flanked by 
a XhoI and a NheI restriction site. As our RHDV VLP constructs are based on flanking BglII 
and EcoRI sites, new constructs were required to facilitate adaptation into this expression 
plasmid. A single synthetic plasmid containing the N-terminus of VP60, SIIN.VP60 and 
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TS.VP60 adapted with flanking XhoI and NheI sites (VSV-VP60-N, VSV-SIIN.VP60-N and 
VSV-TS.VP60-N respectively) was purchased (pUC57-Simple.VSV-VLP3X) (Genescript, 
New Jersey, USA). This plasmid construct was also designed with an interspacing HindIII 
site to facilitate the stepwise excision of specific constructs from the plasmid. The structure 
of the pUC57-Simple.VSV-VLP3X plasmid is summarised in figure 2.5. 
 
 
Figure 2.5 Stucture of the pUC57-Simple.VSV-VLP3X Plasmid 
The pUC57-Simple.VSV-VLP3X plasmid was designed with three different modified VP60 N-termini, 
X1.VP60, X2.VP60 and X3.VP60. The proximal BglII site was replaced for each construct with XhoI, with the 
NheI VSV adaption site inserted distal of the PstI-EcoRI site used for insertion of the VP60 C-terminus. 
Additional HindIII sites were included proximal of X1.VP60, and between X1.VP60 and X2.VP60 to facilitate 
construction using the X2.VP60 component. 
 
2.4.1.1 Production of Individual Adapter Plasmids 
The pUC57-Simple.VSV-VLP plasmid was transformed into calcium competent E.coli, 
amplified, and purified using methods previously described. pUC57-Simple.VSV-VLP3X 
was linearised with PstI, separated by electrophoresis, gel extracted and ligated using 
previously described methods. This process resulted in the production of the first adapter 
plasmid construct, pUC57-Simple.VSV-VP60-N. Separately, pUC57-Simple.VSV-VLP was 
also linearised with HindIII (Roche Diagnostics, Germany), separated by electrophoresis, gel 
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extracted and ligated, resulting in the excision of the VSV-VP60-N sequence. The resulting 
pUC57-Simple.VSV-VLP2X plasmid was linearised with either PstI or XhoI (Roche 
Diagnostics, Germany), separated by electrophoresis, gel extracted and ligated to produce the 
pUC57-Simple.VSV-SIIN.VP60-N and pUC57-Simple.VSV-TS.VP60-N plasmids 
respectively. 
 
2.4.1.2 Incorporation of VP60 C-terminus 
The C-terminus of VP60 was excised from the pAcpol-.VP60 plasmid by restriction digestion 
with PstI and EcoRI, separation by electrophoresis, and purified by gel extraction. Each of 
the VSV-VLP adapter plasmids were linearised with PstI and EcoRI, separated by 
electrophoresis, purified by gel extraction and ligated with the purified VP60 C-terminus 
fragments. This resulted in the production of the completed VSV-VLP adapter plasmids, 
pUC57-Simple.VSV-VP60, pUC57-Simple.VSV-SIIN.VP60 and pUC57-Simple.VSV-
TS.VP60. 50 μL of each plasmid at a concentration of around 500 ng/μL was absorbed onto 
strips of Whatman 3 mm filter paper, and air dried for 30 minutes at room temperature. These 
strips were placed inside individual 2 mL cryo vials for shipment to the Vile laboratory at the 
Mayo Clinc, Minnesota, USA. 
 
2.4.1.3 Transformation of HB101 Cells 
Upon arrival, each completed VSV-VLP adapter plasmid was transformed into HB101 E. 
coli cells. Segments of the plasmid-laced filter paper were submerged into 100 μL of double 
distilled H2O (ddH2O), allowing the plasmid to dissolve into solution for 30 minutes at room 
temperature. 10 μL of each dissolved plasmid was added to aliquots of HB101 E. coli cells 
supplied by the Vile laboratory, that were then placed on ice for 20 minutes. Each aliquot 
was heat shocked at 42 °C for 1 minute, then returned to ice for 2 minutes. 5 mL of super 
optimal broth with catabolite repression (SOC) media (Sigma-Aldrich, Montana, USA) pre-
warmed to 37 °C was added to each transformation reaction, and the resulting broths were 
incubated for 60 minutes at 37 °C. 200 μL of each broth was streaked onto a LB agar plate 
containing 50 μg/mL ampicillin. The plates were incubated overnight at 37 °C, and selected 
colonies were used to inoculate 5 mL of LB broth containing 50 μg/mL ampicillin. These 
broths were incubated for 16 hours at 37 °C, and amplified plasmids were extracting using a 
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QIAprep Spin Miniprep kit (Qiagen, Germany). Purified plasmids were quantified using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific, Delaware, USA). 
 
2.4.1.4 Adaptation into pVSV-XN2 
Purified pVSV-XN2 expression plasmid was supplied by the Vile laboratory. This plasmid 
was linearised with XhoI and NheI, separated by electrophoresis, and purified by gel 
extraction as previously described. Each of the VSV-VLP adapter constructs were excised 
from their respective plasmids with XhoI and NheI (Roche Diagnostics, Germany), separated 
by electrophoresis, and purified by gel extraction. Each purified VSV-VLP adapter construct 
was ligated with linearised pVSV-XN2, and the resulting plasmids pVSV.VP60-XN2, 
pVSV-SIIN.VP60-XN2 and pVSV-TS.VP60-XN2 were transformed into HB101 E. coli. 
Each plasmid was amplified and purified from culture broths as previously described. 
 
2.4.1.5 Verification of pVSV-XN2 Plasmids 
The presence of an inserted VP60 sequence into each construct expression plasmid was 
confirmed by digestion with XhoI and NheI, and separation by electrophoresis as previously 
described. The presence of an insert was confirmed based on the separation of bands 
corresponding to both the linearised plasmid, and the inserted sequence. The identity of each 
insert was confirmed by sequencing undertaken by the Molecular Biology Core facility 
(Mayo Clinic, Minnesota, USA). 
 
2.4.2 Production of Recombinant VSV 
2.4.2.1 Culture of Baby Hamster Kidney Cells 
Baby hamster kidney (BHK) cells were supplied by the Vile laboratory. BHK cells were split 
every 2-3 days by removing the media, and adding 0.5 mL, 2 mL or 3 mL of trypsin-EDTA 
to the T25, T75 or T150 flask respectively. Trypsinised cells were washed with 20 mL 
DMEM + 5% FCS, spun at 300 xg for 5 minutes, and resuspended at 5 x 106 cells/mL in 
DMEM + 5% FCS. 0.5 mL, 2 mL or 5 mL of this cell suspension was used to seed a T25, 
T75 or T150 flask respectively, topped up with 4.5 mL, 18 mL or 45 mL of DMEM + 5% 




2.4.2.2 Co-transfection of Expression Plasmids 
The co-transfection protocol used to generate recombinant VSV requires 3 expression 
plasmids in addition to the pVSV-XN2 construct expression plasmid, in addition to provision 
of T7 RNA polymerase. BHK cells were resuspended at 1 x 106 cells/mL in DMEM + 5% 
FCS, and 5 mL was seeded in 10 cm culture plates. These plates were incubated overnight at 
37 °C + 5% CO2, after which the cells were washed briefly with 5 mL PBS before adding 5 
mL of DMEM with no FCS. 50 μL of stock inoculum containing replication defective 
vaccinia that produces T7 RNA polymerase (MVA-T7) was added to each dish, equating to 
a MOI of 10. These inoculated cultures were incubated for 1 hour at 37 °C + 5% CO2. During 
this time, a transfection mixture consisting of 10 μg pVSV-XN2 construct expression 
plasmid, 1 μg pVSV-L, 5 μg pVSV-P and 3 μg pVSV-N in 60 μL FuGENE HD transfection 
reagent, diluted in sufficient DMEM to bring the total volume to 500 μL. This transfection 
mixture was incubated for 30 minutes at room temperature. The media was removed from 
each MVA-T7 inoculated culture, and replaced with 10 mL DMEM + 5% FCS. 500 μL of 
transfection mixture was added to assigned plates. The plates were swirled to mix, and 
incubated for 48 hours at 37 °C + 5% CO2. Following this incubation the media was 
harvested, centrifuged at 350 xg for 5 minutes, and the supernatant was passed through a 0.2 
μm filter to remove any residual MVA-T7. 3 mL of this supernatant was added to per well 
of a 6-well plate containing BHK cells at >95% confluency. This plate was incubated for 1 
hour at 37 °C + 5% CO2, after which the crude inoculum was removed and replaced with 3 
mL DMEM + 5% FCS. The plate was incubated for 48 hours at 37 °C + 5% CO2, when the 
media was harvested. The resulting solution represented the unpurified recombinant VSV 
inoculum, ready for plaque purification. 
 
2.4.2.3 VSV Plaque Assay 
The VSV plaque assay was used for both purification and quantification of the recombinant 
viruses. A pair of 6-well plates were seeded with 3 mL of BHK cells at 1 x 106 cells/mL, and 
incubated at 37 °C + 5% CO2 until they reached a confluency of >90%. The media was then 
aspirated, and the cells were washed with 3 mL of PBS. A 10-fold serial dilution of VSV 
inoculum was prepared, beginning with 12 μL of inoculum in 1188 μL of DMEM, followed 
by transfer of 120 μL along further aliquots of 1080 μL of DMEM and yielding dilutions 
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corresponding to virus titres in the ranges of between 102 and 1012. The PBS was aspirated 
from the BHK cells, and 1000 μL of each virus dilution was added to assigned wells. 1000 
μL of DMEM was added to the last well as a mock infection control. The plates were 
incubated for 1 hour at 37 °C, after which the media was removed. 1.5 mL of an overlay 
mixture consisting of 2% noble agar pre-warmed to 42 °C and mixed 1:1 with DMEM was 
added to each well, and allowed to set for 10 minutes at room temperature. The plates were 
incubated for 48 hours at 37 °C + 5% CO2, when visible plaques were counted or picked for 
purification of virus. Plaques were picked by excising a core of agar using a sterile pipette 
tip, which was then stored at -80 °C prior to inoculum preparation. 
 
2.4.2.4 VSV Inoculum Preparation 
BHK cells were resuspended at 1 x 106 cells/mL in DMEM + 5% FCS, and 5 mL was seeded 
in 10 cm culture plates. These plates were incubated overnight at 37 °C + 5% CO2. Each 
plaque pick tip was incubated in 100 μL of DMEM + 5% FCS for 10 minutes, and 10 μL of 
this solution was added to an assigned culture plate. The plates were then incubated for 48 
hours at 37 °C + 5% CO2, after which the media was harvested and centrifuged at 350 xg for 
5 minutes. The resulting supernatant was considered purified VSV inoculum, and the VSV 
titre was determined by plaque assay. These inoculums were bulked up through successive 
rounds of infection in BHK cells seeded in T150 flasks, and inoculated at a MOI of 1. 
 
2.4.2.5 Verification of RHDV VP60 Expression 
RHDV VP60 expressed by recombinant VSV was verified by purifying VLP from VSV 
infected BHK cell cultures, and identifying VP60 by Western blot. 5 mL of BHK cells at 5 x 
106 cells/mL in DMEM + 5% FCS was seeded in a T150 flask, and topped up with 45 mL of 
DMEM + 5% FCS. The flask was incubated for 1 hour at 37 °C + 5% CO2, then inoculated 
with VSV at a MOI of 1 and incubated for 24 hours at 37 °C + 5% CO2. 0.5% Triton-X 100 
was added, and the culture was incubated for 30 minutes at room temperature to lyse the 
BHK cells, liberate VLP and inactivated VSV. The resulting solution was centrifuged at 
10,000 xg for 30 minutes to pellet cellular debris, and the supernatant was centrifuged at 
100,000 xg for 1.5 hours. The pellet was resuspended in 200 μL of iPBS. Samples of VLP 
expressed by VSV were separated by SDS-PAGE, transferred and identified by Western blot 




2.4.2.6 Visualisation of VSV-expressed VLP 
Samples of VLP produced by VSV centrifuged at 100,000 xg for 16 hours on a 1.2-1.4 g/cm3 
CsCl gradient as previously described. Purified VLP was harvested from the gradient 
interface, diluted to 0.2 mg/mL in Milli-Q H2O, and 10 μL of the diluted VLP was incubated 
for 1 minute on a plasma glowed carbon-coated grid. Excess sample was removed using 
absorptive filter paper, and replaced with 10 μL of a negative stain consisting of 1% 
phosphotungstic acid at pH 6.8. This negative stain was immediately removed using 
absorptive filter paper. Each grid was dried under a lamp for 5 minutes, before viewing on a 
JEM-1400 TEM (JEOL, Maine, USA) at the Microscopy and Cell Analysis Core Facility 
(Mayo Clinic, Minnesota, USA). 
 
2.5 Statistical Analyses 
Statistical analysis was performed using Prism version 6.0 (GraphPad, California, USA). 
Power calculations, statistical test selection and analysis were performed under advice 





3 Nucleic Acids Associated with RHDV VLP for 
Immunomodulation 
3.1 Introduction 
3.1.1 Nucleic Acids and VLP 
Virus-like particles are considered devoid of an intact genome, rendering them incapable of 
self-replication. However, VLP may not necessary be devoid of all nucleic acids. For 
example, VLP derived from feline herpesvirus (FHV) have been found to contain 
heterologous RNA, predominantly ribosomal but also including host-specific RNA [660]. 
Host RNA packaging has also been reported in satellite tobacco necrosis virus (STNV), 
cowpea chlorotic mottle virus (CCMV) VLP, and MS2 VLP [661-663]. It has been proposed 
that secondary structures present in host RNA may actually facilitate or induce VLP 
formation in the absence of the virus genome, at least for STNV VLP [661]. Beyond the 
encapsulation of host RNA during VLP formation, some VLP also possess the capacity to 
encapsulate DNA plasmids for applications in gene delivery. The concept of using a VLP for 
gene delivery can be traced back to studies on polyoma pseudoviruses, or polyoma-like 
particles [664-666]. Several other VLP have since proven suitable candidates for plasmid 
encapsulation and gene delivery, including human papillomavirus [667], John Cunningham 
virus (JCV) [668], polyomavirus [669, 670], Hepatitis E virus VLP [671] and Hepatitis B 
virus VLP [672]. 
JCV VLP in particular has been extensively explored for their potential to deliver genes in 
vivo. JCV is a polyomavirus that was originally identified in a patient suffering from 
progressive multifocal leukoencephalopathy [673], and has been identified within multiple 
tumours including those of central nervous system [674], colon [675], lung [676], stomach 
[677] and oesophagus [678]. This propensity for infecting tumour tissue has made JCV and 
its VLP a potential candidate for tumour targeted gene delivery. Recombinant expression of 
the JCV VP1 major capsid protein results in the formation of JCV VLP that are 
indistinguishable from virions of their parent virus [679]. Plasmids can be packaged in JCV 
VLP post-production through osmotic shock [680] or disassembly and reassembly [681]; 
however, production of JCV VLP in E. coli that also express the plasmid intended for 
delivery has been found to yield enhanced plasmid loading [682]. Nude mice bearing COLO-
320 HSR human colon carcinoma vaccinated with JCV VLP loaded with a GFP expression 
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plasmid resulted in selective uptake of VLP into tumour nodules, and the expression of GFP 
in tumour cells [682]. The procedure was replicated with a plasmid encoding herpes simplex 
virus (HSV) thymidine kinase (TK), with the selective uptake and gene delivery facilitating 
targeted elimination of the tumour cells through subsequent administration of ganciclovir. 
The capacity of JCV VLP for plasmid encapsulation is also quite substantial, known to be 
capable of encapsulating plasmids up to 9.4 kbp in length [683]. With the ability to 
accommodate plasmids of this length, it may be possible to use JCV VLP to selectively 
deliver large genes, or even multiple genes simultaneously. 
VLP that do not inherently possess the ability to encapsulate DNA plasmids can be afforded 
this ability through recombinant insertion of nucleic acid binding domains derived from other 
viruses. A reported example of this involved the recombinant insertion of the DNA binding 
domain from the L1 or L2 proteins of HPV type 16 onto the N-terminus of the RHDV VP60 
gene [656]. The resulting VLP, containing the L1 binding site (VP60-L1BS) or the L2 
binding site (VP60-L2BS), were evaluated for their capacity to encapsulate and deliver 
plasmids in vitro. Both VP60-L1BS and VP60-L2BS gained the ability to bind DNA as 
detected by south-western blotting, although the VP60-L1BS variant had markedly superior 
binding affinity. This difference was subsequently translated into measures of gene delivery 
efficacy, with the VP60-L1BS variant outperforming VP60-L2BS in delivery of plasmids 
encoding either β-galactosidase or luciferase. Amongst a panel of cell lines used, gene 
delivery by VP60-L1BS was most effective in RK13 rabbit kidney cells, R17 rat/mouse 
hybridoma cells, and Cos-7 monkey fibroblast cells [656].  
Modification of VLP to enable encapsulation of a DNA plasmid has the potential for multiple 
applications in vaccine design. Potential applications may include target antigen expression, 
replacement of defective tumour suppressor genes in tumour cells, or the expression of 
various regulatory genes for alteration of cell phenotype. While selective targeting may not 
be necessary in all applications, those with potentially harmful off-target effects benefit from 
incorporation of some form of selective targeting. For example, DNA-binding VLP can be 
designed to target a specific cell population through conjugation of the Fv fragment of 
antibodies generated against surface antigens of those cells. This process was demonstrated 
with polyoma virus VLP, in which aggregates of purified VL and VH domains from a 
selected antibody were conjugated onto the surface of the VLP [684]. The native binding 
affinity of these VLP was impaired through insertion of a polyionic fusion peptide in the H1 
loop of the polyoma capsid protein, VP1, inhibiting off-target delivery. An alternative means 
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of selective targeting includes the conjugation of proteins or peptides specific for receptors 
expressed by the target cells, such as the conjugation of a human hepatocellular carcinoma 
(HCC)-specific binding peptide (SP) 94, as demonstrated with bacteriophage MS2 VLP 
[685]. 
 
3.1.2 Immunomodulation with VLP Vaccines 
Immunomodulation involves the manipulation of the immune system, altering how it 
responds through the action of an immunomodulator. An immunomodulator is any molecule 
or compound capable of such a manipulation, and includes cytokines, adjuvants and various 
inflammatory or anti-inflammatory compounds. Depending on the type of 
immunomodulator, the action employed may involve the suppression of inflammation, such 
as in an autoimmune or hypersensitivity reaction, or may induce presentation of co-
stimulatory molecules that promote a specific type of immune response, enhancing 
vaccination. Although some VLP have been reported as potentially self-adjuvanting [686, 
687], the inclusion of an adjuvant can alter the responses generated by a VLP vaccine. For 
example, the adjuvant α-galactosylceramide can form a composite particle when combined 
with RHDV VLP, capable of inducing increased activation of antigen-specific T cells [649]. 
VLP derived from enveloped viruses can also support the insertion of immunomodulators 
with a transmembrane motif into their envelope, often mediated by special lipid rafts. This 
unique property has been used to coat enveloped VLP in membrane-bound adjuvants such as 
flagellin [688], or various ligands targeting co-stimulatory receptors such as CD40 [689]. 
Completely independent immunosomes capable of directly stimulating T cell activation have 
also been reportedly constructed from Moloney murine leukemia virus (MoMLV) VLP with 
a surrogate TCR/CD3 ligand and the co-stimulatory receptor CD80 anchored in its envelope 
[690]. 
DNA oligonucleotides containing CpGs have also been investigated extensively for their 
potential as immunomodulators in combination with VLP vaccines. CpGs come in three main 
types, dubbed A, B and C. Type A CpGs feature a palindromic sequence flanked with 
guanosine, usually constructed with phosphodiester bridges, and simulate pDCs to secrete 
IFN-α [691]. Type B CpGs contain phosphorothioate bridges rather than phosphodiester, and 
are potent activators of B cells [692, 693]. Type C CpGs represent a mixture of both the 
structures and functions of Type A and B CpGs [694, 695]. The applications of CpGs in VLP 
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vaccines has been investigated most extensively in Qβ VLP [696], but CpG has also been 
used as an adjuvant with HPV VLP [697] and RHDV VLP [698]. With Qβ VLP, CpGs have 
been encapsulated inside the VLP for both the stimulation of immune responses [696], and 
the suppression of allergic immune responses [699]. Encapsulation of CpG facilitates 
targeted delivery to antigen presenting cells that take up the VLP, preventing potential off-
target pathological effects from systemic administration of CpG, such as splenomegaly.  
RNA nucleic acids have only recently been explored for their potential applications in 
combination with VLP vaccines, ranging from messenger RNA (mRNA) [700, 701], micro-
RNA (miRNA) [702], short hairpin RNA (shRNA) [703] and short interfering RNA (siRNA) 
[704]. Although the underlying concept of RNA delivery by VLP is the induction, 
suppression or alternation of gene expression in target cells, these applications potentially 
take on an immunomodulatory role when designed to manipulate the immune cells. For 
example, targeting components of immune cell signalling pathways, such as signal transducer 
and activator of transcription (STAT) 3, may alter cell phenotype and the immune response. 
STAT3 is activated through tyrosine phosphorylation by Janus kinase (JAK) 1, through 
gp130 signalling induced by IL-6. This pathway is of particular interest in CRC, as a self-
sustained feedback loop between IL-6, STAT3 and miR-34a identified in CRC has been 
implicated in the induction of an EMT transition, invasion and metastasis [705]. This 
feedback loop is completed by the identification of IL-6 expression induced by STAT3 
activation in macrophages and human endothelial cells [706-708]. Targeted knock down of 
STAT3 was found to impair this feedback loop, inhibiting IL-6 induced transformation in a 
murine model of metastatic CRC [705]. The combination of VLP vaccination and siRNA 
delivery has significant potential for immunomodulation by targeting and modifying both 





The purpose of this chapter was to investigate the potential for RHDV VLP to encapsulate 
and deliver short nucleic acids, including CpGs and siRNA, for the purpose of 
immunomodulation. Although CpGs have already been used in conjunction with RHDV VLP 
vaccines, the potential interaction between CpGs and RHDV VLP has not been investigated. 
To promote the encapsulation of CpGs, chimaeric VLP were developed that contained either 
a string of positively charged residues or a known DNA binding site recombinantly inserted 
at the N-terminus of VP60. CpGs were associated with RHDV VLP post-production through 
a combination of disassembly and reassembly, and assessed for their ability to induce NF-κB 
activation, and subsequent activation of DCs. The potential for RHDV VLP to deliver 
encapsulated siRNA was also assessed in this chapter, focusing on STAT3 as a model system 
for targeted immunomodulation. 
 
3.2.1 Aims 
1. Assess the encapsulation and delivery of CpGs inside RHDV VLP as a composite 
adjuvant vaccine particle.  





3.3.1 Production of Chimaeric RHDV VLP Designed for Nucleic 
Acid Association 
Chimaeric RHDV VLP with recombinant VP60 containing the L1BS DNA binding site at its 
internally located N-terminus (DBS.VP60) has previously been described for its ability to 
encapsulate and deliver plasmids [656]. The production of this construct has previously been 
replicated in our laboratory, and was explored for its natural affinity to bind both DNA and 
RNA [709]. An alternative construct consisting of an octaarginine residue at the N-terminus 
of VP60 (R8.VP60) was also previously developed in our laboratory, but its properties had 
not been investigated. The concept behind this variant was to generate a positively charged 
interior surface within the VLP, potentially attracting and facilitating the encapsulation of 
negatively charged nucleic acids. The availability of these binding or attraction motifs would 
be enhanced by disassembling the VLP into subunits, with encapsulation of molecules 
mediated by reassembly into intact VLP. VP60, R8.VP60 and DBS.VP60 were provided pre-
cloned in pAcUW51(GUS) plasmids, and were expressed using the FlashBAC Ultra system 
as has been described. 
VP60, R8.VP60 and DBS.VP60 purified from inoculated Sf21 cultures were identified by 
SDS-PAGE (Figure 3.1 A). Purified preparations of both R8.VP60 and DBS.VP60 VLP 
consistently contain additional protein bands. It is unknown whether these bands represent 
the use of alternate start codons, premature termination of translation, or are indicative of 
post-translational degradation; however, the arginine residues inserted at the N-terminus of 
VP60 in R8.VP60 may act as a cleavage site for various intracellular proteases. DBS.VP60 
VLP has also been identified as relatively unstable in comparison to unmodified RHDV VLP 
[709], and may also be susceptible to some form of degradation process. Formation of intact 
VP60, R8.VP60 and DBS.VP60 VLP was confirmed by transmission electron microscopy 
(Figure 3.1 B, C and D). Both R8.VP60 VLP and DBS.VP60 VLP appear similar to VP60 
VLP in structure and morphology, commonly described as cog-shaped due to its surface 
projections visible on the surface of the icosahedron cross-section. While R8.VP60 VLP 
appeared relatively homogeneous, DBS.VP60 VLP have marked variability in appearance 
with an apparent increase in partially disassembled VLP. This provides some evidence in 
support of the previously reported instability of this VLP construct. It is unknown at this 





Figure 3.1 Production of VP60, R8.VP60 and DBS.VP60 
(A) SDS-PAGE analysis of RHDV VLP comparing 1) VP60, 2) R8.VP60 and 3) DBS.VP60 VLP. RHDV VLP 
have distinct cog-like morphology as identified by electron microscopy, features shared by (B) VP60, (C) 
R8.VP60 and (D) DBS.VP60 VLP. (L) broad range protein ladder. Magnified images inset to demonstrate cog-
like morphology. 
 
3.3.2 Endogenous Nucleic Acids in RHDV VLP 
The presence of endogenous nucleic acids in VP60 and DBS.VP60 VLP has previously been 
investigated [709]. In this study, VP60 VLP were found to contain small amounts of short 
nucleic acids, presumably consisting of fragments encapsulated from their expression cell 
line during assembly. DBS.VP60 demonstrated an enhanced ability to encapsulate 
endogenous nucleic acids, identified to consist of both short RNA fragments, and a distinct 
DNA fragment that could only be dislodged through addition of SDS. These findings 
indicated that while RHDV VLP may be devoid of an intact virus genome, they might still 
contain various genetic materials. The presence of small amounts of endogenous short 
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nucleic acids present in preparations of VP60 VLP was confirmed by agarose gel 
electrophoresis (Figure 3.2 A). R8.VP60 VLP were found to contain an increased amount of 
endogenous nucleic acids, with fragments of much longer length in comparison to VP60 VLP 
(Figure 3.2 B).  
 
 
Figure 3.2 Endogenous Nucleic Acids in VP60 and R8.VP60 VLP 
Identification of endogenous nucleic acids present in 20 µL samples of 1 mg/mL RHDV VLP by staining with 
ethidium bromide. (A) Endogenous nucleic acids present in samples of untreated (UT) VP60 VLP, and 
benzonase (Benz) treated VP60 VLP. (B) Endogenous nucleic acids present in samples of UT R8.VP60 VLP, 
and Benz treated R8.VP60 VLP. (L) 1 kb plus Ladder. These gels are representative of three independent 
repeats, each including triplicate samples. 
 
Benzonase was used to remove any endogenous nucleic acids available for enzymatic 
digestion in the VLP sample, leaving nucleic acids encapsulated within VLP untouched. 
Although the effects of benzonase digestion were difficult to determine in VP60 VLP due 
the low levels of nucleic acids prior to digestion, in R8.VP60 VLP there was a notable partial 
reduction in the endogenous nucleic acids present. This suggests that some of these 
endogenous nucleic acids may be present on or around the surface of VLP, or in solution. 
However, as these nucleic acids are not completely ablated by benzonase treatment, a 
proportion of these nucleic acids are assumed to be physically inaccessible to the benzonase 
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enzyme. These nucleic acids may be contained within the VLP, or held in sufficiently tight 
association as to impair their accessibility to enzymatic degradation. This benzonase 
resistance appeared to be skewed towards shorter nucleic acids, suggesting that there may be 
some kind of size limit, exclusion or preference upon the resistance conferred. 
 
3.3.3 Disassembly and Reassembly of RHDV VLP 
Based on published reports, the efficient encapsulation of exogenous nucleic acids within 
VLP is reliant upon disassembly and reassembly [696]. Disassembly of VLP involves the 
temporary disruption of bonds between the virus capsid proteins, most commonly through a 
combination of disulphide bond reduction and divalent cation chelation. The method for 
disassembly and reassembly of RHDV VLP has been previously published [656]; however, 
direct replication of this method proved insufficient for efficient disassembly of our VLP. 
This discrepancy was rectified following optimisation, identified to be primarily due to 
insufficient EGTA. This may be due to an increased amount of divalent cations associated 
with our VLP, possible acquired from expression cells, growth media, or buffers used. In 
comparison to untreated RHDV VLP (Figure 3.3 A), disassembly with the published method 
including 1 mM EGTA produced few of the capsomere-like particles noted by this 
publication as indicative of disassembly (Figure 3.3 B). These capsomere-like particles are 
morphologically distinct from intact VLP, and vary in size and shape. While the distribution 
of VLP across the surface of the carbon-coated grids is unlikely to be even, it appeared that 
the vast majority of VLP were unaffected by the treatment. When the concentration of EGTA 
was increased ten-fold to 10 mM, there was a notable increase in the number and size of the 
clumps of capsomere-like particles (Figure 3.3 C). Upon reassembly from either treatment, 





Figure 3.3 Disassembly and Reassembly of RHDV VLP 
RHDV VLP were disassembled and reassembled using a previously published method [656]. Electron 
microscopy was used to assess the morphology of RHDV VLP under different treatment conditions, including 
(A) untreated, (B) disassembled using a method including 1 mM EGTA, and (C) disassembled using a method 
including 10 mM EGTA. (D) Reassembled VLP following disassembly, in this example from a disassembly 
method that included 10 mM EGTA. Arrows indicate potential capsomere-like particles, thought to be formed 
during disassembly of RHDV VLP. **** p < 0.0001. 
 
3.3.4 Qualification and Detection of RHDV VLP Disassembly 
During the process of optimising the disassembly and reassembly of RHDV VLP, several 
methods were considered for determining the efficacy of each modified treatment. Methods 
considered for assessing the disassembly and reassembly of VLP included native gel 
electrophoresis, differential ultracentrifugation and dynamic light scattering (DLS). Amongst 
these, differential ultracentrifugation proved a particularly valuable tool for quantification of 
disassembly. Initial attempts at differential ultracentrifugation involving sucrose cushions 
were ineffective; however, the use of CsCl gradients proved suitable. The resulting method 
selected is identical to that used during the purification of RHDV VLP, involving overlaying 
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treated and untreated VLP over a gradient of 1.2-1.4 g/cm3 CsCl, and ultracentrifuging the 
samples at 100,000 xg for 18 hours (Figure 3.4 A).  
 
 
Figure 3.4 Quantification of RHDV VLP Disassembly 
Disassembly of RHDV VLP was quantified using a combination of differential ultracentrifugation and VP60 
western blot. (A) Diagrammatic representation of the differential ultracentrifugation method, with a) CPBS, 
overlaid over b) VLP sample, which was overlaid over a gradient of c) 1.2 g/cm3 CsCl and d) 1.4 g/cm3 CsCl. 
100 μL samples were carefully extracted from the interface between the sample and 1.2 g/cm3 CsCl fraction 
(Int 1), and at the 1.2-1.4 g/cm3 CsCl interface (Int 2). (B) VP60 was quantified at Int 1 and Int 2 for untreated 
and disassembled VLP samples by western blot, based on the fluorescence intensity of the Dylight 800 labelled 
secondary antibody used. The provided western blot is representative of three independent repeats. (C) 
Quantification of VLP disassembly with either 1 mM or 10 mM EGTA. Statistical analysis was performed 
using unpaired t-tests. **** p < 0.0001. 
 
Intact, non-disassembled VLP accumulate at the CsCl gradient interface (Int 2), forming a 
diffuse visible band. When disassembled VLP are applied to this gradient, they do not all 
accumulate at this interface, with VP60 also identifiable at the interface between the sample 
and the CsCl gradient (Int 1). Solutions harvested from each of these interfaces were analysed 
by SDS-PAGE and western blot, facilitating the detection of VP60 at each interface (Figure 
3.4 B). Relative quantification based on band density facilitated the estimation of disassembly 
efficacy, based on the percentage of VP60 identified at each interface. This process enabled 
the optimisation of the disassembly protocol, increasing the concentration of EGTA used 
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from 1 mM to 10 mM (Figure 3.4 C). Disassembly achieved was estimated using this method 
at around 25% with 1 mM EGTA, and around 75% with 10 mM EGTA. It may be possible 
to further increase the efficacy of disassembly by altering the concentration of DTT used; 
however, this may risk impairing reassembly of VLP. 
A suitable method was also sought for the rapid detection of disassembly and reassembly of 
RHDV VLP, as quantification by differential ultracentrifugation and western blot consumed 
the entire sample. DLS can fill this role, involving the calculation of particle diameter based 
on how those particles scatter light when in solution. The average diameter of RHDV VLP 
as determined by DLS was around 37.1 nm (Figure 3.5 A), and does not change following 
dialysis into disassembly buffer. When monitored over time by DLS, the average diameter 
of RHDV VLP gradually decreases following disassembly treatment, stabilising at around 
23.5 nm after 8-12 hours. This state was maintained over the entire monitored period, up to 
24 hours. Particles detected by DLS at around 23.5 nm may represent the capsomere-like 
particles previously identified by electron microscopy. It is unknown whether individual or 
dimerised VP60 are liberated into solution during the disassembly process, and alternative 
methods would be required to detect this occurrence. Following reassembly, RHDV VLP 
were found to return to their normal size, with a post-reassembly average diameter of around 
36.7 nm (Figure 3.5 A). 
Although DLS is suitable for detection and monitoring of RHDV VLP disassembly and 
reassembly, it also consumes the entire sample or exposes it to non-sterile conditions. An 
alternative method was instead proposed, based on the light absorption profile of RHDV 
VLP. It was hypothesised that the process of VLP disassembly and reassembly would result 
in the exposure of previously buried amino acids, some of which possess specific light 
absorption properties, like tyrosine and tryptophan [710, 711]. These aromatic amino acids 
have a characteristic spectrophotometric absorbance over a ratio of A250/A280, and were 
proposed to potentially provide a surrogate determination of VLP assembly state. RHDV 
VLP were found to have a A250/A280 ratio of very close to 1 (Figure 3.5B), which was 
unaffected by dialysis into disassembly buffer. When monitored over time, this ratio 
gradually decreased following disassembly treatment, stabilising at around 0.4 after 8-12 
hours. This ratio was maintained over the entire monitored period, up to 24 hours. Following 
reassembly, this ratio gradually returned to around 1. The kinetics of this analysis closely 
matched that generated by DLS, suggesting that spectrophotometric analysis of absorbance 
at A250/A280 may be a suitable surrogate measure of RHDV VLP assembly state. This 
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method holds significant practical advantages over DLS, as it requires a relatively small 
amount of sample to analyse, and can be performed on commonly available laboratory 
equipment. As a result, the A250/A280 ratio was used as a means of checking for batch 
variability between experiments involving disassembly and reassembly of RHDV VLP. 
 
 
Figure 3.5 Detection of RHDV VLP Disassembly and Reassembly 
A comparison of methods used for monitoring RHDV VLP assembly state following dialysis, disassembly and 
reassembly. (A) Measurement of average particle diameter by DLS. (B) Measurement of A250/A280 light 
absorbance ratio by spectrophotometry. Statistical analysis was performed using unpaired t-tests at each time 
point, with a Bonferonni post hoc adjustment for multiple measures. * p < 0.05, ** p < 0.01, *** p < 0.001, 




3.3.5 Encapsulation of CpGs into RHDV VLP 
The capacity for RHDV VLP to encapsulate CpGs was investigated with and without 
disassembly and reassembly; using dialysis to remove non-encapsulated CpGs. 
Unexpectedly, VP60, R8.VP60 and DBS.VP60 all possessed the ability to retain CpGs in 
solution following dialysis, both with and without disassembly and reassembly (Figure 3.6 
A). This finding may suggest that RHDV VLP possesses a natural affinity for short DNA 
oligonucleotides, and that this affinity may not be reliant on the exposure of internal N-
terminus residues. In addition to retention following dialysis, RHDV VLP were also found 
to resist degradation of CpGs with benzonase (Figure 3.6 B). It is unknown by what 
mechanism this resistance is conferred, but possible sources include steric hindrance of 
benzonase, inhibition of the enzyme by molecules associated with VLP, or disassembly-
independent encapsulation of CpG. 
The ability to separate, detect and relatively quantify CpG on TBE gels using the Odyssey 
FC system also provided the potential for quantification of CpG associated with RHDV VLP. 
Triplicates of VP60, R8.VP60 and DBS.VP60 VLP samples associated with CpG and 
dialysed were electrophoresed on 20% TBE acrylamide gels, and stained with Gel Green 
(Figure 3.7 A). The fluorescence intensity of each Gel Green labelled CpG band was 
compared to a concentration curve of CpG, calculating the relative quantity of CpG 
associated with each VLP sample (Figure 3.7 B and C). Due to the loss of VLP during 
dialysis, each sample was also assessed by western blot and compared to a 1 mg/mL VP60 
VLP standard. Correcting for the concentration of VLP present in each sample, the amount 
loaded onto the TBE acrylamide gels, and calculating up to a 1 mg VLP sample yielded 
estimated quantities of CpG associated with 1 mg of each VLP tested (Figure 3.7 D). While 
DBS.VP60 VLP was found to be associated with significantly more CpG relative to the 
amount of VLP present in comparison to VP60 VLP, R8.VP60 VLP was associated with 
significantly less. This suggests that the octaarginine domain present in R8.VP60 is not 






Figure 3.6 Encapsulation of CpGs into RHDV VLP 
(A) Retention of CpGs following dialysis in the presence of VP60, R8.VP60 or DBS.VP60 VLP with or without 
disassembly/reassembly (Dis/Reas), as assessed by TBE acrylamide gel stained with gel green. (B) Resistance 
of CpGs to benzonase digestion in the presence of RHDV VLP, as assessed by TBE acrylamide gel stained with 







Figure 3.7 Quantification of CpG Associated with RHDV VLP 
(A) TBE acrylamide gel electrophoresis of triplicate samples, indicating the retention of CpGs in dialysed 
samples in the presence of VP60, R8.VP60 or DBS.VP60. (B) TBE acrylamide gel electrophoresis of a 
concentration curve of CpGs, representative of three independent repeats. (C) Concentration curve of CpGs 
graphed respective of their band intensity. (D) Quantification of CpGs associated with VP60, R8.VP60 and 
DBS.VP60 VLP following dialysis, with CpG quantified by TBE acrylamide gel electrophoresis, and VLP 
quantified by western blot. Statistical analysis was performed using unpaired t-tests, comparing each 
recombinant VP60 VLP to control VP60 VLP. * p < 0.05, ** p < 0.01 
 
3.3.5 CpGs Associated with RHDV VLP Enhances NF-κB 
Activation 
CpGs can stimulate the activation of NF-κB through endosomal TLR-9 recognition, with 
CpGs naturally present in bacterial DNA. The ability for CpGs associated with RHDV VLP 
to stimulate NF-κB was investigated using the reporter RAW-Blue cell-line (Invivogen, 
California, USA). In this reporter cell line, based on the murine RAW 264.7 macrophage cell 
line, NF-κB activation induces the expression of SEAP. The amount of SEAP secreted into 
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the culture media is linked to NF-κB activation, and can be quantified using a colorimetric 
assay. Using this reporter system, we can see that CpG is a potent activator of NF-κB, and 
that dialysis completely removes all detectable CpG from a solution (Figure 3.8). VP60, 
R8.VP60 and DBS.VP60 all retained the ability to induce activation of NF-κB following 
dialysis to remove free CpGs, although activation was most pronounced with DBS.VP60. 
R8.VP60 associated with CpG was impaired in its ability to induce NF-κB activation, with 
significantly reduced SEAP secretion. These results matched the trends observed in the 
quantification of CpG associated with each chimaeric VLP. 
 
 
Figure 3.8 NF-κB Activation in RAW-blue Cells 
Activation of NF-κB was compared based on SEAP production. SEAP production was compared between 
VP60, R8.VP60 and DBS.VP60 associated with CpGs, before and after dialysis. CPBS, CpG dialysed and 25 
ug of CpG were used as controls. Statistical analysis was performed using unpaired t-tests between groups. ** 
p < 0.01, **** p < 0.0001. Results are representative of three independent repeats. 
 
3.3.6 CpGs Associated with RHDV VLP Enhances BMDC 
Activation 
Upon stimulation with potent adjuvants such as LPS, APCs such as BMDCs become 
activated and upregulate the expression of co-stimulatory molecules including CD40, CD80 
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and CD86. The relative expression of these co-stimulatory molecules is linked to the 
magnitude of BMDC stimulation. While LPS stimulated potent activation of BMDCs with 
upregulation of all three co-stimulatory molecules, the CpGs used did not appear to stimulate 
the upregulation of CD80, with increases observed in surface presentation of CD40, CD86 
and I-A/I-E (Figure 3.9 A-D). However, when these CpGs were administered in association 
with RHDV VLP, BMDCs upregulated all three co-stimulatory molecules to levels similar 
to those induced by LPS.  
 
 
Figure 3.9 BMDC Activation with CpGs Associated with RHDV VLP 
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Median fluorescent intensity (MFI) of the activation markers (A) CD40, (B) CD80, (C) CD86 and (D) I-A/I-E 
on the surface of murine BMDCs, following stimulation with CpGs associated with RHDV VLP. Dialysed 
CpG, 25 μg CpG and 1 μg LPS treatments were used as controls. Statistical analysis was performed using 
unpaired t-tests between groups. NS = Non-significant, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Results 
are representative of three independent repeats. 
For CD80, CD86 and I-A/I-E, the surface presentation observed was significantly increased 
when the CpG was co-delivered in association with RHDV VLP. These results suggest that 
when CpGs are delivered in association with RHDV VLP, the resulting composite particle 
induces enhanced activation of BMDCs over each component administered individually. 
While RDHV VLP alone did not appear to upregulate CD40, CD80 or CD86, stimulated cells 
had increased surface levels of I-A/I-E. This may represent the background effect of RHDV 
VLP when administered in the absence of a suitable adjuvant. 
 
3.3.7 Association of siRNA with RHDV VLP 
Based on the ability of RHDV VLP to naturally associate with CpGs, it was hypothesised 
that they would also possess the ability to associate with siRNA. The capability of RHDV 
VLP to associate with siRNA was investigated using dialysis to remove free siRNA. RHDV 
VLP were confirmed to possess the ability to naturally associate with siRNA (Figure 3.10 
A). VP60 VLP was found to associate with around 1.6 μg siRNA per 1 mg VLP, while 
R8.VP60 and DBS.VP60 associated with around 0.8 and 2.5 μg siRNA respectively (Figure 
3.10 B). These values are likely an under-representation of this association, as siRNAs are 
highly labile and prone to degradation in solution. The proportions of siRNA associated with 
each type of VLP followed the same trend established by the association of CpGs, with 





Figure 3.10 Association of siRNA with RHDV VLP 
(A) Retention of siRNA following dialysis in the presence of RHDV VLP, as assessed by TBE acrylamide gel 
electrophoresis. (B) Quantification of siRNA associated with VP60, R8.VP60 and DBS.VP60 VLP following 
dialysis, with siRNA detected by TBE acrylamide gel electrophoresis, and VLP quantified by western blot as 
previously used for CpG quantification. ** p < 0.01 
 
3.3.8 Knockdown of Stat3 with siRNA associated with RHDV VLP 
The capacity for RHDV VLP to deliver siRNA to cells in vitro was investigated in the RAW-
Blue cell line. RAW-Blue cells were treated with VP60, R8.VP60 and DBS.VP60 VLP 
associated with STAT3 siRNA. 8 hours later, these cells were stimulated with LPS, which 
should induce the upregulation of Stat3 expression. The media was removed and the cells 
were lysed 12 hours after the addition of LPS. Stat3 expression was assessed by separating 
lysates by SDS-PAGE, transfer onto nitrocellulose membrane, and probing by western blot 
with an anti-Stat3 mAb. Actin expression was used as a control. VP60, R8.VP60 and 
DBS.VP60 VLP were each capable of inducing a targeted knockdown in Stat3 expression in 
RAW-Blue cells, with dose-dependent efficacy observed in both VP60 and DBS.VP60 VLP 
(Figure 3.11 A-D). The extent of the knockdown achieved varied between each VLP, with 
Stat3 expression reduced down to around 70% with 10 μg of either VP60 or R8.VP60 VLP, 
and down to around 60% with DBS.VP60 VLP. As was previously identified with CpG 
association, DBS.VP60 VLP performed slightly better than both VP60 and R8.VP60, 
possibly as a reflection of an increased quantity of siRNA associated with DBS.VP60 VLP. 
Transfection of the STAT3 siRNA using FuGene 6 resulted in a knockdown of Stat3 
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expression to around 20%, demonstrating the limited efficacy of RHDV VLP-mediated 
delivery of siRNA with respect to standard methods. 
 
 
Figure 3.11 Knockdown of STAT3 by siRNA associated with RHDV VLP 
A) Expression of STAT3 and actin in RAW-Blue cells 24 hours after stimulation with LPS, as detected by 
western blot. STAT3 expression was normalised relative to actin expression for cells treated with B) VP60, C) 
R8.VP60 and D) DBS.VP60 delivered in combination with STAT3 siRNA. Untreated and FuGene 6 transfected 




3.4.1 Nucleic Acids Associated with RHDV VLP 
RHDV VLP can associate with various nucleic acids, accumulated endogenously during 
production or added exogenously following purification. While this ability is possessed by 
VP60 VLP, it appears to be enhanced by recombinant insertion of DNA-binding or charge 
associated motifs. R8.VP60 VLP was found to have an increased amount of endogenous 
nucleic acids in preparations, with the length of benzonase resistant fragments reaching up to 
around 400-500 bp. These fragments may be of cytoplasmic origin, potentially consisting of 
mRNA, micro RNA (miRNA) or various other forms of RNA. Alternatively, these 
endogenously encapsulated nucleic acids may include extrachromosomal or extranuclear 
DNA present in the cytoplasm. As the cells producing these VLP are also infected with 
replicating AcMNPV, they may also theoretically encapsulate nucleic acids encoding 
components of their own expression system. The short <100 bp fragments that appeared to 
be associated with all RHDV VLP assessed may consist of building block materials, such as 
transfer RNA (tRNA) or other small nucleic acid structures. 
Although the most likely location of endogenous nucleic acids associated with RHDV VLP 
would be within its intraparticulate space, the ability for exogenously applied fragments to 
be afforded resistance to enzymatic digestion may challenge this assumption. The size 
restriction of this resistance may be due to either: A) The size of gaps between VP60 dimers 
for diffusion between the intraparticulate and extraparticulate spaces; B) The limit of steric 
hindrance of enzymatic digestion on nucleic acids tightly associated to the surface of VLP; 
or C) The distance that nucleic acids can insert themselves within the gaps between VP60 
dimers. While the first two possibilities represent inherent functionality of a hollow particle, 
encapsulating molecules or simply facilitating surface attraction through various motifs, the 
final theory is based on an observation made some time ago with BK virus (BKV) VLP [712]. 
In this study, Touze et al found that BKV VLP could bind to the ends of a linearised plasmid, 
with the DNA strands visibly connecting between two VLP (Figure 3.12). If this phenomenon 
resulted solely from surface interaction, the linearised plasmid should be coiled around the 
VLP surface. Instead, this interaction appears to involve only the terminus of DNA strand, 
with its terminal motifs interacting with the VLP surface, or by partially inserting itself into 
the space between capsid subunits. It would be interesting to investigate whether this 




Figure 3.12 Association Between BKV VLP and a Linearised Plasmid [712] 
An electron micrograph from Touze et al [712], identifying a strand of DNA linking between two BKV VLP. 
Preparations were observed by positive staining with 1.5% aqueous uranyl acetate over a dark field. The white 
bar represents 100 nm. 
 
3.4.2 CpGs associated with RHDV VLP 
CpGs have been used as an adjuvant in a variety of VLP-based vaccines, including with HPV 
VLP [697], Qβ VLP [696] and RHDV VLP [698]. Co-delivery of CpG and VLP together as 
a composite particle through encapsulation, chemical conjugation or direct association 
ensures that APCs that receive the vaccine are also receiving sufficient danger signals as to 
promote activation, and surface presentation of co-stimulatory molecules. As RHDV VLP 
has been found to naturally associate with CpGs, previous studies involving vaccination with 
this VLP and adjuvant combination may have unwittingly benefitted from this effect. The 
association between RHDV VLP and CpGs is reminiscent of its reported affinity for α-
galactosylceramide [649] and mannose [652]. Each of these molecules shares a common 
chemical backbone, consisting of a carbohydrate ring domain. In other caliciviruses, most 
notably norovirus, the P2 domain of the major capsid protein contains a conserved 
carbohydrate-binding domain [713-715]. Several caliciviruses are known to use these 
domains to bind to the carbohydrate moieties that form some of the blood group antigens 
present on the surface of host red blood cells [716-719]. 
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RHDV has been proposed to potentially share this characteristic, with a reduction in disease 
susceptibility following a low virus titre challenge identified amongst adult rabbits with low 
amounts of related blood group antigen ligands [720]. However, hepatocytes, the main target 
for RHDV infection and replication do not possess these blood group antigen ligands, 
indicating that this is unlikely the only mechanism employed by RHDV for infection of its 
host cells [717]. It is intriguing that RHDV VLP may retain the affinity for carbohydrate 
moieties possessed by its parent virus. This further expands the functionality of RHDV VLP 
as a versatile vaccine vector, and potentially opens multiple additional avenues for research. 
Even with CpGs, it would be fascinating to explore whether the delivery of each class of CpG 
in association with RHDV VLP retains or overrides their respective class-defined affinities. 
It would also be interesting to pinpoint the specific location where associated CpGs can be 
found in RHDV VLP through cryo-electron microscopy, though it seems likely that the 
implicated P2 domain is responsible. It is worth noting that there are already patents held that 
restrict some commercial applications of CpG associated with VLP, including a patent 
covering the process of CpG encapsulation (US 8691209 B2), and on the actual vaccination 
applications (WO 2015089114 A1); however, it may be possible to avoid these patents 
through the use of novel vaccine constructs, composites or combinations. Some examples of 
potential alternative constructs that could be explored are discussed in Section 5.1.2.1. 
 
3.4.3 siRNA associated with RHDV VLP 
As with the association between CpGs and VLP, the potential for siRNA associated with 
VLP has already been recognised through the publishing of a patent (US8729038). 
Interestingly, this patent specifically covers siRNA internalised within the interior of the 
VLP, but makes no mention of conjugation or association throughout the remaining structure 
of VLP. As was identified with CpGs, RHDV VLP have a natural affinity for siRNA. 
Although siRNA associated with RHDV VLP was able to induce a detectable targeted 
knockdown in treated cells, the efficacy was such that it is unlikely that VLP will be a viable 
in vitro alternative to traditional transfection or electroporation techniques. Instead, it is 
possible that in vivo is where VLP-mediated delivery of siRNA may yield improved results; 
however, the lability of siRNA may present as a significant limitation. The ability to 
selectively manipulate the expression of target proteins in antigen presenting cells in vivo 




The APC-specific avenue of siRNA associated with VLP is unique compared to similar 
therapies involving viruses for the treatment of cancer, such as the use of an oncolytic virus 
to induce the expression of siRNA or similar RNA interference molecules [721, 722]. The 
ability to target RHDV VLP to specific immune cell populations through the chemical 
conjugation of various receptor ligands could open up further potential for VLP-mediated 
siRNA delivery, with potential applications in combination with prophylactic and therapeutic 
vaccines, therapies for autoimmunity, prevention of graft-versus-host disease or related 
conditions, and even in commercial diagnostic techniques. Before endeavouring on these 
potential applications, it remains that the delivery of siRNA associated with RHDV VLP 
must be confirmed with primary cells in vitro, and then translate in vivo. This represents a 




The addition of nucleic acids further expands the list of molecules known to naturally 
associate with RHDV VLP. Collectively, these adjuvant-vaccine composites represent an 
intriguing novel approach to vaccine formulation, taking advantage of the natural affinity of 
virus capsid proteins for specific chemical moieties. It would be interesting to see whether 
other immunogenic compounds with similar moieties, such as glycolipids, glycoproteins, or 
even glycosylated/glycated proteins and peptides would also naturally associate with VLP. 
Likewise, it would also be interesting to further explore the role this binding affinity may 
play in the infection and replication of host cells with RHDV and other related Caliciviridae. 
These and other potential future applications of RHDV VLP will be discussed further in 
Chapter 5. For the purposes of this study, it was interesting to highlight a mechanistic 
advantage associated with the use of CpGs as an adjuvant, and the potential for formation of 
a composite vaccine particle through the direct association between CpG and RHDV VLP. 
Similarly, if the ability to deliver siRNA in association with RHDV VLP is confirmed in 




4 Development of a Virus-based Vaccine for 
Colorectal Cancer 
4.1 Introduction 
4.1.1 Incorporating Multiple Colorectal Cancer Epitopes into RHDV 
VLP 
Tumour escape and recurrence is a prominent potential adverse outcome amongst 
immunotherapies for cancer, with progression-free survival remaining an important 
prognostic marker of therapeutic efficacy. Tumour escape following immunotherapy may 
result from a multitude of factors, including ineffective vaccination, tolerisation, or due to 
immunoediting of the tumour to suppress or eliminate expression of vaccine-targeted TAAs. 
Although the design of the vaccine itself, incorporation of adjuvants, and an appropriate 
dosage regimen should restrict the former two limitations, tumour immunoediting remains 
particularly challenging to counter. Counteracting this process may be achieved through 
several potential mechanisms. These include immunomodulation, which has been previously 
investigated and discussed in Chapter 3, and broadening the repertoire of the immune 
response induced. As a heterogeneous mass of cells, solid tumours may possess multiple 
subpopulations or variations in TAA expression profiles. This provides redundancies within 
the tumour, with the elimination of populations expressing a specific TAA giving rise to 
populations with low or absent expression. Development of a vaccine targeting and eliciting 
immune responses against multiple epitopes should limit these redundancies, and promote 
the elimination of a broader range of tumour cells. This may include potentially resistant 
subpopulations that do not express all of the individual antigens targeted, and hence may 
survive one or several mono-target therapies. 
Although the concepts behind multi-epitope targeting should provide a significant advantage 
in vaccine development, this construct also yields further complications that may restrict the 
functionality if improperly designed. An important factor for consideration in the 
development of a multi-target vaccine is epitope immunodominance. Although an antigenic 
protein will contain a broad repertoire of potential immune epitopes that may be targeted in 
a vaccine, immunodominance may result in only a select few inducing an epitope-specific 
immune response. Even in the context of a viral infection involving multiple viral genes 
products, cytotoxic immune responses tend to be predominated by a single MHC-I haplotype 
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[723, 724], and may even be restricted to only a single peptide of 8-10 residues [725-727]. A 
similar situation is mirrored in MHC-II, where these predominant immunogenic peptides 
were characterised as immunodominant determinants [728]. Within each antigen, there are 
usually also multiple peptide sequences with variable immunogenicity under specific 
circumstances, including subdominant and cryptic determinants. Subdominant determinants 
generate relatively weak immune responses, while cryptic determinants are generally only 
immunogenic in a synthetic form [728]. Beyond detection of the epitopes themselves, 
mechanisms that can influence immunodominance include cross-reactivity from a prior 
exposure [729], differential thymic selection of T cells [730], and competition between 
activated CTLs during expansion [731]. 
Within the scope of multi-epitope cancer vaccines there are several examples of promising 
candidates, ranging from peptide pools [732], DNA vaccines [733], synthetic polypeptides 
[734], and DC-based vaccines [735]. For example, a triplicate peptide vaccine for treatment 
of esophageal squamous cell carcinoma (ESCC) completed a multicentre phase II clinical 
Trial [736]. This triplicate vaccine consisted of HLA-A24-restricted peptides derived from 
the Cancer-Testis antigens TKK protein kinase (TKK), lymphocyte antigen 6 complex locus 
K (LY6K) and insulin-like growth factor (IGF)-II mRNA binding protein 3 (IMP-3), 
administered subcutaneously with incomplete Freund’s adjuvant (IFA). Progression free 
survival was significantly improved amongst HLA-A24+ ESCC patients in comparison to 
HLA-A24-, with patients that induced CTL response against multiple peptides yielding better 
clinical responses. This group has also completed a phase II clinical trial for a similar 
triplicate peptide vaccine consisting of HLA-A24-restricted peptides from LY6K, IMP-3 and 
cadmium-specific carbonic anhydrase 1 (CDCA1) with IFA, for treatment of head and neck 
squamous cell cancer (HNSCC) [737]. In this trial, they observed a significant improvement 
in overall survival amongst HLA-A24+ HNSCC patients in comparison to HLA-A24-, and 
reported one case of complete remission. 
A peptide pool-based vaccine has also completed a phase II clinical trial for treatment of 
melanoma, consisting of twelve melanoma peptides (12MP) restricted to HLA-A1, A2 or A3 
[738]. This 12MP vaccine was administered with IFA and GM-CSF by itself, or in 
combination with either tetanus peptide or with a six melanoma helper peptide (6MHP) pool. 
Although cytotoxic immune responses against the 12MP vaccine were detected, there was no 
significant improvement in clinical outcome associated with this vaccine. Interestingly, while 
the 6MHP vaccine failed to augment the 12MP vaccine when administered in combination, 
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immune responses generated against the 6MHP vaccine were associated with significant 
improvements in both clinical response and overall survival [738]. Multi-epitope cancer 
vaccines in clinical trials are not limited solely to peptide pools, as a recent phase I trial for a 
multi-epitope peptide-pulsed DC vaccine has also demonstrated promising results in patients 
with glioblastoma multiforme (GBM) [735]. This vaccine consisted of HLA-A1-restricted 
peptides derived from MAGE1 and AIM-2, and HLA-A2-restricted peptides from TRP-2, 
gp100, HER2 and IL13Rα2. These peptides were pulsed onto DCs cultured ex vivo, and 
infused into GBM patients. Expression of MAGE1, absent in melanoma 2 (AIM2), gp100 
and HER2 in patients prior to vaccination were each associated with improved survival. 
Recurrent tumours from 4 HLA-A2 patients had downregulated expression of gp100, HER2 
and IL13Rα2, indicating that the vaccine had induced immunoediting of these tumours [735]. 
 
4.1.2 Prime-Boost and Primary-Recurrent Vaccination 
Prime-boost vaccination involves pairing an initial priming vaccine with a secondary booster, 
during or following the refractory phase of the initial B or T cell activation. Use of a booster 
vaccine significantly enhances vaccination efficacy, and promotes the establishment of 
immunological memory [310]. Prime-boost vaccines can be either homologous, with both 
the prime and boost consisting of the same vaccine, or heterologous, pairing different vaccine 
vectors carrying the same target antigen. Homologous prime-boost vaccination can be 
particularly good at inducing a potent humoral immune response, and is traditionally used 
for the majority of childhood vaccines deployed in developed countries. This form of 
vaccination is particularly useful when the desired outcome is the production of antibodies 
that neutralise the vaccine itself, as the vector is usually a homologue of the invading 
pathogen or its toxic products. However, when the desired effect of the vaccine is the 
production of a potent cell-mediated immune response, homologous vaccination using 
traditional vaccine types can fall short. The exception to this is when a vaccine vector remains 
effective despite the presence of vector neutralising antibodies, a function that has been 
notably observed with some VLP-based vaccine vectors [739, 740]. Heterologous 
vaccination can also be used to avoid the issue of pre-existing immunity established by the 
prime vaccine, and is particularly efficient for establishing robust populations of memory T 
cells [741]. Synergistic stimulation targeting the same antigen can also select for T cells with 
higher avidity, enriching for a more specific and reactive population [742, 743]. This form 
of vaccination has been used against intracellular pathogens that are particularly resistant to 
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traditional vaccines, such as Mycobacterium tuberculosis [744-747], immunodeficiency 
viruses [748-750] and Plasmodium falciparum [751-753]. 
The compatibility of prime-boost vaccination with therapeutic cancer vaccines is primarily 
dependent upon the vaccine vector used. When the vaccine involves the use of a live virus, 
alternating vectors in a heterologous prime-boost vaccination strategy generates superior 
anti-tumour responses in comparison to a homologous regimen [754]. An alternative 
approach is to adoptively transfer virally infected cells, effectively smuggling the virus past 
the protective anti-vector immunity [755-757]. This approach can also be used to combat an 
undesirable phenomenon observed with therapeutic vaccination, the emergence of treatment-
resistant tumours [758-761]. These recurrent tumours no longer express antigens targeted by 
the original vaccine, potentially through either selective elimination of susceptible tumour 
cell populations, or evolutionary development of the tumour. This change in expression 
profile can sometimes represent a shift in tumour state, resembling an epithelial-to-
mesenchymal transition [760, 762-764]. While recurrent tumours may be resistant to the 
vaccine that induced their development, they can be targeted with a second vaccine specific 
for their new antigen expression profile. The resulting combination primary-recurrent 
vaccination schedule uses a vaccine targeting the primary tumour to induce production of 
recurrent tumours, which can be targeted with a second vaccine. This method has been proven 
effective in mouse models of prostate cancer, with 50% overall survival with combination 
vaccination in comparison to no survival amongst mice vaccinated with the primary vaccine 
alone [760]; However, these experiments required adoptive cell pre-loading for the secondary 
vaccine due to the induction of anti-vector immunity from the primary vaccine. Substitution 
with an alternative secondary vector would alleviate the complication of using adoptive cell 
transfer in this vaccination strategy. 
 
4.1.3 Colorectal Cancer-associated Epitopes 
Although there have been many immunotherapeutic vaccines designed for treatment of CRC, 
targeting a multitude of different antigens, the vast majority have predominantly focused on 
CEA and mucin 1 (MUC1). CEA is a glycoprotein of the immunoglobulin superfamily 
expressed during oncofetal development, predominantly in cells of the normal colonic 
mucosa, and is commonly overexpressed in CRC. It has been attributed with multiple roles, 
including cell adhesion, inhibition of extracellular matrix detachment-associated cell death 
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(anoikis), promoting of entrance into a G0-like cell cycle state, and in processes of cellular 
transformation [765-769]. The closest potential analogue of human CEA in mice is the biliary 
glycoprotein Bgp1, which has a similar expression profile and a similarly late onset of 
expression in the intestine during embryogenesis [770]. The murine analogue of MUC1 is 
strikingly different from its human counterpart, with significant homology only observed at 
the O-glycosylation sites, and in the transmembrane and cytoplasmic domains [771]. MUC1 
is expressed on the luminal surface of polarised epithelial cells, and is overexpressed across 
the surface of adenocarcinomas [772]. Due to the lack of homology, studies that assess the 
efficacy of immunotherapeutic vaccines targeting either CEA or MUC1 tend to involve the 
use of transgenic mice and CRC cells lines expressing the human form of these proteins [773-
777]. In an attempt to limit the complexity of this study, alternative CRC-associated targets 
were sought, preferably that shared sequence homology, expression profile, and function 
between humans and mice. 
The first target antigen selected for this study was survivin. Survivin is overexpressed in a 
range of solid tumours including CRC, and is notably absent in normal differentiated tissues 
[778]. It inhibits apoptosis through mitochondria-dependent caspases [779], with 
overexpression in tumour cells attributing a reduction in apoptotic index in vivo [780]. 
Survivin also plays an important role in angiogenesis, as its expression is increased in 
endothelial cells during vascular remodelling [781, 782], and the targeted suppression of 
survivin during angiogenesis can induce capillary involution [783]. Survivin has been 
heralded as a potential pan-tumour antigen, capable of eliciting targeted anti-tumour 
immunity against a broad range of tumour types [784]. A phase I clinical trial investigating 
the potential of survivin-derived peptides as an immunotherapeutic vaccine for CRC 
concluded that targeting survivin was safe for use in humans [785]. More recently, a peptide 
pool vaccine consisting of five survivin epitopes restricted for HLA-A1, HLA-A2, HLA-A3, 
HLA-A24 and HLA-B7 administered with Montanide completed a phase I clinical trial [786]. 
Montanide is a proprietary water in oil emulsion adjuvant, an improvement over transitional 
emulsion adjuvants such as IFA [787]. Peptide-specific T cell responses were detected in 
63% of vaccinated patients, who possessed a broad range of different solid tumours, 
including cancers of the breast, colon, kidney, lung, ovary, rectum, skin and testicle. Again, 
this vaccine was well tolerated amongst recipients, with the best clinical outcomes reported 
as stable disease in 28% of patients. Importantly, survivin has been previously studied in 
mice in the context of H-2Kb-restricted CTL epitopes, and immunotherapeutic vaccination 
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against CRC. The murine survivin epitopes Msur57 (CFFCFKEL), Msur82 (SGCAFLSV), 
and Msur97 (TVSEFLKL) were screened as candidate peptides by Hofmann et al [788]. 
Msur82 was eliminated early in the study due to an inability to bind stably to H-2Kb. Both 
Msur57 and Msur97 were capable to inducing target specific lysis in in vitro restimulation 
microcytotoxicity assays, and also delayed the growth of B78D14 murine melanoma when 
the peptides were administered loaded on DCs [788]. Of these two survivin epitopes, Msur97 
was selected for use in the chimaeric VLP constructs developed in this study due to a 
marginal advantage in binding affinity for H-2Kb, and a desire to avoid potential issues with 
repeats that might be encountered during cloning of the Msur57 sequence. 
The second target antigen selected for this study was another potential pan-tumour antigen, 
topoisomerase II alpha (topIIα). TopIIα is expressed in proliferating tissues [789, 790], and 
is overexpressed in a range of solid tumours including CRC [791], prostate cancer [792] and 
glioma [793], as well as lymphoma [794]. Topoisomerases are involved in regulating the 
high order structural state of DNA, altering superhelices and disentangling interlinked 
chromosomes [795]. TopIIα is involved in chromosome segregation and DNA replication 
[796, 797]; hence, its predominant association with proliferating cells. Although topIIα has 
previously been used as a prognostic marker in prostate and liver cancer [798, 799], and as a 
target of chemotherapeutic agents [800], immunotherapies targeting this potential antigen are 
scarce. Fortunately, candidate H-2Kb-restricted epitopes derived from topIIα have already 
been identified and studied in mice by Park et al [801]. The topIIα peptides p1327 
(DSDEDFSGL), p1339 (DEDEDFLPL), p1470 (SDSDFERAI), p1490 (EEQDFPVDL) and 
p1509 (RARKPIKYI) were identified as potential candidate epitopes using two online 
prediction tools. Amongst these peptides, Park et al found only p1327 was capable of 
inducing IFN-γ production when pulsed on splenocytes from mice previously vaccinated 
with topIIα RNA-loaded DCs [801]. When loaded onto DCs, p1327 was also capable of 
inducing topIIα-specific lysis of target cells, and delayed the growth of MC-38 tumours. In 
accordance with these results, p1327 was selected as the H-2Kb-restricted topIIα epitope used 
in the chimaeric VLP constructs developed for this study. 
 
4.1.4 Spacer and Linker Sequences used in Chimaeric RHDV VLP 
RHDV VLP has previously been engineered to contain various model epitopes at the N-
terminus of the VP60 capsid protein, including the ovalbumin antigen epitope SIINFEKL 
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(SIIN.VP60) [633], and the gp33 antigen epitope SAVYNFATM (gp33.VP60) [632]. These 
VLP included a glycine-glycine-serine (GGS) spacer sequence between the recombinant 
peptide and the N-terminus of VP60, as glycine and serine residues provide flexibility [802-
804]. In these VLP constructs, this GGS sequence is predicted to limit the interference of 
recombinantly inserted peptides with folding of the VP60 protein, or with interactions 
involved in the formation of stable VLP. More recently, chimaeric RHDV VLP have also 
been developed containing the human melanoma-associated gp100 antigen epitope 
KVPRNQDWL singularly, in multiple copies, and in multiple copies interspaced by linker 
sequences [652]. The largest of these constructs, a triplicate copy human gp100 VLP 
interspaced with linkers sequences, encompassed a 36 amino acid insertion at the N-terminus 
of VP60. This construct was only 6 amino acids shorter than the longest reported stable 
insertion into VP60 at 42 amino acids [805]. Other than the aforementioned GGS spacer 
linker, further linkers used in this construct include an alanine-leucine-leucine (ALL) 
sequence inserted between each individual epitope. This ALL linker is an immunoprotease 
cleavage sequence [806], and its incorporation into the multi-epitope construct was predicted 






The purpose of this chapter is to adapt the RHDV VLP vaccine vector for targeting murine 
CRC, providing justification for humanisation of the resulting vaccine construct. 
Specifically, this will be attempted through the recombinant insertion of murine H-2kb 
epitopes derived from CRC TAAs. This chapter will explore the hypothesis that the 
incorporation of multiple epitopes into a single VLP construct will enhance anti-tumour 
immune responses. This enhancement may be immediately apparent following therapeutic 
vaccination in tumour-bearing mice, or it may be represented by the ability to prevent the 
emergence of recurrent tumours. The resulting candidate VLP vaccine will then be explored 
in a combination vaccine therapy with the oncolytic virus, vesicular stomatitis virus (VSV), 
with the objective of exploring this combination to facilitate the development of a primary-
recurrent vaccination strategy. 
 
4.2.1 Aims 
1. Development of chimaeric RHDV VLP containing single and multiple murine H-2kb 
restricted epitopes derived from CRC TAAs. 
2. Investigation of the efficacy of these chimaeric VLP to induce epitope-specific 
immune responses, and anti-tumour immunity in a murine model of CRC. 
3. Exploration of the potential of primary-recurrent vaccination using a combination of 




4.3.1 Chimaeric RHDV VLP containing Murine CRC Epitopes 
The CRC epitope containing RHDV VLP constructs used in this study were designed to build 
upon the foundation of previously developed VLP. To that effect, the N-terminus of VP60 
was engineered to incorporate a single copy of either the topIIα p1327 peptide (T.VP60) or 
the survivin Msur97 peptide (S.VP60), or a combination of both peptides in series separated 
by an ALL linker (TS.VP60) (Figure 4.1). Each of these constructs also included the GGS 
spacer linker separating the recombinantly inserted peptide from VP60. The additional linker 
used in the multi-epitope TS.VP60 construct was selected by repeating the immunoprotease 
cleavage analyses previously employed during development of the gp100 VLP construct 
[652]. This analysis was performed using the three online prediction tools, the Immune 
Epitope Database (IEDB) Analysis Resource Consensus tool [807], the Proteasome Cleavage 
Prediction Server (PCPS) [808] and NetChop [809]. The assessed list of linker sequences 
included the GGS spacer sequence and the ALL cleavage sequence, in addition to two 
alternative predicted immunoprotease cleavage sequences serine-serine-leucine (SSL) [806] 
and alanine-alanine-tyrosine (AAY) [806, 810]. Each prediction tool utilises its own 
proprietary algorithms and database for prediction of cleavage sites, resulting in differing 
rankings for each sequence between programs (Table 4.1 and 4.2).  
 
 
Figure 4.1 CRC Epitope RHDV VP60 Constructs 
Chimaeric RHDV VP60 constructs developed containing murine CRC-associated TAAs included (A) T.VP60, 
(B) S.VP60 and (C) TS.VP60. Each construct included the spacer linker GGS between the inserted sequence 
and the N-terminus of VP60. TS.VP60 also included an immunoproteasome cleavage linker ALL between its 
two TAA epitopes. 
 
The results from these prediction tools indicated that the incorporation of a linker was 
unnecessary for the processing of the N-terminal topIIα epitope from the TS.VP60 construct, 
but was advantageous for the processing of the survivin epitope. The ALL linker was the 
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optimal linker based on these predictions, and was selected for use in the construct. It is also 
noteworthy that the incorporation of a GGS spacer linker between the epitopes significantly 
impaired processing of the survivin epitope in 2 out of 3 prediction tools, corroborating 
published observations that incorporation of inappropriate linkers may be detrimental to 
epitope processing [811, 812]. This illustrates the importance of cross-referencing between 
multiple processing prediction tools, as each utilises its own set of algorithms to provide 
unique analysis. 
 
Table 4.1 Linker Comparison for TopIIα Processing 
 
Ranked Score: A rank of 1 indicates optimal predicted linker 
 
Table 4.2 Linker Comparison for Survivin Processing 
 
Ranked Score: A rank of 1 indicates optimal predicted linker, Nil indicates predicted incompatibility 
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4.3.2 Production of Chimaeric RHDV VLP 
pUC57 DNA plasmids containing sequences encoding N-term-T.VP60, -S.VP60 and -
TS.VP60 were obtained for ligation with the remainder of the VP60 gene. Each sequence 
was manually codon optimised for expression in Spodoptera frugiperda (Sf21) cells by silent 
mutation of each codon, using the Kazusa Codon Usage Database as a reference [813]. N-
term insertion sequences were excised from their pUC57 vector plasmids by digestion with 
BglII and PstI (Figure 4.2 A and B). Upon gel purification, each fragment was ligated with 
the remainder of the VP60 gene excised from a pAcpol-.VP60 plasmid by digestion with PstI 
and EcoRI (Figure 4.2 C), and a pAcUW51(GUS) plasmid linearised by digestion with BglII 
and EcoRI (Figure 4.2 D). Successful formation of the pAcUW51(GUS).T.VP60, 
pAcUW51(GUS).S.VP60 and pAcUW51(GUS).TS.VP60 was confirmed through 
identification of each VP60 sequence excised by digestion with BglII and EcoRI (Figure 4.2 
E). The predicted difference in fragment size between each construct can be difficult to 
interpret on an agarose gel when the comparative fragments are greater than 1 kb; however, 
the construct fragment for TS.VP60 appears to migrate slightly above both T.VP60 and 
S.VP60 (Figure 4.2 E). 
Upon confirmation of construct integrity by sequencing, each plasmid was co-transfected 
into Sf21 cells using the FlashBAC ULTRA transfection system. FlashBAC ULTRA negates 
the requirement to separate recombinant and parent baculovirus, as the parent strain is non-
viable [655]. Viable baculovirus for each construct was picked from plaque assays, and 
bulked up through repeated culture in Sf21 cells until at least their third passage. Baculovirus 
inoculums were harvested directly from the growth media, with Sf21 separated through 
pelleting by centrifugation. Expression of each VP60 construct was confirmed by SDS-
PAGE in a small culture volume prior to upscaling to batch VLP production. This production 
involves infection of Sf21 cultures with the recombinant baculovirus over a period of 3 days, 
followed by lysis with the detergent Triton-X to liberate intracellular VLP, and inactivate the 
recombinant baculovirus. VLP were then separated from cellular debris, before being 
concentrated and purified by differential ultracentrifugation. As RHDV VLP have a density 
of 1.34 g cm-3 [645], they band at the interface between two caesium chloride layers at 1.2 
and 1.4 g/cm3. VLP harvested from this band can be stored short-term at 4 °C in CsCl, or can 
be dialysed or diluted into 50% glycerol for long-term storage at -20 °C. Yields of T.VP60 
and S.VP60 from a 400 mL Sf21 culture varied between 6 and 12 mg total protein as 
150 
 
determined by spectrophotometry, while TS.VP60 had slightly lower yields averaging 
around 6 mg total protein. 
 
 
Figure 4.2 Production of T.VP60, S.VP60 and TS.VP60 Expression Plasmids 
DNA electrophoresis on 2% agarose gels stained with ethidium bromide. (A) Isolation of the N-term fragment 
from 1) pUC57.T.VP60 + BglII + PstI and 2) pUC57.S.VP60 + BglII + PstI; (B) Isolation of the N-term 
fragment from 1) pUC57.TS.VP60 + BglII + PstI; (C) Isolation of the remainder of the VP60 gene from 1) 
pAcpol-.VP60-SL + PstI + EcoRI; (D) Linearisation of the delivery vector, 1) pAcUW51(GUS), 2) 
pAcUW51(GUS) + BglII + EcoRI. Constructs produced through ligation were checked prior to co-transfection 
with the baculovirus expression system FlashBac Ultra (E) 1) pAcUW51(GUS).T.VP60 + BglII + EcoRI, 2) 
pAcUW51(GUS).S.VP60 + BglII + EcoRI, 3) pAcUW51(GUS).TS.VP60, based on the production of a DNA 
fragment corresponding to the length of the VP60 gene with the additional epitope sequence insertion. The 
arrows indicate the desired band position for each digest. 1 kb plus DNA Ladder is provided as a reference. 
 
Samples of T.VP60, S.VP60 and TS.VP60 were separated by SDS-PAGE, transferred onto 
nitrocellulose and probed for by western blot with anti-RHDV VP60 (Figure 4.3 A). The 
assembly of these constructs into intact VLP was confirmed by electron microscopy (Figure 
4.3 B-D). Each chimaeric VLP produced possessed structural similarities comparable to 
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native RHDV virions [639], including an icosahedral shape with indentations around the 
circumference often referred to as cog-like in appearance.  
 
 
Figure 4.3 Production and Purification of T.VP60, S.VP60 and TS.VP60 VLP 
(A) Western blot of CsCl purified chimaeric VLP following separation by SDS-PAGE and transfer onto 
nitrocellulose film. Carbon-coated grids were loaded and negatively stained with phosphotungstic acid for 
visualisation by transmission electron microscopy of (B) T.VP60, (C) S.VP60 and (D) TS.VP60. NEB broad 
protein ladder was used as a marker. The scale bar represents 200 nm. 
 
Although the size of the VLP was consistent between each construct at between 36-40 nm in 
diameter, TS.VP60 VLP did appear to possess a visible increase in intraparticulate density 
(Figure 4.3 D). This may be attributable to the length of the recombinantly inserted peptide 
sequence in this construct, as a similar appearance has been observed in preparations of 
chimaeric RHDV VLP with insertions of similar lengths. Chimaeric VLP identify was also 
confirmed by mass spectrometry, with the 60 kDa band excised for each VLP construct from 
SDS-PAGE gels, digested with trypsin and analysed by MALDI-TOF. Trypsin can cleave 
peptides at the site of a lysine (K) or arginine (R), in the absence of a subsequent proline (P). 
Mass spectrometric analysis confirmed the presence of N-terminal insertions in each 
construct, with a predicted peptide fragment identified corresponding with 
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MDSDEDFSGLGGSEGK for T.VP60, TVSEFLKLGGSEGK for S.VP60, and 
MDSDEDFSGLALLTVSEFLK for TS.VP60 (Figure 4.4). 
 
 
Figure 4.4 Mass Spectrometric Analysis of T.VP60, S.VP60 and TS.VP60 
SDS-PAGE gel extracted, trypsinised samples were analysed by MALDI-TOF mass spectrometry to confirm 
the presence of an N-terminal insertion in CsCl purified samples of (A) T.VP60, (B) S.VP60 and (C) TS.VP60. 
Emboldened and underlined sequences represent individual peptide sequences detected by mass spectrometry. 
 
4.3.3 Simultaneous N- and C-terminus Insertion into RHDV VP60 
In addition to supporting recombinant insertion of epitopes at its N-terminus RHDV VP60 
can also tolerate insertion at alternative sites such as the C-terminus. Originally intended as 
a potential site for insertion of B cell epitopes, the C-terminus of VP60 has previously been 
modified to incorporate a model six-residue epitope tag derived from bluetongue virus capsid 
protein VP7 (Btag), and detectable with the mAb 20D11 [814]. The Btag was successfully 
inserted at the C-terminus of VP60, producing stable VLP, and could be detected with the 
20D11 mAb by western blot. Recently, our laboratory experimented with insertion of an H-
2kb-restrict epitope from murine topIIα at the C-terminus of VP60 (VP60.T). Based on the 
successful formation of this VLP containing an MHC-I epitope at its C-terminus, we decided 
to briefly explore whether it was possible use simultaneous insertion at both the N- and C-
terminus to increase the number of epitopes that could be incorporated into a single chimaeric 
RHDV VLP. The VP60.T construct was used as a base scaffold, excised from its plasmid by 
digestion with PstI and EcoRI (Figure 4.5 A). This C-terminus VP60 fraction was combined 
with the N-terminus of the S.VP60 and TS.VP60, which were liberated from each of their 
own plasmid constructs by digestion with BglII and PstI, and ligated into pAcUW51(GUS) 
linearised with BglII and EcoRI. Each resulting plasmid construct was screened for inserts 
by digestion with BglII and EcoRI (Figure 4.5 B). Both combinations produced detectable 
inserts, represented as two new RHDV VLP constructs, one with a single epitope at each the 
153 
 
N- and C- terminus (S.VP60.T) (Figure 4.5 C), and one with both epitopes at the N-terminus 
and a second topIIα epitope at the C-terminus (TS.VP60.T) (Figure 4.5 D). 
 
 
Figure 4.5 Production of S.VP60.T and TS.VP60.T Expression Plasmids 
DNA electrophoresis on 2% agarose gels stained with ethidium bromide. (A) Excision of the C-terminus from 
VP60.T in a pAcUW51(pol-) plasmid by digestion with PstI and EcoRI. (B) Screening of BglII-EcoRI insert 
size in 1) pAcUW51(GUS).S.VP60, 2) pAcUW51(GUS).TS.VP60, 3) pAcUW51(GUS).S.VP60.T and 4) 
pAcUW51(GUS).TS.VP60.T. A diagrammatic representation is provided illustrating the structure of (C) 
S.VP60.T and (D) TS.VP60.T. The arrows indicate the desired band position for each digest. 1 kb plus DNA 
Ladder was used as a marker. 
 
The pAcUW51(GUS).S.VP60.T and pAcUW51(GUS).TS.VP60.T plasmids were co-
transfected into Sf21 cells along with the FlashBac Ultra vector as previously described. The 
resulting baculovirus was bulked up to generate a concentrated inoculum prior to inoculation 
of Sf21 cell cultures, and production of VLP. S.VP60.T and TS.VP60.T expression was 
confirmed through separation by SDS-PAGE, transfer onto nitrocellulose film, and probing 
with western blot with anti-RHDV VP60 mAb (Figure 4.6 A). The S.VP60.T band was 
notably higher than the S.VP60 control band, while TS.VP60.T was higher than both S.VP60 
and S.VP60.T. Intact VLP were also visualised by electron microscopy in preparations of 
S.VP60.T and TS.VP60.T (Figure 4.6 B & C), with each construct forming VLP with the 
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characteristic cog-like morphology and size. Unfortunately, the sequence structure of VP60 
is such that these constructs could not be confirmed by mass spectrometry. Although the size 
shift identified between these chimaeric VLP predicted that these constructs were likely to 
be of correct identity, the inability to provide confirmation halted development of chimaeric 
VLP with simultaneous N- and C-terminus insertion. Additionally, due to the inward tertiary 
folding at the C-terminus of VP60, recombinant insertion at this site may have additional 
restrictions. Insertions made at this site may be particularly limited in size, and may be more 
significantly influenced by specific amino acid sequences that interact with or disrupt the 
formation of other motifs within the VP60 protein structure. 
 
 
Figure 4.6 Production and Purification of S.VP60.T and TS.VP60.T VLP 
(A) Western blot of 1) S.VP60, 2) S.VP60.T and 3) TS.VP60.T. Electron microscopy and negative staining was 
used to visualise (B) S.VP60.T and (C) TS.VP60.T VLP. NEB broad protein ladder was used as a marker. The 
scale bar represents 200 nm. 
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4.3.4 Vaccination with chimaeric RHDV VLP 
The ability to stimulate target epitope-specific immune responses with T.VP60, S.VP60 and 
TS.VP60 was assessed using an in vivo cytotoxicity assay. This method has been used 
previously for assessing new chimaeric VLP constructs, and is effective for the determination 
of epitope-specific immunogenicity. In order to evaluate the ability to generate simultaneous 
immune responses against multiple targets, the standard method was modified to 
accommodate multiple target cell populations by adding the dye VPD to combinations of 
CFSE at different concentrations. Vaccines were administered subcutaneously on days 0 and 
21, consisting of 100 μg of VLP or an equimolar amount of peptides, combined with 25 μg 
of CpG adjuvant. Peptide-pulsed, fluorescently-labelled target cells were administered 
intravenously on day 28. Spleens were harvested 48 hours later, and splenocyte preparations 
were analysed by flow cytometry (Figure 4.7 A). Gating was used to exclude cell doublets 
by comparing side scatter height and area, and to exclude dead cells with near-IR Live/Dead 
dye (Figure 4.7 B).  
Each peptide pulsed target splenocyte population was then assessed for % specific lysis 
relative to an unpulsed population, compensating for background non-specific lysis. Both the 
T.VP60 and TS.VP60 vaccinated groups mounted an epitope-specific immune response 
against target cells laced with the topIIα p1327 peptide, while S.VP60 vaccinated mice did 
not (Figure 4.7 C). Similarly, S.VP60 and TS.VP60 vaccinated groups mounted an epitope-
specific immune response against target cells laced with the survivin Msur97 peptide, while 
T.VP60 vaccinated mice did not (Figure 4.7 D). T.VP60, S.VP60 and TS.VP60 each mounted 
epitope-specific immune responses against target cells laced with equimolar amounts of both 
the topIIα p1327 peptide and the survivin Msur97 peptide (Figure 4.7 E). The combination 
of these results indicates that TS.VP60 successfully vaccinated mice against both epitopes, 
without apparent detriment. This may provide an indication that any potential 
immunodominance that exists between these epitopes does not impair the ability to induce 





Figure 4.7 In vivo Cytotoxicity Assay 
In vivo cytotoxicity assays were used to assess the ability of each chimaeric VLP to induce epitope-specific 
immune responses. (A) Diagrammatic representation of the modified in vivo cytotoxicity assay used, explained 
in Section 2.3.2. (B) Flow cytometry gating strategy, excluding doublets [Gate A] and dead cells [Gate B].  % 
Specific lysis was determined by comparing the proportion of each peptide pulsed target cell population, topIIα 
pulsed [Gate D] and survivin pulsed [Gate G] to an unpulsed population [Gate C]. Percent (%) specific lysis 
was determined relative to (C) topIIα, (D) survivin, and (E) topIIα/survivin peptide pulsed populations. 
Statistical analysis was performed using one-way ANOVA, with multiple comparisons and Dunnett correction 




Vaccination with a combination of topIIα p1327 and survivin Msur97 synthetic peptide did 
not induce significant cytotoxicity against either target, demonstrating the superior 
cytotoxicity induced by these epitopes when recombinantly inserted into RHDV VLP (Figure 
4.7 C-E). Although the difference between the specific lysis between the peptide vaccinated 
and control VP60 vaccinated mice was not significant, this population did display and 
interesting trend. Across each target population, the percent specific lysis was tightly grouped 
marginally above the control population. This may be indicative of an immune response 
induced under impairment, perhaps in uptake, presentation or priming. 
 
4.3.5 Vaccination with Chimaeric RHDV VLP using a Multi-dosage 
Regimen 
Although there is significant variability in the infection kinetics amongst different species 
and strains of viruses, RNA viruses tend to reach a peak post-infection titre at around 72 hrs 
post infection [815-817]. As a potent cytotoxic immune response is preferential for tumour 
clearance, it logically follows that mimicking an active viral infection may enhance cytotoxic 
immune responses and improve tumour vaccine efficacy. A multi-dosage regimen with daily 
injections over a 3 day period simulates the natural ability of an RNA virus to replicate and 
accumulate at the infection site. Vaccination efficacy induced by different dosage regimens 
of S.VP60 and SIIN.VP60 were compared to VP60 VLP using a modified version of the in 
vitro VITAL assay, a cytotoxicity assay developed by Hermans et al [658]. The original 
VITAL assay involved isolation of CD8+ T cells from pre-vaccinated mice, and in vitro co-
culture with peptide pulsed Jurkat/A2Kb cells labelled with either CFSE or CMTMR. The 
modified form used in this study included replacing Jurkat/A2Kb cells with whole 
splenocytes due to the unavailability of the cell line, and substituted CMTMR dye for VPD. 
An in vitro cytotoxicity assay holds the advantage of requiring only a week post vaccination 
before assessing CTL efficacy against target cells. This provides an efficient platform for 
screening multiple VLP constructs, while providing justification for an in vivo cytotoxicity 
assay, or direct transition into a tumour trial. The primary flaw with this shortened timespan 
is a marked reduction in cytotoxic activity in the absence of boosting, especially when 
vaccinating against self-antigens. 
Mice were vaccinated subcutaneously with 100 μg of VLP in combination with 25 μg of CpG 
adjuvant on day 0 (1D), days 0 and 1 (2D) or days 0, 1 and 2 (3D), and culled at day 7. CD8+ 
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T cells were isolated from the draining lymph node of each mouse, and co-cultured with 
peptide pulsed, fluorescently labelled splenocytes for 4 hours prior to analysis by flow 
cytometry (Figure 4.8 A). Gating was used to exclude cell doublets by comparing side scatter 
height and area, and to exclude dead cells unable to process near-IR Live/Dead dye (Figure 
4.8 B). Each peptide pulsed target splenocyte population was then assessed for % specific 
lysis relative to an unpulsed population, compensating for background non-specific lysis. 
VP60 was used as a negative control, and analysis of its inability to induce cytotoxicity 
against SIINFEKL is provided as an example (Figure 4.8 C). Cytotoxicity induced by the 
model VLP SIIN.VP60 was significantly enhanced with both 2D and 3D vaccination over 
1D (Figure 4.8 D). The effect on the cytotoxicity induced by S.VP60 was less striking, but 
did result in a statistically significant enhancement with 3D vaccination over 1D (Figure 4.8 
E). These results indicate that while multiple doses appear to enhance the potency of VLP 
vaccination, the effect is seemingly impaired against tolerised antigens. Theoretically, this 
may represent the comparative responses generated in a primary naïve T cell population 
(SIINFEKL), and a secondary chronically tolerised T cell population (survivin). If this is the 
case, then it is intriguing that the chimaeric VLP can stimulate effector cytotoxicity in this 





Figure 4.8 Multi-dosage Regimens for Enhancing Epitope-specific Cytotoxicity 
In vitro cytotoxicity assays were used to assess the immunogenicity of multi-dosage regimens with chimaeric 
VLP. (A) Diagrammatic representation of the modified VITAL assay, explained in section 2.3.3. (B) Flow 
cytometry gating strategy, excluding doublets [Gate A] and dead cells [Gate B].  % Specific lysis was 
determined by comparing the proportion of each peptide pulsed target cell population, survivin pulsed [Gate 
D], and SIINFEKL pulsed [Gate F] to an unpulsed population [Gate C]. (C) Percent specific lysis relative to 
the survivin pulsed group for mice vaccinated with VP60, calculated for each dosage regimen including 
vaccination on day 0 (1D), days 0 and 1 (2D) and days 0, 1 and 2 (3D). (D) Cytotoxicity relative to SIINFEKL 
pulsed group for mice vaccinated with SIIN.VP60. (E) Cytotoxicity relative to survivin pulsed group for mice 
vaccinated with S.VP60. Statistical analysis was performed using an unpaired t-test comparing between dosage 




4.3.6 Kinetics of MC38-OVA Tumours in B57BL/6 Mice 
MC38 is a murine colon adenocarcinoma cell line that was induced through injection of 
dimethyl-hydrazine into the colonic lining of C57BL/6 mice [818]. As a model of CRC, 
MC38 is commonly engrafted subcutaneously into CD57BL/6 mice at amounts ranging from 
1x105-1x106 cells per mouse [819-821]. The growth rate of MC38 tumours is comparatively 
slow relative to other commonly used tumour cell lines, reaching 1 cm3 in an average of 31.3 
days [819]; however, the growth rate can be notably variable, reaching 1 cm3 anywhere 
between around 24.4 and 44.1 days. The use of a tumour model with a longer growth window 
is advantageous in studies of immunotherapeutic vaccines, as it provides sufficient time for 
the induction of immune responses to the tumour cells, the infiltration of the tumour with 
immune cell populations, and the subsequent exhaustion and establishment of an 
immunosuppressive tumour microenvironment. Additionally, an extended growth window 
provides sufficient time to investigate longer vaccination schedules, such as a prime-boost 
regimen. The MC38-OVA used in this study was produced by infection of the MC38 parent 
line with a retrovirus based on the pMIG/MSCV-IRES-eGFP plasmid, engineered to express 
membrane-bound ovalbumin [822]. MC38-OVA is notably more immunogenic than its 
parent cell line. This may attributable to the natural potency of ovalbumin as a model antigen, 
the high expression of ovalbumin from incorporation of multiple gene copies, or the potential 
release of ovalbumin into the tumour microenvironment. 
During initial experiments with MC38-OVA, dosages corresponding to protocols established 
for the parent cell line proved incapable of guaranteeing subcutaneous engraftment (Figure 
4.9 A). This issue was seemingly resolved by increasing the dosage of MC38-OVA cells 
injected, and may have been influenced by the length of time the cells spent in culture post-
thaw. MC38-OVA tumours engrafted into control C57BL/6 mice were palpable by day 7-10 
post injection, and usually grew slowly over the first 2-3 weeks, before expanding rapidly 
over the remaining 1-2 weeks. Striking variability in growth kinetics matched reports of the 
parent strain [819], on average taking 27.5 days to reach the ethically approved maximum of 
150 mm2 in area, ranging between 19-35 days (Figure 4.9 B and C). It is important to note 
that the previously mentioned ethical limit of 1 cm3 used by Pajtasz-Piasecka et al in their 
study of MC38 is smaller than the ethical limit of 150 mm2 used in these MC38-OVA studies. 
This means that the aforementioned kinetics for MC38 were for a smaller tumour, yet with a 
longer growth window, further identifying the differences in the growth kinetics of the parent 




Figure 4.9 MC38-OVA Engraftment and Growth Rate Kinetics 
Although subcutaneously engrafted MC38-OVA tumours share the spread of variation in growth kinetics of its 
parent strain, there are differences that can distinguish between them. (A) Engraftment rates of MC38-OVA 
tumours with different numbers of subcutaneously injected cells. (B) The average tumour sizes from individual 
mice in negative control populations of one VLP vaccination trial. (C) Kaplan-Meier curve plotting the survival 
of control mice. Groups X and Y represent tumours with seemingly different growth kinetics. 
 
Counterintuitively, these results suggest that MC38-OVA tumours grow faster than tumours 
established from MC38 cells. It is possible that prolonged passage in combination with 
retroviral infection has selected for a more robust or aggressive population of cells, while the 
predicted increase in immunogenicity contributed by the expression of ovalbumin manifests 
as increased rejection early during tumour establishment. Engrafted MC38-OVA tumours 
also appear to follow patterns of growth kinetics that can be tentatively clustered into two 
groups, X and Y (Figure 4.9 B and C). These groups are particularly distinguishable based 
on monitoring tumour growth, with group X tumours appearing to grow faster than group Y 
tumours. Group X tumours reached 150 mm2 within 26 days, while group Y tumours required 
between 31-35 days to grow to this size. The separation of these tumour groups may be due 
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to the presence of subpopulations within the MC38-OVA cell line, possibly from differing 
numbers of proviral transduction events between each cell. 
As the MC38-OVA cell line demonstrated differences in growth kinetics in comparison to 
its parent strain, it became necessary to confirm that the modified cell line had retained the 
expression of the selected CRC-associated antigens. Cultures of MC38 and MC38-OVA cells 
were lysed, and the resulting lysate was separated by SDS-PAGE, transferred onto 
nitrocellulose membrane, and probed with anti-topIIα or anti-survivin by western blot. 
MC38-OVA was found to express both topIIα and survivin, though possibly at slightly 
reduced levels relative to the parent strain (Figure 4.10 A and B). Expression of ovalbumin 
by MC38-OVA was also confirmed by co-culture of live MC38-OVA cells with splenocytes 
isolated from OT-I mice. Co-culture of MC38-OVA cells with OT-I splenocytes induced 
production of IFN-γ to levels comparable to co-culture with a SIINFEKL peptide pulsed 




Figure 4.10 Confirmation TopIIα, Survivin and Ovalbumin Expression in MC38-OVA 
The MC38-OVA cell line was screened for expression of (A) topIIα and (B) survivin by western blot. 
Expression was compared to the MC38 parent strain, with actin as a control. (C) Expression of OVA was 
confirmed based on secretion of IFN-γ at 24 and 48 hours following co-culture of MC38-OVA cells with 
splenocytes isolated from OTI mice (OTI), using naive C57BL/6 splenocytes as a negative control (Spl). NEB 
broad protein ladder was used as a marker. 
 
4.3.7 Chimaeric RHDV VLP as an Immunotherapy for CRC 
Induction of an epitope-specific cytotoxic immune response in an in vivo cytotoxicity assay 
is indicative that each chimaeric VLP was capable of successfully vaccinating against their 
target epitope; however, the efficacy of these responses may be impaired when combined 
with the predominantly immunosuppressive microenvironment of an established tumour. A 
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murine model of CRC was used to investigate the ability of these vaccines to induce a anti-
tumour immune responses. MC38-OVA tumours were engrafted subcutaneously on the left 
flank of C57BL/6 mice. On day 7, the mice were sorted according to tumour size and 
distributed evenly between each treatment group, ensuring that the average tumour size and 
distribution was consistent between each group. VLP vaccines were administered on days 7, 
8 and 9 using the 3D protocol, injected subcutaneously proximal to but away from the tumour 
site.  Vaccination was specifically administered at this site to facilitate drainage of VLP to 
the lymph node draining the tumour site, which may contain T cell populations primed for 
anti-tumour immunity. Tumour growth was monitored by measuring the cross-sectional area 
of each tumour, and mice were culled once these tumours reached the ethically approved 
maximum of 150 mm2 (Figure 4.11 A).  
Vaccination with either T.VP60 or S.VP60 delayed tumour growth, with 60% overall 
survival (Figure 4.11 B and C). These vaccines matched the efficacy of the SIIN.VP60 
vaccine, with complete remission of tumours in mice that responded to these vaccines. 
Vaccination with TS.VP60 further delayed tumour growth, inducing regression that came 
close to complete remission across all mice at around days 19-21 (Figure 4.11 B and C). 
Tumours in 30% of the mice in this group continued to grow from around day 21 onward 
following this prolonged regression period. Interestingly, tumour escape was also observed 
in an additional mouse in this group at day 68, over two months after tumour cell engraftment 
(Figure 4.12 F). This mouse last had a palpable tumour on day 16, suggesting that its tumour 
must have regressed down to a small resilient population, possibly under prolonged 
immunoediting. The emergence of this tumour illustrates the importance of a prolonged 
monitoring period following complete tumour remission in animal tumour models, as 




Figure 4.11 Efficacy of VLP constructs against engrafted MC38-OVA tumours 
Subcutaneously engrafted MC38-OVA tumours were used as a model for investigating efficacy of candidate 
vaccines. (A) Diagrammatic representation of tumour trials, with injection of 1x106 MC38-OVA cells on the 
left flank of each mouse, followed by vaccination with 100 μg of VLP and 25 μg CpG adjuvant on days 7, 8 
and 9. Mice were monitored for a period of 100 days, with survivors rechallenged with a second subcutaneous 
dose of 1x106 MC38-OVA cells in the opposing flank. (B) Tumour size was monitored based on cross-sectional 
area, and mice were culled upon reaching the ethically approved maximum of 150 mm2. (C) Survival was 
plotted on a Kaplan-Meier curve. Statistical analysis was performed using the Log-rank (Mantel-Cox) test, ** 




This was the only significantly delayed tumour recurrence observed amongst the treatment 
groups, with all other mice either succumbing to their tumour, or achieving complete 
remission (Figure 4.12 A-F). The TS.VP60 group achieved an overall survival of 70%, which 
was not a statistically significant benefit over either T.VP60 or S.VP60; however, the trend 
of both improvement in overall survival and further delayed tumour growth was replicated 
in a repeat tumour trial. 
 
Figure 4.12 Individual tumour growth curves 
Growth curves were plotted for individual mice within each group, (A) CPBS, (B) VP60, (C) SIIN.VP60, (D) 
T.VP60, (E) S.VP60, and (F) TS.VP60. Mice were culled after their tumour reached the ethically approved 




4.3.8 Rechallenge of Tumour-free Mice 
Following a period of 100 days of monitoring post tumour engraftment, mice in complete 
remission were rechallenged with a second dose of MC38-OVA cells. This rechallenge was 
injected subcutaneously into the mice, on the opposite flank to their original tumour site 
(Figure 4.11 A). A control group of naïve C57BL/6 mice were also engrafted to ensure the 
viability of the injected cells. The control group developed tumours that grew unhindered, 
reaching the ethically approved maximum size of 150 mm2 between days 20-37 post 
engraftment (Figure 4.13 A and B). None of the mice previously cured of their primary 
MC38-OVA tumour following vaccination with SIIN.VP60, T.VP60, S.VP60 or TS.VP60 
were susceptible to rechallenge, with no palpable tumours identified in any of the groups.  
 
 
Figure 4.13 Rechallenge with MC38-OVA 
Rechallenge of mice in complete remission from their primary tumour with a secondary injection of 1x106 
MC38-OVA cells. A group of naïve C57BL/6 mice were also challenged as a control. (A) Tumour size was 
monitored based on cross-sectional area in mm2. (B) Survival was plotted on a Kaplan-Meier curve. Statistical 
analysis was performed using the Log-rank (Mantel-Cox) test. ** p < 0.01, *** p < 0.001. 
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As the rechallenge was injected on the opposing flank, this represents the establishment of 
systemic immunity capable of selectively targeting the MC38-OVA cells. While this may be 
attributable to the immune response directly induced by each vaccine, there may be 
contributions from additional responses generated during periods of tumour regression. 
Targeted elimination of tumour cells through induction of apoptosis by cytotoxic immune 
cells would liberate additional TAAs for APCs to process and present, potentially triggering 
multiple responses that compound to promote tumour rejection. While the development of 
these bystander immune responses may potentially occur from any tumour cell line, the 
expression of ovalbumin by MC38-OVA represents a potent immunogenic target that may 
exacerbate this effect. 
 
4.3.9 Effect of Pre-existing Immunity to RHDV VLP 
Pre-existing immunity in the form of vaccine vector neutralising antibodies can impair the 
ability of some vaccines to induce an immune response against their target antigen. The effect 
of pre-existing immunity on the functionality of VLP-based vaccines is mixed, with some 
reports of deleterious effects [646], while others have reported no adverse effect [739, 740]. 
We have not previously observed any noteworthy interference from pre-existing immunity 
with our RHDV VLP vaccines, such as when using RHDV VLP in a homologous prime-
boost vaccination schedule for in vivo cytotoxicity assays. In order to confirm that 
establishing pre-existing immunity against RHDV VLP does not impair their ability to induce 
a cytotoxic immune response against recombinantly inserted epitopes, we set up a prime-
boost vaccination schedule in a MC38-OVA tumour trial. MC38-OVA tumours were 
engrafted subcutaneously, injected into the left flank of C57BL/6 mice. Prime vaccinations 
were delivered on days 7, 8 and 9 by subcutaneous injection proximal to but separate from 
the tumour site. Boost vaccinations were delivered on days 21, 22 and 23. Mice were 
monitored for a period of 50 days, and culled when their tumours reached the ethically 
approved maximum of 150 mm2 (Figure 4.14 A). Delayed vaccination with SIIN.VP60 at 
days 21, 22 and 23 (2’ SIIN.VP60) noticeably disrupts growth of MC38-OVA tumours 
(Figure 4.14 B), but does not provide a statistically significant survival advantage over the 




Figure 4.14 Prime-boost Vaccination with RHDV VLP 
Establishment of pre-existing immunity against the RHDV VLP vaccine vector was emulated using a prime-
boost vaccination schedule, administered in the context of a MC38-OVA tumour trial. (A) Diagrammatic 
representation of the tumour trial, with injection of 2x105 MC38-OVA cells on the left flank of each mouse, 
followed by primary vaccination with 100 μg VLP and 25 μg CpG adjuvant on days 7, 8 and 9, and/or boost 
vaccination with 100 μg VLP and 25 μg CpG adjuvant on days 21, 22 and 23. Mice were monitored for a period 
of 50 days. (B) Tumour size was monitored based on cross-sectional area in mm2. (C) Survival was plotted on 
a Kaplan-Meier curve. Statistical analysis was performed using the Log-rank (Mantel-Cox) test. NS = Non-




Establishment of pre-existing immunity through vaccination with VP60 prior to 
administration of SIIN.VP60 (1’ VP60, 2’ SIIN.VP60) impairs growth to the same degree as 
the 2’ SIIN.VP60 group, with matching 40% overall survival. These findings indicate that an 
RHDV VLP vaccine used as a booster retains its ability to induce an anti-tumour immune 
response even if the primary vaccine is also based on the RDHV VLP vector. This means 
that it should be theoretically possible to pair RHDV VLP vaccines containing epitopes 
derived from primary tumour antigens, and recurrent tumour antigens, in a primary-recurrent 
vaccination schedule for preventing tumour escape. Unfortunately, this particular trial was 
undertaken prior to the optimisation of MC38-OVA engraftment and growth kinetics, as 
identified by the incomplete engraftment of MC38-OVA amongst the CPBS treated group. 
 
4.3.10 Expression of RHDV VLP by Vesicular Stomatitis Virus 
Oncolytic viruses, such as VSV, preferentially infect and replicate in tumour cells. The 
combination of this infection preference with a lytic replication cycle allows oncolytic viruses 
to be used as a therapeutic virotherapy for cancer, homing in on and destroying tumour cells. 
VSV is a member of the Rhabdoviridae family, with a negative sense genome that encodes 
for five individual proteins, the surface glycoprotein (G), nucleocapsid (N), polymerase 
proteins (L and P), and the peripheral matrix protein (M). Together these proteins are 
arranged to produce the characteristic Rhabdoviridae bullet shape, with the VSV genome 
encased within a protective shell consisting of nucleocapsid (N) and polymerase proteins (L 
and P). The matrix (M) protein binds the nucleocapsid-enclosed RNA genome to the surface 
glycoproteins (G), and is encapsulated within a lipid bilayer (Figure 4.15) [823, 824]. The 
exposed portions of the surface glycoproteins facilitates infection of target host cells through 
an undefined receptor [825], and also serves as the primary target for neutralisation of the 





Figure 4.15 Structure of Vescicular Stomatitis Virus (VSV) 
VSV is a bullet shaped member of Rhabdoviridae family, consisting of a negative-sense RNA genome encased 
within a nucleocapsid (N) and polymerase (L/P) protein shell. This nucleocapsid is linked to the surface 
glycoproteins (G) through matrix proteins (M), enveloped within a lipid bilayer [823, 824]. 
 
VSV can tolerate the insertion of foreign genes at a specific site between the G and L genes, 
with functional transcription and translation along with the rest of the VSV genome [659]. 
Recombinant VSV expressing libraries of TAAs have been developed as an effective 
therapeutic cancer vaccine vector for both melanoma and prostate cancer [760]; however, the 
use of a live virus makes this form of vaccination susceptible to neutralisation with vector-
specific antibodies. The adaptation of VSV to express our RHDV VLP represents a potential 
combination vaccine strategy, and may facilitate the development of a heterologous primary-
recurrent vaccination regimen. The combination of VSV and RHDV VLP should 
theoretically provide the potency of a live virus vaccine and the tumour homing properties of 
an oncolytic virus, with both the epitope cross-presentation capabilities and the repeated 
vaccination potential of RHDV VLP. The first step in formulating this potential vaccination 
system is evaluating the viability of using an oncolytic virus to express a heterologous VLP. 
Sequences derived from the RHDV VP60 constructs VP60, SIIN.VP60 and TS.VP60 were 
adapted to facilitate insertion of these sequences into the primary VSV expression plasmid, 
pVSV-XN2 (Figure 4.16). Each subsequent plasmid construct was co-transfected along with 
the pVSV-L, pVSV-N and pVSV-P expression plasmids, into BHK cells pre-infected with 
the vaccinia virus MVA-T7. The pre-infection with MVA-T7 provides the T7 RNA 





Figure 4.16 Adaptation of RHDV VP60 Constructs for the VSV Expression system 
The RHDV VP60 gene was adapted for insertion into the VSV genome by introducing the flanking 
endonuclease cleavage sites XhoI and NheI at the N- and C-terminus respectively. Each of the three candidate 
constructs, (A) VP60, (B) SIIN.VP60 and (C) TS.VP60, were recombinantly inserted between the G and L 
genes of VSV. 
 
Following plaque purification, the resulting viruses VSV-VP60, VSV-SIIN.VP60 and VSV-
TS.VP60 were amplified through replication in BHK cells. Expression of each VP60 
construct was confirmed by western blot (Figure 4.17 A). Each recombinant VSV expressed 
VP60, with sizes corresponding with the recombinant insertion of one or two epitopes at the 
N-terminus relative to unmodified VP60. Additional bands were also picked up by western 
blot with anti-RHDV VP60, which may represent a truncated form of VP60, degraded VP60, 
or cross-reactivity with VSV products. Intact VLP were subsequently isolated with the same 
purification methods used for production of RHDV VLP in Sf21 insect cells. VLP produced 
by each recombinant VSV were identified by transmission electron microscopy, with 
characteristic cog-like morphology indicating that the expressed VP60 protein was capable 
of forming intact RHDV VLP (Figure 4.17 B-D). The background material in these TEM 
images consists of an unidentified stringy substance, which may be comprised of remnants 
of VSV. TS.VP60 VLP expressed by VSV also appear to have a dense core, a feature that 




Figure 4.17 Detection of RHDV VP60 VLP Produced by Recombinant VSV 
(A) Expression of each VP60 construct was confirmed by western blot, comparing 1) VSV-VP60, 2) VSV-
TS.VP60 and 3) VSV-SIIN-VP60. Formation of intact VLP was identified by transmission electron microscopy 
for (B) VSV-VP60, (C) VSV-SIIN.VP60 and (D) VSV-TS.VP60. The scale bar represents 200 nm. 
 
4.3.11 VSV Expressing RHDV VLP as an Immunotherapy for CRC 
Production of the recombinant VSV constructs VSV-VP60, VSV-SIIN.VP60 and VSV-
TS.VP60 produced titres roughly equivalent to that of a control VSV expressing GFP (VSV-
GFP). The predominant cytopathic effects (CPE) observed included detachment and 
rounding of cells, and were clearly identifiable within virally infected plaques and across 
virally infected cultures (Figure 4.18). The VSV constructs did not demonstrate any 
distinguishable growth characteristics or induce CPE different from those observed with 
VSV-GFP. Based on these observations, it was deemed unlikely that the expression of VP60 
or its variants in virally infected cells was having an effect on VSV viability, infectivity or 




Figure 4.18 Cytopathic effect of recombinant VSV 
Cytopathic effects were used as a visual determinant of VSV infection when examining plaque assays. (A) 
Mock infected BHK cells. (B) BHK cells inoculated with VSV-VP60. 
 
A screening trial was undertaken to assess the efficacy of these candidate constructs against 
subcutaneous MC38-OVA tumours. Vaccinations were administered using the 3D regimen 
on days 7, 8 and 9 following tumour engraftment. Vaccination with VSV constructs was 
performed intravenously, while VLP vaccines were administered subcutaneously with CpG 
adjuvant (Figure 4.19 A). Neither vaccination with VSV-SIIN.VP60 or VSV-TS.VP60 
induced significant effects on tumour growth rate or overall survival, with only SIIN.VP60 
vaccination providing any notable effect (Figure 4.19 B and C). These findings suggest that 
the in vitro efficacy of RHDV VLP expression by VSV may not translate in vivo, or that the 
quantity of VLP produced is insufficient for inducing anti-tumour immune responses. Further 
experiments are required to elucidate the specific cause of this discrepancy, representing a 
significant avenue for further investigation into the potential for a combination vaccine 






Figure 4.19 Screening VSV constructs for efficacy against MC38-OVA tumours 
VSV constructs VSV-VP60, VSV-SIIN.VP60 and VSV-TS.VP60 were screened for efficacy against 
subcutaneous MC38-OVA tumours. (A) Diagrammatic representation of the tumour trial, with injection of 
2x105 MC38-OVA cells on the left flank of each mouse, followed by vaccination with 100 μg VLP and 25 μg 
CpG adjuvant subcutaneously, or 5x106 PFU of VSV intravenously, on days 7, 8 and 9. Mice were monitored 
for a period of 50 days. (B) Tumour size was monitored based on cross-sectional area, and mice were culled 
upon reaching the ethically approved maximum of 150 mm2. (C) Survival was plotted on a Kaplan-Meier curve. 




4.4.1 Chimaeric RHDV VLP Vaccine for Colorectal Cancer 
Chimaeric RHDV VLP have previously been developed to incorporate a variety of immune 
epitopes, as immunotherapeutic vaccines for LL-LCMV and melanoma models in mice [632, 
633, 652]. In this study, new constructs were developed containing epitopes derived from the 
CRC TAAs topIIα and survivin as an immunotherapeutic vaccine for a CRC model in mice. 
These constructs proved capable of inducing targeted immune responses against their 
incorporated epitopes, which subsequently translated into the development of anti-tumour 
immune responses in murine CRC tumour trials of these vaccines; however, there remain 
several issues arising from these results that require further discussion. While the immune 
responses induced were epitope specific, the magnitude of these responses does not appear 
to translate directly with their in vivo efficacy. In previous work, the magnitude of target-
specific immune responses induced by chimaeric VLP as represented by percent specific 
lysis in in vivo cytotoxicity assays may be close to 100% with the model epitope SIINFEKL 
[633, 828]. When targeting a cross-species epitope from human gp100, percent specific lysis 
was still around a respectable 50% in vaccinated mice; however, when an epitope from 
murine gp100 was used, these responses dropped to around 10% [652]. These values are 
consistent with those achieved against murine topIIα and survivin in this study, but appear 
comparatively low in comparison to those achieved against model or xenogeneic epitopes. 
The impaired cytotoxicity induced may be the result of potent inherent immunotolerance for 
these epitopes. In this scenario, the ability to induce responses against these epitopes at all is 
testament to the capacity of chimaeric VLP vaccines to challenge immunotolerance. What 
remains unexplained is how these apparently low levels of cytotoxicity translate into anti-
tumour immune responses, especially those achieved in this study. One possible explanation 
is that the ability to break tolerance with chimaeric VLP vaccines may differ between 
vaccination of naïve mice, and tumour-bearing mice. The engraftment of a tumour in mice 
will include immunoediting, potentially priming responses against select TAAs. While the 
incompetence of these responses can be observed through the ability for tumours to establish 
and grow in naïve mice, when coupled with chimaeric VLP vaccination these responses may 
be magnified. Vaccination of mice with chimaeric VLP in the absence of this tumour 
immunoediting process may lack this initial priming, limiting the observed cytotoxicity of 
the responses induced in in vivo or in vitro cytotoxicity assays. This potential phenomenon 
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may be investigated by repeating these assays in tumour bearing mice, providing a more 
relevant representation of responses that may be induced in tumour bearing patients. 
 
4.4.2 Targeting Multi-epitopes with a Chimaeric VLP Vaccine 
In an ideal world, tumour cells would express a core antigen that is immunogenic, expressed 
in abundance, and critical for tumour cell survival. Such a situation does exist for some 
malignancies, such as in select cases of chronic myelogenous leukemia (CML) that have 
arisen from the balanced reciprocal translocation of chromosomes 9 and 22, forming the 
BCR-ABL1 fusion gene [829, 830]. Similarly, the majority of HER2 mutant breast cancers 
respond well to therapies targeted to block HER2 [831, 832]. However, in the absence of 
such a critical central mutation, the complex genetic background of tumour cells may include 
multiple redundancies, or such redundancies may develop during immunoediting of the 
tumour. These redundancies may enable tumour cells to survive, evolve, and resist selective 
targeting of a single antigen. Alternatively, amongst the heterogeneous mass of tumour cells 
there may dwell a resistant subpopulation capable of regenerating the tumour completely 
following vaccination. 
Through careful epitope selection and design, multi-epitope vaccines can be produced with 
the ability to elicit simultaneous cytotoxic immune responses, designed to limit the ability 
for inherent redundancies to facilitate tumour escape. However, multi-epitope vaccines pose 
additional complications in design and development, ensuring that immune responses are 
generate simultaneously against each target. An important consideration is the relative 
abundance of each epitope, and the requirement for epitopes to be processed efficiently. 
When delivered in equal proportion, epitopes of relatively similar processing compatibility 
should be presented equally and stimulate simultaneous immune responses, as demonstrated 
in studies of vaccines consisting of equimolar peptide pool [833]. The use of chimaeric VLP 
as a multi-epitope vaccine construct holds an advantage with regards to this concept over 
other design forms, such as those involving chemical conjugation, as the number of epitopes 
incorporated is consistent. For each VP60 capsid protein amongst the 180 copies that form 
each RHDV VLP, there is one of each epitope, providing equimolar delivery. Assuming that 
the processing and binding affinity of each epitope is relatively equal, this provides an ideal 
delivery platform for a multi-epitope vaccine. This concept is supported by this study, which 
provides the foundation for the use of chimaeric RHDV VLP as a multi-epitope vaccine for 
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cancer by demonstrating the ability to induce simultaneous immune responses against 
multiple CRC TAAs. 
Although the multi-epitope chimaeric VLP TS.VP60 appeared to induce some benefit over 
its mono-epitope counterparts T.VP60 and S.VP60 with regards to delaying tumour growth, 
and improving survival, these benefits were not found to be statistically significant. This 
outcome was an unexpected scenario, and resulted from the efficacy achieved with these 
mono-target therapies. Although it is possible that targeting two epitopes simultaneously is 
indeed not enough to counteract the redundancies present within a heterogeneous tumour, it 
is also possible that the model used was inappropriate for detecting the intended difference. 
As the cell line used in this model of CRC included the expression of the potent model 
antigen, ovalbumin, the induction of any targeted anti-tumour cytotoxicity may have been 
sufficient to liberate this protein and induce anti-ovalbumin immune responses. This 
bystander response may have been additive with the mono-target vaccines, blurring the 
potential differences that may exist between each therapy. While such bystander responses 
are likely to be induced as a side-effect of many targeted anti-tumour vaccines, the presence 
of ovalbumin as a potent antigen may have exacerbated an otherwise minimally significant 
effect. This potential issue would be rectified by replicating these trials using the MC38 
parent strain. Otherwise, additional targets could be added through recombinant insertion to 
further expand the repertoire of the multi-target chimaeric VLP. 
 
4.4.3 Combination Vaccine Therapies 
The concept behind combination vaccine therapies is to administer two or more vaccines 
and/or therapeutic agents that would theoretically cooperate, resulting in additive or 
complementary effects. Examples include the use to chemotherapy or radiotherapy to 
increase the production and release of DAMPs or other immunogenic molecules in tumour 
cells prior to targeted vaccination, or as a means to enhance the potency of whole cell 
vaccines. An example of this is the use of irradiated, α-galactosylceramide laced autologous 
tumour cells as a vaccine in a murine model of glioma [834]. The approach used with this 
vaccine also utilised another therapeutic in its most effective combination formulation, 
administering anti-CTLA mAbs as an immune checkpoint inhibitor in support of the vaccine. 
The use of checkpoint inhibitors in combination with vaccines is becoming increasingly 
common [835-837], attempting to enhance marginal or minimal clinical responses induced 
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by vaccines alone through immunomodulation. Other potential vaccine therapy combinations 
include the use of therapeutic vaccines or checkpoint blockade to boost the efficacy of 
adoptively transferred T cells [838], or targeting cytotoxic or radioactive compounds to 
tumour cells aboard anti-TAA antibodies [491, 839]. 
The combination vaccine therapy investigated in this study involved the use of chimaeric 
RHDV VLP, and the oncolytic virus VSV. Rather than simply exploring the potential 
cumulative effects of co-delivery or sequential delivery of these vaccines, these vaccine 
constructs were combined to produce an oncolytic virus expressing a virus-like particle. This 
concept was previously reported by Ma et al, who developed a recombinant VSV that 
expressed the VP1 protein (VSV-VP1) of human norovirus (HuNoV) VLP [840]. VSV-VP1 
were found to induce the formation of intact HuNoV VLP through expression of VP1 in vitro, 
and induced comparable and in some instances elevated titres of anti-VP1 antibodies in 
comparison to baculovirus expressed HuNoV VLP. Although the RHDV VLP expressing 
VSV developed for this study were likewise capable of inducing the formation of intact 
RHDV VLP in vitro, this did not translate into anti-tumour activity. In fact, there was some 
evidence that suggested that the inherent oncolytic activity of VSV might have been impaired 
in these combination constructs. While these results may seem contradictory, there is a major 
factor that may contribute to this discrepancy, that of dosage. While the expression of VLP 
by VSV in vivo may result in sufficient production and release of VLP for induction of anti-
vector humoral immune responses, these same expressed levels may be insufficient for 
induction of cell-mediated immune responses against recombinantly inserted epitopes. 
Alternatively, VSV expressed RHDV VLP may be immunologically inferior in comparison 
to baculovirus expressed RHDV VLP, or the VSV constructs produced may be have 
possessed some detrimental flaw. Despite these complications, the underlying concept of 
using oncolytic viruses in combination with VLP vaccines remains intriguing and merits 




The successful incorporation of murine H-2kb epitopes derived from CRC TAAs into 
recombinant RHDV VP60 further expands the list of chimaeric VLP developed as potential 
cancer vaccines. In this study, the focus was predominantly on the comparison between 
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targeting multiple epitopes in comparison to targeting individual epitopes. Although the 
distinction between TS.VP60 and both T.VP60 and S.VP60 was not statistically significant, 
the trends in both reduced tumour growth rate and improved survival with the multi-epitope 
vaccine suggest that this concept is worth further investigation. The ability to express the 
TS.VP60 chimaeric VLP with recombinant VSV also provides multiple options for 
combination vaccine therapies, although further work and optimisation is required for 
completion of translation from in vitro to in vivo efficacy of these vaccines. The lack of 
efficacy with the recombinant VSV constructs also impaired the ability to assess the 
combination of VSV and RHDV VLP in a primary-recurrent vaccination strategy, a concept 
that still has the potential to alleviate the issues plaguing VSV vaccination with regards to 




5 Future Directions and Conclusion 
5.1 Delivery of Molecules Associated with RHDV VLP 
The versatility of RHDV VLP as a vaccine platform is profound, possessing the capacity to 
support the recombinant insertion of peptides and the chemical conjugation of various 
molecules. Natural affinity of these VLP for specific compounds provides an additional level 
of complexity, facilitating the formation of composite particles from a relatively simple 
preparation. This functionality adds to the list of benefits attributable to VLP over synthetic 
vaccine nanoparticles, which already includes the immunogenicity of repetitive surface 
structures and the ability to induce cross-presentation of recombinantly inserted epitopes. In 
addition to adding as a vaccine scaffold, together these components may facilitate the 
development of complex VLP-based combination vaccine therapies. Some of the potential 
components that may be incorporated into future VLP vaccines may include different types 
of adjuvants with different forms of binding or association with VLP, the use of other forms 
of immunomodulation and gene manipulation with VLP vaccines, and the development of 
personalised vaccines for cancer. 
 
5.1.1 Adjuvant Delivery 
An adjuvant can be considered any molecule, compound or formulation that can act as either 
a non-specific, or specific immunostimulant. A non-specific adjuvant would include most 
commonly used commercial adjuvants, such as hydrated aluminium sulfate-based 
compounds (Alum), squalene-based emulsions (e.g. MF59, AS03), or monophosphoryl lipid 
A (MPL-A). These compounds promote general immune cell activation; however, they can 
still favour activation of a particular type of immune response above others. For example, 
Alum is known to stimulate high antibody titres, while the liposomal adjuvant CAF01 
induces a mixed TH1/TH17 phenotype [841]. In contrast, specific immunostimulants, such as 
the different types of CpG or α-galactosylceramide, target relatively narrow populations of 
immune cells. These adjuvants induce reasonably predictable responses, and can help tailor 
a vaccine towards achieving a specific outcome. The role of a vaccine adjuvant is to provide 
the PAMP/DAMP signals that usually accompany infection or inflammation, stimulating 
their respective receptors and priming APCs. This results in the increased expression and 
presentation of co-stimulatory molecules, and the release of cytokines. The modality of 
adjuvant delivery is another important consideration. Co-delivery of the vaccine and adjuvant 
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together as a composite provides compounding benefits, enhancing vaccination efficacy over 
the delivery of each component separately [842]. This compounding effect may be 
responsible for the benefits observed when CpG was associated with RHDV VLP. 
In addition to co-delivery of adjuvants that naturally associate with RHDV VLP, this 
interaction may also be utilised for alternative vaccine enhancement application. The ability 
for these molecules to associate with RHDV VLP may be harnessed as an alternative, non-
covalent linkage to associate other molecules with VLP. For example, it would be interesting 
to see if peptides chemically conjugated to CpG can associate with RHDV VLP. Any such 
potential interaction is likely to be restricted by the specific location that nucleic acids 
associate with RHDV VLP, as while surface association may allow conjugated molecules to 
eject from the surface of VLP, internal association may not. Similarly to this conjugated 
peptide concept, it would be interesting to see if naturally glycosylated peptides can associate 
with RHDV VLP. The flexibility of this interaction is particularly intriguing, as the formation 
of the composite particle need only be induced prior to administration. This may allow each 
component of the vaccine to be stored under their individually ideal storage conditions, and 
allow on site interchanging of the vaccine components used for specific formulations. 
Possessing a repertoire of adjuvants, glycosylated/conjugated receptor ligands, or peptides 
that alter intracellular processing to add to a range of vaccine constructs could provide the 
foundation for tailored VLP-based vaccines. 
 
5.1.2 Manipulation of Gene Expression 
Multiple molecular techniques are available for manipulation of gene expression, both in 
vitro and in vivo. Examples include the transformation of cells through crude biolistic 
projectiles, transfection with liposomal particles, infection with genetic modifying viruses 
and utilisation of the clustered regularly interspaced short palindromic repeats (CRISPR) / 
CRISPR-associated protein (Cas) system. Each of these tools may be used to introduce 
xenogeneic genes, additional copies of allogeneic genes, or gene expression regulatory 
elements such as siRNA, shRNA or miRNA. While each of these techniques have broad 
biotechnical applications in vitro, in vivo applications for most have been hampered by 
significant safety concerns, predominantly regarding off-target effects. The relatively modern 
CRISPR/Cas system for gene editing is unique in this regard, as this technique does contain 
some inherent guidance and control in its delivery. This tool can be delivered in vivo using 
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conventional virus-based gene delivery techniques, and has already proven effective for 
inducing expression of target genes in mice [843-846]. 
Manipulation of gene expression using siRNA associated with VLP is not likely to be as 
momentous as the utilisation of the CRISPR/Cas system, but does represent an alternative 
delivery system with some unique potential applications. As VLP are predominantly 
consumed by APCs, VLP as a vector for siRNA inherently possess a form of targeted 
delivery. Additionally, conjugation of peptides, ligands and various other molecules onto the 
surface of VLP that promote uptake into a particular cell population could be used to further 
specify delivery. In comparison to reported knock-down rates achieved though JCV VLP-
mediated delivery of siRNA at around 60-90% [704], variable rates of 10-60% across 
different dosages of siRNA delivered with RHDV VLP may not be as practically efficacious; 
however, delivery and knockdown rates may be enhanced through improved chimaeric VLP 
designs. Alternatively, RHDV VLP-based delivery may have applications in the 
manipulation of genes in pathways that are sensitive to minor changes in expression. 
 
5.1.2.1 R8.VP60 and DBS.VP60 
Despite the intention of establishing a net positive charge at the intraparticulate surface of 
VLP, R8.VP60 did not appear to have an increased affinity for negatively charged nucleic 
acids over the base association with unmodified VP60. This may have been due to the 
degradation or cleavage of this octaarginine domain, or truncation due to a mutation 
introducing an alternative start codon. Either of these scenarios may provide an explanation 
for both the duel bands identified by western blot in preparations of R8.VP60, and its 
apparent inability to benefit from its proposed innate positive charge. If degradation of the 
octaarginine domain does occur in R8.VP60, the liberation of poly-arginine peptides may 
also interfere with the natural association between nucleic acids and the R8.VP60 VLP. An 
alternative explanation may be that the polarised charge introduced at the N-terminus of 
VP60 may alter the position of the N-terminus within the tertiary structure of the protein. 
Prediction modelling using the I-TASSER server (Zhang Laboratory, University of 
Michigan, Michigan, USA) predicts that in comparison to VP60 (Figure 5.1 A), the N-
terminus of R8.VP60 may be folded into the protruding (P) domain (Figure 5.1 B) [847]. 
Although server modelling is predictive only, such an orientation may mask the charged 
octaarginine motif within the P domain. By contrast, the I-TASSER server predicted that the 
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N-terminus of DBS.VP60 would retain its orientation below the shell (S) domain, remaining 
at the interparticulate surface (Figure 5.1 C). This might explain why DBS.VP60 VLP 
appears to have an increased affinity for nucleic acids over unmodified VP60 VLP. 
 
 
Figure 5.1 Modelling Predictions of VP60, R8.VP60 and DBS.VP60 
3D models generated using the I-TASSER server from sequences of (A) VP60, (B) R8.VP60 and (C) 
DBS.VP60, using the catalogued reference model of the RHDV VP60 conformational structure 3ZUE as a 
reference [805]. Portions highlighted in red indicate recombinantly inserted sequences. P = Protruding, S = 
Shell. 
 
The next step for research into these current constructs would be to confirm their predicted 
structural differences through crystallography, and to link how this structure functionally 
applies to concepts such as the association of nucleic acids with RHDV VLP. As has been 
previously mentioned, it would be interesting to investigate how and where these nucleic 
acids are associating with the VLP; however, it may be of greater interest to investigate how 
the N-terminus DBS insertion affects this association. If the association is peripheral, perhaps 
differences in charge can account for the increased association, or perhaps the DBS motif 
provides a cumulative effect, with its binding interface additive to the natural association. 
Should the association be internal, or involve projection through gaps in the shell domain as 
suggested by Touze et al in BKV VLP [712], perhaps the internal DNA binding site is merely 
functioning as intended. These concepts represent only a fraction of the research that would 
be required to bring the investigation of these constructs closer to completion. 
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5.1.2.2 Potential Construct Designs 
Although DBS.VP60 possessed an enhanced ability to associate with nucleic acids, it also 
suffered from significant instability and low production yields. The L1 binding site of human 
papilloma virus type-16 is only one of many naturally occurring DNA binding sites that may 
be incorporated at the N-terminus of RHDV VP60, and it may be prudent to consider 
alternative constructs with potentially superior stability. For example, protamines are a group 
of short nuclear proteins that are involved in the packaging of DNA during spermatogenesis 
[848], containing arginine-rich regions that are highly conserved between different species. 
Based on its ability to shuttle DNA, incorporation of sequences derived from protamine into 
RHDV VLP may enhance its ability to associate with nucleic acids.  
 
 
Figure 5.2 Charge Maps of Proposed Recombinant VP60 for Enhanced siRNA Association 
Charge density maps generated in Protean 3D, Lasergene 10 (DNAStar, Wisconsin, USA), comparing the 
relative positive charge at the N-terminus of (A) VP60, (B) R8.VP60, (C) DBS.VP60, (D) PRM.VP60 and (E) 
DPS.VP60. 
 
In comparison to VP60, R8.VP60 and DBS.VP60, insertion of protamine at the N-terminus 
of VP60 (PRM.VP60) results in the formation of a domain with a positive charge of a 
relatively higher magnitude than R8.VP60 (Figure 5.2 A-D). Due to this excessive charge 
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level, it is unknown whether a theoretical PRM.VP60 would possess the same functionality 
issues as R8.VP60. Another alternative construct may be developed based on the DNA-
binding proteins from starved cells (DPS) proteins, derived from bacteria. These DPS 
proteins are thought to confer protection from damage induced due to the accumulation of 
reactive oxygen species by binding directly to DNA, and preventing ferroxidation through 
sequestration of iron [849]. 
Insertion of the hypothesised DNA-binding site of a Dps protein derived from 
Mycobacterium smegmatis (UniProt Accession #P0C558) at the N-terminus of VP60 
(DPS.VP60) yields the formation a domain with relatively low positive charge in magnitude 
compared to either R8.VP60 or DBS.VP60 (Figure 5.2 E); however, this positive charge is 
spread over a longer sequence. 3D models generated for both PRM.VP60 and DPS.VP60 
predict that these N-terminus insertions may not adversely interact with the P domain, and 
hence may functionally more closely resemble DBS.VP60 rather than R8.VP60 (Figure 5.3 
A and B). It would be interesting to find out whether either of these constructs are suitable 
candidates for promoting association or binding of nucleic acids with RHDV VLP, especially 
as there are multiple isoforms of each DNA-binding domain available for assessment across 
a broad range of species and strains. 
 
 
Figure 5.3 Predicted 3D Models of PRM.VP60 and DPS.VP60 
Predicted 3D models generated for (A) PRM.VP60 and (B) DPS.VP60 using the I-TASSER server [847], with 
3ZUE used as a scaffold [805]. Portions highlighted in red indicate recombinantly inserted sequences. 
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5.1.2.2 Potential Immunomodulation Pathways 
While further optimisation is required for efficiency delivery of siRNA associated with 
RHDV VLP, potential appropriate target genes may still be theorised. There are multiple key 
regulatory, signal transduction, cell surface receptor or cytokines that may serve as 
appropriate targets amongst APCs. Amongst these, two candidates were selected for further 
discussion, namely suppressor of cytokine signalling 1 (SOCS1), and forkhead box O3 
(FOXO3). These genes were selected based on their central roles in immune cell regulation, 
and from published evidence manipulation of these genes in immune responses. SOCS1 and 
SOCS3 are unique amongst the various members of the SOCS protein family, in that they 
contain an N-terminus kinase inhibitory domain. This domain serves to suppress cytokine-
induced signalling pathways, compounding with the inhibition of JAK/STAT signal 
transduction pathways through the neighbouring SH2 domain shared between SOCS proteins 
[850, 851]. While deletion of Socs1 in mice can induce a severe inflammatory syndrome that 
eventually results in polycystic kidney disease and other inflammatory lesions [852], 
deficiency in Socs3 causes failure to thrive entirely, with mice incapable of completing 
embryogenesis due to excessive leukaemia inhibitory factor signalling [853]. Socs1 has been 
previously explored as a potential siRNA target in combination with vaccines, including in 
combination with a polymer nanoparticle vaccine for cancer [854], and a DC-based vaccine 
for lymphoma [855]. 
Amongst the FoxO orthologs expressed in mice, FoxO1 and FoxO3 are the primary isoforms 
expressed in immune cells such as dendritic cells [856]. FoxO3 is an important regulator of 
APC function, with dysregulation of cytokine expression in response to infection when mice 
are deficient in FoxO3 [857]. While FoxO1 has been implicated in both primary CD8+ T cell 
responses and memory formation [858, 859], FoxO3 appears to be restricted to mediating 
primary responses [860]. FoxO3 siRNA have also been investigated in combination with an 
immunotherapeutic vaccine for cancer, using a chimaeric peptide nanoparticle [861]. 
Silencing Socs1 and/or FoxO3 with siRNA in combination with an RHDV VLP-based 
vaccine may enhance responses to the vaccine. Broad dampening of inhibitory signalling in 
APCs could also theoretically facilitate the emergence of suppressed inherent anti-tumour 
responses, similar in functionality to checkpoint inhibition with monoclonal antibodies. 
Immunomodulation through manipulation of gene expression in APCs may become an 
important component of immunotherapeutic vaccine design.  
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5.2 RHDV VLP Vaccines for Cancer 
Amongst subunit vaccines, VLP possess a unique balance of immunogenicity, versatility and 
scalability. RHDV VLP have been identified to possess each of these qualities, serving as a 
potentially ideal vaccine scaffold. Although significant progress has already been made to 
bring RHDV VLP-based vaccines for cancer closer towards clinical applications, further 
work is necessary to realise this goal. These remaining hurdles include: 1) identifying 
tumour-associated antigen targets that can be translated into human tumours; 2) finalising the 
optimal RHDV VLP vaccine design and delivery regimen; and 3) manufacture of the vaccine 
to a standard suitable for use in humans. While the first and third hurdles are limited 
predominantly by infrastructure, it is the second that may be more immediately solvable. 
RHDV VLP are amenable to recombinant insertion, chemical conjugation, and naturally 
associate with an expanding list of molecules. Although in previous studies each of these 
properties have been explored individually, perhaps it is time to consider how each of these 
properties may be utilised together in one coherent vaccine construct. 
 
5.2.1 Chimaeric RHDV VLP 
RHDV VLP can tolerate insertion of peptides at the C-terminus, N-terminus, and at 
additional sites such as at AA306 of the P domain [862]. Inherent restrictions in insertion 
length and sequence lends towards conservative approaches, pitting quality against quantity. 
On the one hand, insertion of a single peptide corresponding to a ubiquitously expressed 
tumour-specific antigen may produce a robust vaccine, but such targets are rare amongst 
cancers. More epitopes equates to longer insertions, increasing the risk of VLP instability, 
and the looming threat of immunodominance. Add in the complexity of providing epitopes 
specific for multiple HLA isoforms to produce a vaccine relevant across a diverse human 
population, and the demands for recombinant insertion begin to stretch thin the restrictions 
imposed by the particle.  
One potential solution that has been investigated is to develop truncated variants of VP60 
[636], potentially providing additional capacity for insertion. An alternative approach 
involving simultaneous insertion at both the N- and C-terminus was also explored in Chapter 
4. This approach may be suitable for further research into expanding the recombinant 
insertion capacity of RHDV VLP. Alternatively, the AA306 insertion site may be a potential 
target. While this site was previously investigated for the insertion of immune domains 
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suitable for inducing humoral immune responses due to its surface orientation, this site may 
also accommodate insertion of epitopes for cytotoxic responses. Minimisation of the effect 
this insertion has on the P domain of VP60 would be imperative to the formation of intact, 
stable VLP. A proposed solution to this issue would be to project the inserted peptide away 
from the P domain, with the α-helical coiled coil structure of keratin suggested as a possible 
candidate Cytokeratin (C) domain. For this concept, a portion of the α-helical sequences from 
human keratin type I cytoskeletal (KRT) 10 (UniProt Accession #P13645) and KRT1 
(UniProt Accession #P04264) were obtained for prediction modelling of a potential 
construct, CYK306.VP60, based on model 4ZRY from x-ray crystallography work by 
Bunick et al (unpublished data). The resulting model of CYK306.VP60 suggests that the 
proposed C domain would extend away from the protruding domain, and hence away from 
the surface of the VLP (Figure 5.4).  
 
 
Figure 5.4 Proposed VP60 Construct for Long Peptide Insertion 
A Predicted model of CYK306.VP60 using the I-TASSER server [847], with 3ZUE used as a scaffold [805]. 




This model also predicts that the central epitope, in this example SIINFEKL, would be 
exposed at the tip of the C domain. The potential elongation of this domain and its 
incorporated epitope away from the surface of the resulting VLP also harkens back to the 
initial research done using the AA306 insertion site [862]. While the use of the AA306 site 
for direct insertion of epitopes proved ineffective at inducing epitope-specific antibody 
production, it is possible the elongation of such an epitope away from the surface of VLP 
would increase its availability for detection by B cells. Finally, this elongated domain may 
also be suitable for insertion of peptides that facilitate receptor-mediated endocytosis, 
potentially providing an additional pathway for VLP uptake and processing. 
 
5.2.2 Conjugated RHDV VLP 
Although recombinant insertion of epitopes into RHDV VLP is a robust means of vaccine 
design, each construct must be developed individually with a comparatively significant initial 
investment of time and resources. An alternative, rapid approach is to chemically conjugate 
the epitope peptides onto the surface of RHDV VLP. In a direct comparison, VLP conjugated 
with SIINFEKL peptide were found to be significantly less immunogenic than chimaeric 
SIIN.VP60 [828]; however, the presence of the conjugation motifs on the end of the 
SIINFEKL peptide may have affected its ability to be processed and presented. This may be 
rectified by including an immunoprotease cleavage domain in between the peptide and the 
conjugation motif, potentially facilitating the release an unmodified version of the peptide 
(Figure 5.5 A).  
 
Figure 5.5 Proposed Peptide Conjugation Constructs 
Proposed modified peptide conjugation chemistries based on NHS-phosphine/Azide bond formation, and 
separation of the peptide epitope from the conjugation chemistry with either (A) ALL or (B) GGG. 
 
Alternatively, a general spacer such as a glycine triplicate may be sufficient to facilitate 
processing of the epitope (Figure 5.5 B). These proposed conjugation systems may 
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theoretically bring chemically conjugated RHDV VLP in line with chimaeric VLP with 
regards to immunogenicity. Chemical conjugation also facilitates the incorporation of 
additional functionality, such as targeted delivery through the conjugation of receptor 
ligands, receptors or mAbs onto the surface of VLP. 
 
5.2.3 Personalised RHDV VLP Vaccines for Cancer 
Personalised cancer vaccines are based on the ability to tailor each vaccine to target specific 
antigens expressed by a particular patient’s tumour. This vaccine would then be redesigned 
for the next patient based on their specific antigen expression profile, and so forth. This 
concept deals with heterogeneity between patients with tumours of the same type, providing 
a vaccine with the best chance of inducing potent anti-tumour immune responses. The 
primary limiting factor with this vaccine model is the identification of the specific antigens 
expressed by each patient’s tumour. This may be rectified by arranging the known expression 
profiles for a particular tumour line into a form of antigen library, which may be screened 
against for each individual patient. While theoretically possible, current techniques are 
limited in their ability to provide the desired functionality. For example, RNAseq could be 
used to assess the transcriptome of individual patient’s tumours, providing the capacity to 
establish both a transcriptome library and to screen for candidate vaccine targets within in 
individual transcriptomes of patients; however, gene expression does not necessarily result 
in protein translation, which may result in discrepancies between the transcriptome and 
proteome. 
Alternatively, the proteome or similar protein-based markers may be screened by mass 
spectrometry or other techniques; however, the multitude of proteins that would be present 
in low concentrations relative to cytoskeletal and other structural proteins would make 
detection relatively difficult or tedious. While each of these approaches are individually 
flawed, a combination of each may provide sufficient compensation. The proposed method, 
referred to as the peptide library method, would involve a combination of both RNAseq for 
transcriptome analysis (Figure 5.6 A, B), and mass spectrometry for analysing a portion of 
the proteome. Rather than analysing the entire proteome amongst tumours, peptides loaded 
in MHC-I on the surface of tumour cells may be isolated, with peptides eluted from the MHC-





Figure 5.6 Establishment of a Tumour-associated Peptide Library 
Establishment of a peptide library for personalised vaccines in a murine tumour model. (A) Engrafted tumours 
and normal tissue harvested from mice would be isolated. (B) RNA extracted from samples would be analysed 
by RNAseq, providing a transcriptome data. (C) Peptides eluted from MHC-I isolated from the surface of 
tumour cells would be analysed by mass spectrometry. (D) Bioinformatic analysis of the resulting data 
correlating the transcriptome expression with peptide presentation would result in a list of candidate peptide 
targets for potential cancer vaccines. 
 
As with the original proteome analysis, this MHC-I restricted peptide pool would contain 
many different peptides in potentially low concentrations. This issue can be rectified by 
screening for a list of genes selected based on the RNAseq data, using this transcriptome data 
as guidance for the peptide pool mass spectrometry (Figure 5.6 D). Through the analysis of 
tumour samples across a comprehensive patient cohort, the result would be a list of MHC-I 
restricted peptides that are overexpressed for the particular tumour type. Repetition of the 
peptide elution and guided mass spectrometry from tumour samples resected from each 
subsequent patient would allow the selection of potential vaccine targets from this peptide 
library. When combined with the rapid chemical conjugation of peptides on the surface of 
RHDV VLP, which may be undertaken over a period of around 48 hours, this may represent 




5.2.4 Combination Vaccination 
The concept of combination vaccination involving VLP has been mentioned previously, and 
includes the use of VLP with other vaccines in both prime-boost or primary-recurrent 
vaccination strategies, or synergy between two homologous vaccines. Examples of the latter 
include the use of immunomodulatory agents such as checkpoint blockade mAbs in 
combination with VLP, or the use of VLP to stimulate adoptively transferred cells in vivo. 
One of the concepts explored in this study included the use of recombinant VSV to express 
RHDV VLP, forming a combination vaccine construct that should theoretically combine the 
effector functions of both the host oncolytic virus and the derivative VLP vaccine. While the 
constructs produced to explore this combination proved ineffective, the use of alternative 
oncolytic viruses or optimisation of the vaccination strategy used may improve the potential 
synergy between these vaccine components. A similar concept that was not explored in this 
study is the expression of VLP induced by VLP. Essentially, VLP that can be used as a gene 
delivery tool should theoretically be capable of delivering a gene encoding their capsid 
protein, potentially inducing the formation of VLP in vivo. This concept may be stretched 
further by using VLP to deliver a gene encoding the capsid protein or a different VLP, 
bypassing anti-vector immunity against the encoded VLP. These ideas represent only a few 
of the potential concepts that could utilise VLP as a component of a combination vaccine, 







RHDV VLP are a promising vector for development of immunotherapeutic cancer vaccines. 
This thesis covered a broad range of applications related to improving the efficacy and 
versatility of RHDV VLP-based vaccines, including through the formation of a composite 
particle with CpG, the delivery of associated siRNA, simultaneously induction of targeted 
immune responses in a multi-epitope vaccine, and the expression of RHDV VLP by VSV. 
Immunomodulation with adjuvants and other regulatory molecules is an intriguing concept; 
probably most predominantly exhibited clinically using checkpoint inhibitors and other 
immunomodulatory mAbs. In this study, both CpG and siRNA was found to associate with 
RHDV VLP, forming composite particles capable of delivery of these molecules into cells in 
vitro, as well as in vivo for CpG. This portion of work confirmed that there is something 
unique about the combination of RHDV VLP and CpG, allowing the formation of a potent 
vaccine construct.  
Chimaeric RHDV VLP were also found to be capable of inducing targeted immune responses 
against murine epitopes derived from the CRC TAAs topIIα and survivin. These responses 
also translated in a murine model of CRC, significantly improving survival amongst 
vaccinated mice. Although the multi-target vaccine TS.VP60 did not provide a statistically 
significant advantage over the individual mono-target vaccines, the trends observed suggest 
that the incorporation of additional epitopes may be significantly advantageous. Finally, 
RHDV VLP were successfully expressed by recombinant VSV in vitro; however, these 
recombinant VSV constructs proved ineffective in vivo. There were multiple potential issues 
relating to the expression of RHDV VLP by recombinant VSV, with multiple potential 
avenues for further research. Together this body of work provides another step along the 
progression towards the use of RHDV VLP as a cancer vaccine platform, though as with 
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7 Appendix I: Supplementary Figures 
 
Figure 7.1 Chimaeric VLP Sequencing Data 
N-terminal sequencing data provided for (A) T.VP60, (B) S.VP60 and (C) TS.VP60, sequenced from 
pAcUW51(GUS) expression plasmids by Massey Genome Service (Massey University, NZ) . (D) Identification 
of peptide sequences confirmed through mass spectrometry by the Centre for Protein Research (University of 




Figure 7.2 Mass Spectrometry Data 
Mass spectrometry data for (A) T.VP60, (B) S.VP60 and (C) TS.VP60, by the Centre for Protein Research 
(University of Otago, NZ). 
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8 Appendix I: Antibody Compendium 
 
Antibody* Fluorophore Clone Supplier 
Anti-CD11c APC N418 BioLegend 
Anti-CD40 PE-Cy7 3123 BioLegend 
Anti-CD80 Pacific Blue 16-10A1 BioLegend 
Anti-CD86 PE GL-1 BioLegend 
Anti-I-A/I-E FITC M5/114.15.12 BioLegend 
Rabbit Anti-Stat3 None 79D7 Cell Signalling Technology 
Rabbit Anti-TopIIα None 4733S Cell Signalling Technology 
Rabbit Anti-Survivin None 7164B7 Cell Signalling Technology 
Goat Anti-Actinβ None I-F1 Santa Cruz Biotechnology 
Donkey anti-Rabbit DyLight 800 SA5-10044 Thermo Scientific 
Donkey anti-Goat DyLight 680 SA5-10090 Thermo Scientific 
Anti-IFN-γ None R4-6A2 BD Pharmingen 
Anti-IFN-γ Biotinylated XMG1.2 BD Pharmingen 
* The target species is mouse unless otherwise stated.  
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9 Appendix II: Recipes 
9.1 Assorted PBS Solutions 
9.1.1 10X PBS 
10X PBS was prepared with 160 g sodium chloride (NaCl), 4 g potassium chloride (KCl), 
22.7 g disodium hydrogen phosphate (Na2HPO4) and 4 g potassium dihydrogen phosphate 
(KH2PO4), with sufficient dH2O as to bring the total volume up to 2000 mL. 
 
9.1.3 iPBS 
iPBS was prepared with 0.14 g Na2HPO4, 1.43 g KH2PO4, 8.18 g NaCl and 2.98 g KCl, with 
sufficient dH2O as to bring the total volume up to 1000 mL. iPBS was autoclaved, and stored 
at room temperature. 
 
9.1.4 cPBS 
cPBS was prepared with 5.2 g sodium dihydrogen phosphate dehydrate (NaH2PO4.2H2O), 
23.66 g Na2HPO4 and 17.54 g NaCl, with sufficient dH2O as to bring the total volume up to 
1000 mL. cPBS was autoclaved, and stored at 4 °C. 
 
9.2 Transformation Reagents 
9.2.1 LB Broth and Agar 
LB broth was prepared with 10 g bactotryptone (BD Biosciences, California, USA), 5 g bacto 
yeast extract (BD Biosciences, California, USA) and 5 g NaCl in 1000 mL of distilled H2O 
(dH2O). The broth was distributed into 3 mL aliquots in glass bijous, autoclaved, and stored 
at 4 °C. LB agar was prepared using the recipe for LB broth, with the addition of 15 g 
bacteriological agar (Scharlau, Spain). The LB agar solution was autoclaved, and then cooled 
to 50 °C before adding 12.5 μg/mL tetracycline or 50 μg/mL ampicillin. LB agar containing 
the appropriate antibiotic was poured into petri dishes, left to set and dry overnight at room 




9.2.2 Transformation Buffer I 
Transformation buffer I was prepared with 0.3 g potassium acetate (KCH3COO), 0.15 g 
CaCl2, 1 g magnesium chloride (MgCl2), 1.21 g rubidium chloride (RbCl) and 15 mL 
Glycerol, made up to 100 mL with Milli-Q H2O, adjusted to pH 5.6 with acetic acid and 
sterilised by passing through a 0.45 μm filter. 
 
9.2.3 Transformation Buffer II 
Transformation buffer II was prepared with 1.1 g CaCl2, 0.12 g RbCl, 0.2 g 3-(N-
Mopholino)propanesulfonic (MOPS) acid and 15 mL Glycerol, made up to 100 mL with 
Milli-Q H2O, adjusted to pH 6.5 with 1 M potassium hydroxide (KOH) and sterilised by 
passing through a 0.45 μm filter. 
 
9.3 Electrophoresis Reagents 
9.3.1 50X TAE Buffer 
50X TAE buffer was prepared with 242 g Tris base, 57 mL acetic acid and 100 mL 0.5 M 
EDTA pH 8, made up to 1000 mL with dH2O. 
 
9.3.2 Agarose Gels 
Agarose gels were prepared by adding 0.6 g (1%) or 1.2 g (2%) DNA grade agarose 
(HydraGene, China) to 60 mL 1X TAE, microwaving for 2 minutes or until completely 
dissolved and melted, and cooled slightly before pouring into gel moulds. Gels were allowed 
to set for 30 minutes at room temperature. 
 
9.3.3 2X Sample Buffer 
2X sample buffer was prepared with 500 μL 10% SDS in Milli-Q H2O, 200 μL glycerol, 120 
μL 1M Tris-HCl at pH 6.8, 10 μL 1% bromophenol blue and 70 μL Milli-Q H2O. 5 μL of 2-




9.3.4 SDS-PAGE Stacking Gel Buffer 
Stacking gel buffer was prepared with 0.4 g SDS and 6.04 g Tris in 70 mL Milli-Q H2O. The 
solution was adjusted to pH 6.8 with HCl, and then topped up with Milli-Q H2O to a total 
volume of 100 mL. 
 
9.3.5 SDS-PAGE Resolving Gel Buffer 
Resolving gel buffer was prepared with 0.4 g SDS and 18.2 g Tris in 70 mL Milli-Q H2O. 
The solution was adjusted to pH 8.8 with HCl, and then topped up with Milli-Q H2O to a 
total volume of 100 mL. 
 
9.3.6 SDS-PAGE Gel Production 
A 10% resolving gel solution was prepared with 1.9 mL 40% acrylamide, 1.9 mL resolving 
gel buffer, 3.8 mL Milli-Q H2O, 37.5 μL 10% ammonium persulphate (APS) and 7.5 μL 
tetramethylethylenediamine (TEMED). This solution was added to the interlocked space 
between glass SDS-PAGE gel plates (Bio-Rad, California, USA) until around half-full. A 
thin layer of water-saturated butanol was layered on top, and the cassette was agitated slightly 
to produce an even horizontal interface. The gel was then allowed to set for 45 minutes at 
room temperature. A 4% stacking gel was prepared with 0.25 mL 40% acrylamide, 1.25 mL 
stacking gel buffer, 1 mL Milli-Q H2O, 17.5 μL 10% APS and 3.5 μL TEMED. The water-
saturated butanol was poured of the set resolving gel, and excess was blotted with filter paper. 
4% stacking gel solution was layered over the resolving gel, filling the remaining of the 
cassette up to and around the inserted comb. The gel was then allowed to set for 45 minutes 
at room temperature. SDS-PAGE gels were stored at 4 °C for up to 7 days prior to use, sealed 
in a plastic bag containing tissues moistened with dH2O to prevent dessication. 
 
9.3.7 10X SDS-PAGE Electrophoresis Buffer 
10X SDS-PAGE electrophoresis buffer was prepared with 144 g glycine, 30 g Tris and 10 g 




9.3.8 Coomassie Blue Stain 
Coomassie blue stain solution was prepared with 1.25 g Coomassie brilliant blue G-250 
dissolved in 225 mL methanol, 45 mL acetic acid and 230 mL Milli-Q H2O. The stain was 
filtered through Whatman filter paper to remove insoluble precipitates. 
 
9.3.9 Destain Solution 
Destain solution was prepared with 100 mL methanol, 100 mL acetic acid, and 800 mL dH2O. 
 
9.4 Western Blot Reagents 
9.4.1 Anode Buffer I 
Anode buffer I was prepared with 36 g Tris and 100 mL methanol, with sufficient dH2O as 
to bring the total volume up to 1000 mL, at pH 10.4. 
 
9.4.2 Anode Buffer II 
Anode buffer II was prepared with 3.03 g Tris and 100 mL methanol, with sufficient dH2O 
as to bring the total volume up to 1000 mL. 
 
9.4.3 Cathode Buffer 
Cathode buffer was prepared with 3.03 g Tris, 3 g glycine and 100 mL methanol, with 
sufficient dH2O as to bring the total volume up to 1000 mL, at pH 9.4. 
 
9.4.4 PBS-T Wash Buffer 
PBS-T wash buffer was prepared with 20 mL 10X PBS and 1 mL Tween 20 (Sigma-Aldrich, 
Montana, USA), with sufficient dH2O as to bring the total volume up to 2000 mL. 
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9.5 Cell Culture Reagents 
9.5.1 Trypan Blue 
Trypan blue cell viability stain was prepared by added 0.5 g trypan blue to sufficient Milli-
Q H2O as to produce a total volume of 10 mL. The solution was sterilised by passing it 
through a 0.45 μm filter. 
 
9.5.2 SeaPlaque Agarose 
SeaPlaque agarose was prepared by dissolving 1.5 g of SeaPlaque (Lonza, Switzerland) in 
50 mL of Milli-Q H2O. The solution was autoclaved, and stored at 4 °C. 
 
9.5.3 cIMDM 
cIMDM was prepared by adding 500 μL of sterile 5.5x10-2 M 2-mercaptoethanol to 500 mL 
of IMDM. 
 
9.6 VLP-specific Reagents 
9.6.1 CsCl Solutions 
CsCl solutions were prepared with 2.86 g CsCl for 1.2 g/cm3, and 6.15 g for 1.4 g/cm3, 
dissolved in 10 mL Milli-Q H2O and sterilised by passing through a 0.45 μm filter. 
 
9.6.2 Disassembly Buffer 
Disassembly buffer was prepared with 12.1 g Tris and 17.5 g NaCl dissolved in 1800 mL 
dH2O. The solution was adjusted to pH 7.5 with HCl, and sufficient dH2O was added as to 




9.7 Flow Cytometry Reagents 
9.7.1 Red Cell Lysis Buffer 
Red cell lysis buffer was prepared with 4.15 g ammonium chloride (NH4Cl), 0.5 g potassium 
hydrogen carbonate (KHCO3) and 0.0186 g EDTA, with sufficient Milli-Q H2O as to bring 
the total volume up to 500 mL. Red cell lysis buffer was filter sterilised, and stored at 4 °C. 
 
9.7.2 FACS Buffer 
FACS buffer was prepared with 0.1 g sodium azide and 1 g BSA, with sufficient 1X PBS as 
to bring the total volume up to 1000 mL. 
 
9.7.3 AutoMACS Buffer 
AutoMACS buffer was prepared with 29.2 g EDTA and 0.25 g BSA, with sufficient DPBS 
as to bring the total volume up to 50 mL. AutoMACS buffer was filter sterilised, and stored 
at 4 °C. 
 
9.7.4 AutoMACS Running Buffer 
AutoMACS running buffer was prepared with 29.2 g EDTA, with sufficient DPBS as to bring 
the total volume up to 50 mL. AutoMACS running buffer was filter sterilised, and stored at 
4 °C.  
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Presentation: Multi-Epitope Chimaeric VLP as a Therapeutic Vaccine for Colorectal Cancer 
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